Pharmaceutical composition comprising 1,3-benzodioxole derivative compound
Patent Information
- Application Number
- MYPI2026000035
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-07-06
- Filing Date
- 2024-07-04
- Publication Date
- 2025-01-06
AI Technical Summary
Current treatments for cancers with elevated EZH1 or EZH2 activity are limited, as existing therapies do not effectively inhibit these enzymes, leading to challenges in managing diseases such as prostate, breast, and pancreatic cancers, where EZH2 overexpression is associated with poor prognosis and increased cell proliferation.
A pharmaceutical composition containing a 1,3-benzodioxole derivative compound, its stereoisomers, pharmaceutically acceptable salts, and hydrates/solvates, which inhibit EZH1 and EZH2 activity, thereby preventing or treating diseases related to these enzymes.
The composition effectively inhibits EZH1 and EZH2 activity, potentially reducing tumor growth and improving treatment outcomes for cancers with elevated EZH2 expression by suppressing cell proliferation and preventing disease progression.
Abstract
Description
[0001]
specification
[0002]
Title of invention
[0003] Pharmaceutical composition comprising a 1,3-benzodioxole derivative compound
[0004]
Technical Field
[0005]
Background Technology
[0006]
Detailed Description of the Invention
[0007]
Technical Problem
[0008] (1) A compound represented by the following chemical formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof:
[0009] <Chemical Formula 1>
[0010] R1 is H; C1-C6 alkyl; C2-C6 alkenyl; C2-C6 alkynyl; C3-C8 cycloalkyl; C3-C8 cycloalkenyl; Cl-C6 alkoxy; 3- to 12-membered heterocycloalkyl or heterocycloalkenyl containing 1 to 3 heteroatoms independently selected from the group consisting of N, 0 and within the ring; 6- to 14-membered aryl; 5- to 12-membered heteroaryl containing 1 to 3 heteroatoms independently selected from the group consisting of N, 0 and within the ring; - (C=0)- (Ci- C6 alkyl); -CN; benzodioxolyl or halogen, and Ci-C6 alkyl; C3-C8 cycloalkyl of Ri; A 3- to 12-membered heterocycloalkyl or heterocycloalkenyl having 1 to 3 heteroatoms independently selected from the group consisting of N, 0 and in the ring; A 6- to 14-membered aryl; A 5- to 12-membered heteroaryl or benzodioxolyl having 1 to 3 heteroatoms independently selected from the group consisting of N, 0 and S in the ring, wherein one or more of the groups may be substituted or unsubstituted with R a, wherein R a is Ci-C6 alkyl; Ci-C6 alkoxy; A 3- to 12-membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from the group consisting of N, 0 and in the ring; - NR x R y ; or halogen, and one or more of the groups of R a may be substituted or unsubstituted with R b, wherein R b is Ci-C6 alkyl; A 3- to 12-membered heterocycloalkyl ring containing 1 to 3 heteroatoms independently selected from the group consisting of N, 0, and ; or a halogen,
[0011] R2 is H; Ci-C6 alkyl; C3-C8 cycloalkyl; 3-12 membered heterocycloalkyl or heterocycloalkenyl containing 1 to 3 heteroatoms independently selected from the group consisting of N, 0 and in the ring; 6-14 membered aryl; or 5-12 membered heteroaryl containing 1 to 3 heteroatoms independently selected from the group consisting of N, 0 and S in the ring, and at least one of R2 may be substituted or unsubstituted, wherein Ci-C6 alkyl; C3-C8 cycloalkyl; 3-12 membered heterocycloalkyl containing 1 to 3 heteroatoms independently selected from the group consisting of N, 0 and in the ring; - NRpRq; - (HC=O); -(C=0)-(Ci-C6 alkyl); - S(=0)『 (Ci-C6 alkyl); or halogen, and one or more of the above-described groups may be substituted or unsubstituted with Rd, wherein Rd is Ci-C6 alkoxy which may be substituted or unsubstituted with halogen; 3- to 12-membered heterocycloalkyl containing 1 to 3 heteroatoms in the ring independently selected from the group consisting of N, 0 and; 6- to 14-membered aryl; halogen; or - 0H,
[0012] R3 is H; or Ci-C6 alkyl,
[0013] R4 is H; Ci-C6 alkyl; or halogen, and Rs and R6 are each independently H; or C1-C6 alkyl,
[0014] Rx and Ry are each independently H; or Ci-C6 alkyl,
[0015] Rp and Rq are each independently H; Ci-C6 alkyl, C3-C8 cycloalkyl or - (C=0)-(Ci-C6 alkyl),
[0016] V is a single bond; or - (Ci- C6 alkylene)-.
[0017] (2) In the above (1), in the chemical formula I,
[0018] Ri is a 6- to 14-membered aryl; a 5- to 12-membered heteroaryl or benzodioxolyl having 1 to 3 heteroatoms independently selected from the group consisting of N, 0 and S in the ring, wherein at least one group of Ri may be substituted or unsubstituted with Ra, wherein Ra is Ci-C6 alkyl; Ci-C6 alkoxy; a 3- to 12-membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from the group consisting of N, 0 and ; -NRxRy; or halogen, and at least one group of Ra may be substituted or unsubstituted with Rb, wherein Rb is Ci-C6 alkyl; a 3- to 12-membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from the group consisting of N, 0 and ; or halogen,
[0019] R2 is C3-C8 cycloalkyl; or a 3- to 12-membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from the group consisting of N, 0 and , wherein at least one of R2 may be unsubstituted or substituted with , wherein , is C1-C6 alkyl; C3-C8 cycloalkyl; a 3- to 12-membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from the group consisting of N, 0 and , wherein -NRpRq or - (C=0)- (C「 C6 alkyl), and at least one of , may be unsubstituted or substituted with Rd, wherein Rd is Ci-C6 alkoxy which may be unsubstituted or substituted with halogen; A 3- to 12-membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from the group consisting of N, 0 and ; a 6- to 14-membered aryl; a halogen; or - 0H,
[0020] Rs to R6 are each independently Ci-C6 alkyl,
[0021] Rx and Ry are each independently Ci-C6 alkyl,
[0022] Rp and Rq are each independently H; Ci- C6 alkyl, C3-C8 cycloalkyl or - (C=0)- (Ci- C6 alkyl),
[0023] V is a single bond.
[0024] (3) In the above (1) or (2), in the chemical formula I,
[0025] Ri is phenyl, pyridinyl, pyrimidinyl, indolyl, thiophenyl, isoxazolyl, furanyl, benzofuranyl or benzodioxolyl, and one or more of Ri may be substituted or unsubstituted with Ra, and Ra is methyl, methoxy, -N(CH3)2, -N(CH3)(CH2CH3), -
[0026] N(CH3)(CH2CH2CH2CH3), morpholinyl, thiomorpholinyl, pyrrolidinyl, piperidinyl, piperazinyl, or halogen, and one or more of the above Ra may be substituted or unsubstituted with Rb, wherein Rb is methyl, ethyl, morpholinyl or halogen,
[0027] R2 is cyclohexyl or piperidinyl, and one or more of the above R2 may be substituted or unsubstituted, and the above R2 is methyl, ethyl, propyl, isopropyl, butyl, cyclohexyl, azetidinyl, - NH2, -N(CH3)2, -N(CH3)(CH2CH3), -N(CH3)(CH2CH2CH3), -
[0028] N(CH3)(CH)(CH3)2, -N(CH3)(CH2CH2CH2CH3), -N(CH3)(C6HII), -N(CHS)(C=0)CH3 or - (C=0)CH3, and one or more of the above may be substituted or unsubstituted with Rd, and the Rd is methoxy, ethoxy which may be substituted or unsubstituted with halogen, propoxy, butoxy which may be substituted or unsubstituted with halogen, isopropoxy, dioxolanyl, phenyl, halogen or - 0H,
[0029] Rs to R6 are methyl. In the present invention, "Cm-Cn" (wherein m and n are each independently an integer of 1 or more) means the number of carbons, for example, 'Ci-C5alkyl' means alkyl having 1 to 5 carbons. In the present invention, unless otherwise specified, "alkyl" means a straight-chain or branched-chain saturated hydrocarbon group represented by CnH2n+l. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, isobutyl, n-pentyl, sec-pentyl, tert-pentyl, isopentyl, sec-isopentyl, neo-pentyl, n-hexyl, etc. In the present invention, unless otherwise specified, "alkenyl" means an unsaturated hydrocarbon group including at least one carbon-carbon double bond in the alkyl. In the present invention, unless otherwise stated, "alkynyl" means an unsaturated hydrocarbon group containing at least one carbon-carbon triple bond in the alkyl. In the present invention, unless otherwise stated, "alkoxy" means an unsaturated hydrocarbon group containing 0C nIt refers to a monovalent group derived from a straight or branched saturated hydrocarbon moiety represented by H2n+l. Examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, pentoxy, and hexoxy. In the present invention, unless otherwise specified, "cycloalkyl" means a saturated hydrocarbon ring group having 3 or more carbon atoms, and the saturated hydrocarbon ring includes both monocyclic and polycyclic structures. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. In the present invention, unless otherwise stated, "cycloalkenyl" means a cyclic group including at least one carbon-carbon double bond in the cycloalkyl. In the present invention, "heterocycloalkyl" means a cyclic group in which at least one carbon atom forming the ring in the cycloalkyl is independently substituted with a heteroatom or functional group selected from the group consisting of N, 0, S, SO, and S02, unless otherwise stated. Examples of heterocycloalkyl include, but are not limited to, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothiophenyl, oxepanyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, azetidinyl, aziridinyl, azepanyl, and the like. As used herein, "heterocycloalkenyl" means a cyclic group having at least one carbon-carbon double bond in the heterocycloalkyl, unless otherwise specified. As used herein, "aryl" means a monocyclic or polycyclic cyclic group having one or more aromatic rings, fused or non-fused, unless otherwise specified. Examples of aryl include, but are not limited to, phenyl, naphthyl, tetrahydronaphthyl, indenyl, and andracenyl.In the present invention, unless otherwise stated, "heteroaryl" means a monocyclic or polycyclic cyclic group containing 1 to 3 heteroatoms selected from the group consisting of N, 0 and S and having one or more aromatic rings, which are fused or non-fused. Examples of heteroaryl include, but are not limited to, thiazolyl, oxazolyl, thiophenyl, furanyl, pyrrolyl, imidazolyl, isooxazolyl, pyrazolyl, triazolyl, thiadiazolyl, tetrazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolyl, benzothiophenyl, benzofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzthiazolyl, benzthiadiazolyl, benztriazolyl, quinolinyl, isoquinolinyl, purinyl, furopyridinyl, etc. In the present invention, "halogen" may be F, Cl, Br, or I.
[0030] (4) In any one of the above (1) to (3), the compound represented by the above chemical formula I may be a compound described in the table below.
[0031]
[0032] (5) The following compounds, stereoisomers thereof, pharmaceutically acceptable salts thereof, hydrates or solvates thereof:
[0033] 1) 2- (trans- 4- (dimethylamino) cyclohexyl)- 7- (6- ((2S,6R)- 2,6- dimethylmorpholino) pyridin- 3 -yl)- 2,4 - dimethyl- N- ((6 - methyl- 4- (methylthio)- 2 - oxo-
[0034] 1,2-Dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
[0035] 2) 2-(trans-4-(dimethylamino)cyclohexyl)-7-(2-((2S,6R)-2,6-dimethylaminomorpholino)pyrimidin-5-yl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
[0036] 3) 7-(6-(4,4-difluoropiperidin-1-yl)pyridin-3-yl)-2-(trans-4-(dimethylamino)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
[0037] 4) 2-(trans-4-(dimethylamino)cyclohexyl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(2-(piperidin-1-yl)pyrimidin-5-yl)benzo[d][1,3]dioxole-5-carboxamide
[0038] 5) 2-(trans-4-(dimethylamino)cyclohexyl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(2-(pyrrolidin-1-yl)pyrimidin-5-yl)benzo[d][1,3]dioxole-5-carboxamide
[0039] 6) 2-(trans-4-(dimethylamino)cyclohexyl)- 2,4-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3 -yl)methyl)- 7-(4-
[0040] (morpholinomethyl)phenyl)benzo[d][1,3]dioxole-5-carboxamide
[0041] 7) 2-(trans-4-(dimethylamino)cyclohexyl)- 2,4-dimethyl- 7-(1-methyl- 1H- indol- 5 -yl)- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3-yl)methyl)benzo [d] [l,3]dioxole- 5 -carboxamide
[0042] 8) 7-(2-(4,4-difluoropiperidin-1-yl)pyrimidin-5-yl)-2-(trans-4-(dimethylamino)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
[0043] 9) 2-(trans-4-(dimethylamino)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(4-morpholinophenyl)benzo[d][l,3]dioxole-5-carboxamide
[0044] 10) 2-(trans-4-(dimethylamino)cyclohexyl)-7-(4-fluorophenyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][l,3]dioxole-5-carboxamide
[0045] 11) 2-(trans-4-(dimethylamino)cyclohexyl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(thiophen-3-yl)benzo[d][l,3]dioxole-5-carboxamide
[0046] 12) 2-(trans-4-(dimethylamino)cyclohexyl)-7-(5-fluoro-2-methoxyphenyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
[0047] 13) 2-(trans-4-(dimethylamino)cyclohexyl)-7-(3,5-dimethylisoxazol-4-yl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
[0048] 14) 7-(2,6-difluoropyridin-3-yl)-2-(trans-4-(dimethylamino)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
[0049] 15) 7-(2-(2-oxa- 7-azaspiro [3.5]nonane- 7-yl)pyrimidin- 5-yl)-2- (trans- 4-(dimethylamino)cyclohexyl)- 2,4-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3-yl)methyl)benzo [d] [1,3]dioxole- 5-carboxamide 16) 2-(trans- 4-(dimethylamino)cyclohexyl)- 7-(6-(3,5-dimethylpiperidin—!—yl)pyridin— 3 —yl)— 2,4-dimethyl- N-((6-methyl- 4-(methylthio)- 2 -Oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
[0050] 17) 2-(trans-4-(dimethylamino)cyclohexyl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(6-thiomorpholinopyridin-3-yl)benzo[d][1,3]dioxole-5-carboxamide
[0051] 18) 2-(trans-4-(dimethylamino)cyclohexyl)-7-(furan-3-yl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][l,3]dioxole-5-carboxamide
[0052] 19) 7-(5-chlorothiophene-2-yl)-2-(trans-4-(dimethylamino)cyclohexyl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
[0053] 20) 7-(6-((2S, 6R)-2,6-dimethylmorpholino)pyridin-3-yl)- 2,4-dimethyl- 2-(trans- 4-(methyl(2,2,2-trifluoroethyl)amino)cyclohexyl)- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3-yl)methyl)benzo[d][1,3]dioxole- 5-carboxamide
[0054] 21) 2, 4 -Dimethyl- 2- (trans- 4- (methyl (2,2,2-trifluoroethyl) amino) cyclohexyl) - N- ( (6 -methyl- 4- (methylthio)- 2 -oxo- 1 , 2 - dihydropyridin- 3 -yl) methyl) - 7- (2- (piperidin- 1-yl) pyrimidin- 5-yl) benzo [d] [l , 3] dioxole- 5 -carboxamide
[0055] 22) 7-(2-(dimethylamino)pyrimidin-5-yl)- 2,4-dimethyl- 2-(trans- 4-
[0056] (methyl(2,2,2-trifluoroethyl)amino)cyclohexyl)- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3-yl)methyl)benzo[d][ 1,3]dioxole- 5-carboxamide
[0057] 23) 7-(2-((2S, 6R)-2,6-dimethylmorpholino)pyrimidin-5-yl)-2,4-dimethyl-2-(trans-4-(methyl(2,2,2-trifluoroethyl)amino)cyclohexyl)- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
[0058] 24) 7-(6-((2S, 6R)-2,6-dimethylmorpholino)pyridin-3-yl)- 2-(trans-4-((2-methoxyethyl)(methyl)amino)cyclohexyl)- 2,4-dimethyl- N-((6-methyl- 4-
[0059] (Methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
[0060] 25) 7-(2-((2S, 6R)-2,6-dimethylmorpholino)pyrimidin- 5 -yl)- 2-(trans- 4- ((2-methoxyethyl)(methyl)amino)cyclohexyl)- 2,4-dimethyl- N-((6-methyl- 4-
[0061] (Methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
[0062] 26) 7-(2-(dimethylamino)pyrimidin-5-yl)- 2-(trans- 4-((2-methoxyethyl)(methyl)amino)cyclohexyl)- 2,4-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3-yl)methyl)benzo[d][ 1,3 ]dioxole- 5-carboxamide
[0063] 27) 7-(6-(4, 4 -difluoropiperidin- 1-yl)pyridin- 3 -yl)- 2-(trans- 4-((2-methoxyethyl)(methyl)amino)cyclohexyl)- 2, 4 -dimethyl- N-((6 -methyl- 4-(methylthio)- 2-oxo- 1, 2 -dihydropyridin- 3 -yl)methyl)benzo [d] [ 1, 3 ]dioxole- 5 -carboxamide
[0064] 28) 2-(trans-4-((2-methoxyethyl)(methyl)amino)cyclohexyl)- 7-(6-methoxypyridin— 3 -yl)- 2,4-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3 -yl)methyl)benzo[d][1,3]dioxole- 5 -carboxamide 29) 7-(6-((2S,6R)- 2,6-dimethylmorpholino)pyridin- 3 -yl)- 2-(trans- 4-
[0065] (((S)-2-hydroxypropyl)(methyl)amino)cyclohexyl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
[0066] 30) 7-(6-((2S, 6R)-2,6-dimethylmorpholino)pyridin-3-yl)- 2,4-dimethyl- 2- (trans- 4-(methyl(2-propoxyethyl)amino)cyclohexyl)- N-((6-methyl- 4-
[0067] (Methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
[0068] 31) 2-(trans-4-((2,2-dimethoxyethyl)(methyl)amino)cyclohexyl)- 7-(6-((2S, 6R)-2,6-dimethylmorpholino)pyridin- 3 -yl)- 2,4-dimethyl- N-((6-methyl- 4-
[0069] (Methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
[0070] 32) 2-(trans-4-(((1,3-dioxolan-2-yl)methyl)(methyl)amino)cyclohexyl)- 7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)- 2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo- 1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
[0071] 33) 7-(6-((2S, 6R)-2,6-dimethylmorpholino)pyridin-3-yl)- 2,4-dimethyl- N-((6-methyl-4-(methylthio)- 2-oxo- 1,2-dihydropyridin-3-yl)methyl)- 2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzo[d][1,3]dioxole- 5-carboxamide
[0072] 34) 2,4-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3-yl)methyl)- 7-(6-thiomorpholinopyridin- 3-yl)- 2-(1-(2,2,2-trifluoroethyl)piperidin- 4-yl)benzo[d][1,3]dioxole- 5-carboxamide 35) 7-(2-(dimethylamino)pyrimidin- 5-yl)- 2,4-dimethyl- N-((6-methyl- 4-
[0073] (Methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide
[0074] 36) 7-(6-methoxypyridin-3-yl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzo[d][l,3]dioxole-5-carboxamide
[0075] 37) 7-(6-(3,5-dimethylpiperidin-1-yl)pyridin-3-yl)- 2,4-dimethyl- N-((6-methyl— 4-(methylthio)- 2-oxo- 1,2-dihydropyridin-3-yl)methyl)- 2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzo[d][1,3]dioxole- 5-carboxamide
[0076] 38) 7-(2-((2S, 6R)-2,6-dimethylmorpholino)pyrimidin-5-yl)- 2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo- 1,2-dihydropyridin-3-yl)methyl)- 2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide
[0077] 39)2,4-Dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3 -yl)methyl)- 7-(2-(piperidin- 1-yl)pyrimidin- 5 -yl)- 2-(1-(2,2,2-trifluoroethyl)piperidin- 4 -yl)benzo[d][1,3]dioxole- 5 -carboxamide
[0078] 40) 7-(6-((2S,6R)- 2, 6 -dimethylmorpholino)pyridin- 3 -yl)- 2-(1-((S)- 2-hydroxypropyl)piperidin- 4 -yl)- 2 , 4 -dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo-
[0079] 1,2-Dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
[0080] 41) 2-(1-(2, 2 -dimethoxyethyl)piperidin- 4 -yl)- 7-(6-((2S , 6R)~2 , 6 -dimethylmorpholino)pyridin- 3 -yl)- 2 , 4 -dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo-
[0081] 1,2-Dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
[0082] 42) 2-(4-(dimethylamino)cyclohexyl)- 2,4-dimethyl- N-((6-methyl- 4- (methylthio)- 2-oxo- 1,2-dihydropyridin- 3 -yl)methyl)- 7-(thiophen- 3-yl)benzo [d] [l,3]dioxole- 5 -carboxamide
[0083] 43) 2-(4-(dimethylamino)cyclohexyl)- 7-(5-fluoro- 2-methoxyphenyl)- 2,4-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3-yl)methyl)benzo [d] [l,3]dioxole- 5-carboxamide
[0084] 44) 7-(6-((2S , 6R)-2 , 6 -dimethylmorpholino)pyridin- 3 -yl)- 2 , 4 -dimethyl- N-
[0085] Stereoisomer B of ((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide
[0086] 45)7-(6-((2S , 6R)-2 , 6 -dimethylmorpholino)pyridin- 3 -yl)- 2 , 4 -dimethyl- N-
[0087] Stereoisomer A of ((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide
[0088] 46) 2-(1-(2, 2-difluoroethyl)piperidin- 4 -yl)- 7-(6-((2S , 6R)~2 , 6 -dimethylmorpholino)pyridin- 3 -yl)- 2 , 4 -dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo-
[0089] 1,2-Dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
[0090] 47) 2-(1-(2, 2 -difluoroethyl)piperidin- 4 -yl)- 7-(6-((2S , 6R)~2 , 6 -dimethylmorpholino)pyridin- 3 -yl)- 2 , 4 -dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo-
[0091] Stereoisomer B of 1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
[0092] 48) Stereoisomer A of 2-(1-(2, 2-difluoroethyl)piperidin- 4 -yl)- 7-(6-((2S , 6R)~2 , 6 -dimethylmorpholino)pyridin- 3 -yl)- 2 , 4 -dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo- 1 , 2 -dihydropyridin- 3 -yl)methyl)benzo [d] [ 1 , 3 ]dioxole- 5 -carboxamide
[0093] 49) Stereoisomer B of 7-(6-((2S,6R)- 2,6 -dimethylmorpholino)pyridin- 3 -yl)- 2-(1-ethylpiperidin- 4 -yl)- 2,4 -dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo- 1,2 -dihydropyridin- 3 -yl)methyl)benzo [d] [ 1,3]dioxole- 5 -carboxamide
[0094] 50) Stereoisomer A of 7-(6-((2S,6R)- 2,6-dimethylmorpholino)pyridin- 3 -yl)- 2-(1-ethylpiperidin- 4 -yl)- 2,4-dimethyl- N-((6-methyl- 4-(methylthio)- 2 -oxo- 1,2-dihydropyridin- 3 -yl)methyl)benzo[d][ 1,3]dioxole- 5-carboxamide
[0095] 51) Stereoisomer B of 7-(6-((2S,6R)- 2,6 -dimethylmorpholino)pyridin- 3 -yl)- 2-(1-isopropylpiperidin- 4 -yl)- 2,4 -dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo- 1,2 -dihydropyridin- 3 -yl)methyl)benzo [d] [ 1,3]dioxole- 5 -carboxamide
[0096] 52) Stereoisomer A of 7-(6-((2S,6R)- 2,6-dimethylmorpholino)pyridin- 3 -yl)- 2-(1-isopropylpiperidin- 4 -yl)- 2,4-dimethyl- N-((6-methyl- 4-(methylthio)- 2 -oxo- 1,2-dihydropyridin- 3 -yl)methyl)benzo[d][ 1,3]dioxole- 5-carboxamide
[0097] 53) 2-(1-Cyclohexylpiperidin-4-yl)- 7-(6-((2S, 6R)-2,6-dimethylmorpholino)pyridin-3-yl)- 2,4-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo-
[0098] 1,2-Dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide stereoisomer B 54) 2-(1-cyclohexylpiperidin-4-yl)- 7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)- 2,4-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo-
[0099] Stereoisomer A of 1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
[0100] 55) Stereoisomer B of 7-(6-((2S, 6R)-2,6-dimethylmorpholino)pyridin-3-yl)- 2,4-dimethyl- N-((6-methyl-4-(methylthio)- 2-oxo- 1,2-dihydropyridin-3-yl)methyl)- 2-(1-phenethylpiperidin-4-yl)benzo[d][l,3]dioxole- 5-carboxamide
[0101] 56) Stereoisomer A of 7-(6-((2S, 6R)-2,6-dimethylmorpholino)pyridin-3-yl)- 2,4-dimethyl- N-((6-methyl-4-(methylthio)- 2-oxo- 1,2-dihydropyridin-3-yl)methyl)- 2-(1-phenethylpiperidin- 4-yl)benzo[d][l,3]dioxole- 5-carboxamide
[0102] 57) 7-(6-((2S , 6R)-2 , 6 -dimethylmorpholino)pyridin- 3 -yl)- 2 , 4 -dimethyl- N-
[0103] Stereoisomer B of ((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(4,4,4-trifluorobutyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide
[0104] 58) 7-(6-((2S , 6R)-2 , 6 -dimethylmorpholino)pyridin- 3 -yl)- 2 , 4 -dimethyl- N-
[0105] Stereoisomer A of ((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(4,4,4-trifluorobutyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide
[0106] 59) 7-(6-((2S , 6R)-2 , 6 -dimethylmorpholino)pyridin- 3 -yl)- 2 , 4 -dimethyl- N- ((6 -methyl- 4-(methylthio)- 2 -oxo- 1 , 2 -dihydropyridin- 3 -yl)methyl)- 2-(1-(2 , 2 , 2 -trifluoroacetyl)piperidin- 4 -yl)benzo [d] [ 1 , 3 ]dioxole- 5 -carboxamide Stereoisomer B 60) 7-(6-((2S , 6R)-2 , 6 -dimethylmorpholino)pyridin- 3 -yl)- 2 , 4 -dimethyl- N- ((6 -methyl- 4-(methylthio)- 2 Stereoisomer A of -oxo- 1 , 2 -dihydropyridin- 3 -yl)methyl)- 2- (1- (2 , 2 , 2 -trifluoroacetyl)piperidin- 4 -yl)benzo [d] [ 1 , 3 ]dioxole- 5 -carboxamide
[0107] 61) 2, 4 -Dimethyl- N- ((6 -methyl- 4- (methylthio) - 2 -oxo - 1 , 2 - dihydropyridin - 3 -yl)methyl) - 7- (6 -morpholinopyridin - 3 -yl) - 2- (1- (2 , 2 , 2 - trifluoro) piperidin - 4-yl) benzo [d] [l , 3]dioxole - 5 -carboxamide
[0108] 62) Stereoisomer B of 2,4-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3-yl)methyl)- 7-(6-morpholinopyridin- 3-yl)- 2-(1-(2,2,2-trifluoro)piperidin- 4-yl)benzo[d][1,3]dioxole- 5-carboxamide
[0109] 63)2, 4 -Dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo- 1 , 2 -dihydropyridine-
[0110] Stereoisomer A of 3-methyl-7-(6-morpholinopyridine-3-yl)-2-(1-(2,2,2-trifluoro)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide
[0111] 64) 2-(1-(2, 2 -difluoroethyl)piperidin- 4 -yl)- 2, 4 -dimethyl- N-((6 -methyl-
[0112] 4-(Methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(6-morpholinopyridine-
[0113] 3-day) Stereoisomer B of benzo[d][1,3]dioxole-5-carboxamide
[0114] 65) 2-(1-(2, 2 -difluoroethyl)piperidin- 4 -yl)- 2, 4 -dimethyl- N-((6 -methyl-
[0115] Stereoisomer A of 4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(6-morpholinopyridin-3-yl)benzo[d][1,3]dioxole-5-carboxamide
[0116] 66) 2-(1-Ethylpiperidin-4-yl)- 2, 4-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1, 2-dihydropyridin- 3-yl)methyl)- 7-(6-morpholinopyridin- 3-yl)benzo[d] [1,3]dioxole- 5-carboxamide Stereoisomer B 67) 2-(1-Ethylpiperidin-4-yl)- 2, 4-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1, 2-dihydropyridin- 3-yl)methyl)- 7-(6-morpholinopyridin- 3-yl)benzo[d] [1,3]dioxole- 5 -Stereoisomer A of carboxamide
[0117] 68)2,4-Dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridine-
[0118] 3-yl)methyl)- 7-(2-morpholinopyrimidine-5-yl)- 2-(1-(2, 2, 2-trifluoro)piperidine-
[0119] 4-day)benzo[d][l,3]dioxol-5-carboxamide
[0120] 69)2,4-Dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridine-
[0121] 3-yl)methyl)- 7-(2-morpholinopyrimidine-5-yl)- 2-(1-(2, 2, 2-trifluoro)piperidine-
[0122] 4-day) Stereoisomer B of benzo[d][1,3]dioxole-5-carboxamide
[0123] 70)2,4-Dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridine-
[0124] 3-yl)methyl)- 7-(2-morpholinopyrimidine-5-yl)- 2-(1-(2, 2, 2-trifluoro)piperidine-
[0125] 4-day) Stereoisomer A of benzo[d][1,3]dioxole-5-carboxamide
[0126] 71) Stereoisomer B of 2-(1-(2, 2-difluoroethyl)piperidin- 4-yl)- 2, 4-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1, 2-dihydropyridin- 3-yl)methyl)- 7-(2-morpholinopyrimidin- 5-yl)benzo[d][l, 3]dioxole- 5-carboxamide
[0127] 72) Stereoisomer A of 2-(1-(2, 2-difluoroethyl)piperidin- 4-yl)- 2, 4-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1, 2-dihydropyridin- 3-yl)methyl)- 7-(2-morpholinopyrimidin- 5-yl)benzo[d][l, 3]dioxole- 5-carboxamide
[0128] 73) Stereoisomer B of 2-(1-ethylpiperidin-4-yl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(2-morpholinopyrimidin-5-yl)benzo[d][1,3]dioxole-5-carboxamide
[0129] 74) Stereoisomer A of 2-(1-ethylpiperidin-4-yl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(2-morpholinopyrimidin-5-yl)benzo[d][1,3]dioxole-5-carboxamide
[0130] 75) 7-(2-(4-ethylpiperazin-1-yl)pyrimidin-5-yl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide
[0131] 76) Stereoisomer B of 7-(2-(4-ethylpiperazin-1-yl)pyrimidin-5-yl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide
[0132] 77) Stereoisomer A of 7-(2-(4-ethylpiperazin-1-yl)pyrimidin-5-yl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide
[0133] 78) 7-(2-(ethyl(methyl)amino)pyridin- 5 -yl)- 2,4 -dimethyl- N-((6 -methyl- 4- (methylthio)- 2 -oxo- 1,2 -dihydropyridin- 3 -yl)methyl)- 2-(1-(2,2,2 -trifluoroethyl)piperidin- 4 -yl)benzo [d] [1,3]dioxole- 5 -carboxamide
[0134] 79) 7-(2-(ethyl(methyl)amino)pyridin- 5 -yl)- 2,4 -dimethyl- N-((6 -methyl- 4- (methylthio)- 2 -oxo- 1,2 -dihydropyridin- 3 -yl)methyl)- 2-(1-(2,2,2 -trifluoroethyl)piperidin- 4 -yl)benzo [d] [1,3]dioxole- 5 -carboxamide Stereoisomer B 80) 7-(2-(ethyl(methyl)amino)pyridin- 5 -yl)- 2,4 -dimethyl- N-((6 -methyl- 4-
[0135] Stereoisomer A of (methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide
[0136] 81) Stereoisomer B of 2-(1-(2, 2-difluoroethyl)piperidin- 4 -yl)- 7-(2- (ethyl(methyl)amino)pyrimidin- 5 -yl)- 2, 4 -dimethyl- N-((6-methyl- 4-(methylthio)- 2 -oxo- 1, 2 -dihydropyridin- 3 -yl)methyl)benzo [d] [ 1, 3 ]dioxole- 5 -carboxamide
[0137] 82) Stereoisomer A of 2-(1-(2, 2-difluoroethyl)piperidin- 4 -yl)- 7-(2- (ethyl(methyl)amino)pyrimidin- 5 -yl)- 2, 4 -dimethyl- N-((6-methyl- 4-(methylthio)- 2 -oxo- 1, 2 -dihydropyridin- 3 -yl)methyl)benzo [d] [ 1, 3 ]dioxole- 5 -carboxamide
[0138] 83) Stereoisomer B of 7-(2-(ethyl(methyl)amino)pyrimidin- 5 -yl)- 2-(1-ethylpiperidin- 4 -yl)- 2,4 -dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo- 1,2 -dihydropyridin- 3-yl)methyl)benzo [d] [1,3]dioxole- 5 -carboxamide
[0139] 84) Stereoisomer A of 7-(2-(ethyl(methyl)amino)pyrimidin- 5 -yl)- 2-(1-ethylpiperidin- 4 -yl)- 2,4 -dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo- 1,2 -dihydropyridin- 3-yl)methyl)benzo [d] [1,3]dioxole- 5 -carboxamide
[0140] 85) 7-(6-(ethyl(methyl)amino)pyridin-3-yl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(2,2,2-trifluoro)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide
[0141] 86) Stereoisomer B of 7-(6-(ethyl(methyl)amino)pyridin-3-yl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide
[0142] 87) Stereoisomer A of 7-(6-(ethyl(methyl)amino)pyridin-3-yl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide
[0143] 88) 2-(1-(2, 2-difluoroethyl)piperidin- 4 -yl)- 7-(6- (ethyl(methyl)amino)paridin- 3 -yl)- 2, 4 -dimethyl- N-((6-methyl- 4-(methylthio)- 2 -oxo-
[0144] Stereoisomer B of 1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
[0145] 89) Stereoisomer B of 7-(6-(ethyl(methyl)amino)pyridin- 3 -yl)- 2-(1-ethylpiperidin- 4 -yl)- 2,4 -dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo- 1,2 -dihydropyridin- 3-yl)methyl)benzo [d] [1,3]dioxole- 5 -carboxamide
[0146] 90)2,4-Dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridine-
[0147] 3-yl)methyl)- 7-(4-(piperidin- 1-yl)phenyl)- 2-(1-(2, 2, 2-trifluoroethyl)piperidine-
[0148] 4-day)benzo[d][l,3]dioxol-5-carboxamide
[0149] 91) 2, 4 -Dimethyl- N- ((6 -methyl- 4- (methylthio) - 2 -oxo - 1 , 2 -dihydropyridin- 3 -yl)methyl) - 7- (6- (piperidin- 1 -yl)pyridin- 3 -yl) - 2- (1- (2, 2,2-trifluoroethyl)piperidin- 4 -yl)benzo [d] [1 , 3]dioxole- 5 -carboxamide
[0150] 92)2,4-Dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridine-
[0151] 3-yl)methyl)-7-(2-thiomorpholinopyrimidine-5-yl)-2-(1-(2, 2, 2-trifluoroethyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide
[0152] 93) 2',2'-difluoro- 2,7-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3 -yl)methyl)- 2-(1-(2,2,2-trifluoroethyl)piperidin- 4 -yl)- [4,5'-bibenzo[d][1,3]dioxole]- 6-carboxamide
[0153] 94)2,7-Dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridine-
[0154] 3-yl)methyl)-2-(1-(2,2,2-trifluoroethyl)piperidine-4-yl)-[4,5'-bibenzo[d][1,3]dioxole]-6-carboxamide
[0155] 95) 2-(1-(2, 2-difluoroethyl)piperidin- 4-yl)- 2, 7-dimethyl- N-((6-methyl-
[0156] 4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-[4,5'-bibenzo[d][1,3]dioxole]-6-carboxamide
[0157] 96)7-(Benzofuran-5-yl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzo[d][l,3]dioxole-5-carboxamide
[0158] 97) 7-(Benzofuran- 5-yl)- 2-(1-(2, 2-difluoroethyl)piperidin- 4-yl)- 2,4-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1, 2-dihydropyridin- 3-yl)methyl)benzo [d] [l, 3]dioxole- 5-carboxamide
[0159] 98) 7-(6-(butyl(methyl)amino)pyridin-3-yl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide
[0160] 99) 7-(6-(butyl(methyl)amino)pyridin-3-yl)- 2,4-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1 ,2-dihydropyridin- 3 -yl)methyl)- 2-(1-(2 , 2 , 2 -trifluoroethyl)piperidin- 4-yl)benzo[d][1 ,3]dioxole- 5 -carboxamide 100) 2-(trans- 4-aminocyclohexyl)- 7-( 6-(( 2S , 6R )- 2 , 6-dimethylmorpholino)pyridin- 3 -yl)- 2 , 4-dimethyl- N-((6-methyl- 4-(methylthio)- 2 -oxo- 1 ,2 -Dihydropyridine-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide hydrochloride
[0161] 101) 7-(6-((2S,6R)- 2, 6 -dimethylmorpholino)pidirin- 3 -yl)- 2-(trans- 4- (3 -hydroxyazetidine- 1-yl)cyclohexyl)- 2 , 4 -dimethyl- N-((6 -methyl- 4-
[0162] (Methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
[0163] 102) 7-(6-((2S, 6R)-2,6-dimethylmorpholino)pyridin-3-yl)- 2,4-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3-yl)methyl)- 2-(trans- 4- (3-(2,2,2-trifluoroethyl)azetidin- 1-yl)cyclohexyl)benzo[d][1,3]dioxole- 5-carboxamide
[0164] 103) 2-(trans-4-(3-(2,2-difluoroethoxy)azetidin-1-yl)cyclohexyl)-7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][l,3]dioxole-5-carboxamide
[0165] 104) 2-(trans-4-(3-(2,2-difluoroethoxy)azetidin-1-yl)cyclohexyl)-7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][l,3]dioxole-5-carboxamide
[0166] 105) 7-(6-((2S,6R)- 2, 6 -dimethylmorpholino)pyridin- 3 -yl)- 2-(trans- 4- (3 -isopropoxyazetidine- 1-yl)cyclohexyl)- 2 , 4 -dimethyl- N-((6 -methyl- 4-
[0167] (Methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
[0168] 106) 7-(6-((2S,6R)- 2,6 -dimethylmorpholino)pyridin- 3 -yl)- 2-(trans- 4- (3 -methoxyazetidine- 1-yl)cyclohexyl)- 2,4 -dimethyl- N-((6 -methyl- 4- (methylthio)- 2-oxo- 1,2 -dihydropyridin- 3 -yl)methyl)benzo [d] [ 1,3 ]dioxole- 5 -carboxamide
[0169] 107) Stereoisomer B of 7-(6-((2S, 6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethyl-2-(trans-4-(methyl(2,2,2-trifluoroethyl)amino)cyclohexyl)- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
[0170] 108) Stereoisomer A of 7-(6-((2S, 6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethyl-2-(trans-4-(methyl(2,2,2-trifluoroethyl)amino)cyclohexyl)- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
[0171] 109) 2-(trans-4-((2,2-difluoroethyl(methyl)amino)cyclohexyl)-7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
[0172] 110) 7-(6-((2S,6R)- 2,6 -dimethylmorpholino)pyridin- 3 -yl)- 2-(trans- 4- (isopropyl(methyl)amino)cyclohexyl)- 2,4 -dimethyl- N-((6 -methyl- 4-(methylthio)- 2-oxo- 1,2 -dihydropyridin- 3 -yl)methyl)benzo [d] [ 1,3 ]dioxole- 5 -carboxamide
[0173] 111) 7-(6-((2S,6R)- 2, 6 -dimethylmorpholino)pyridin- 3 -yl)- 2-(trans- 4- (ethyl(methyl)amino)cyclohexyl)- 2 , 4 -dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo-
[0174] 1,2-Dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide 112) 7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)- 2,4-dimethyl-2-
[0175] (trans-4-(methyl(phenethyl)amino)cyclohexyl)- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
[0176] 113) 7-(6-((2S, 6R)-2,6-dimethylmorpholino)pyridin-3-yl)- 2,4-dimethyl- 2-(trans-4-(methyl(phenethyl)amino)cyclohexyl)- N-((6-methyl-4-(methylthio)- 2-oxo- 1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole- 5-carboxamide
[0177] 114) 2-(trans-4-(cyclohexyl(methyl)amino)cyclohexyl)- 7-(6-((2S, 6R)-2,6-dimethylmorpholino)pyridin- 3 -yl)- 2,4-dimethyl- N-((6-methyl- 4-
[0178] (Methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
[0179] 115)7-(6-((2S, 6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo- 1,2-dihydropyridin-3-yl)methyl)- 2-(trans- 4-(2,2,2-trifluoro- N-methylacetamido)cyclohexyl)benzo[d][ 1,3]dioxole- 5-carboxamide In the present invention, “pharmaceutically acceptable” may mean physiologically acceptable and not causing allergic reactions such as gastrointestinal disorders, dizziness or similar reactions when administered to a subject. The pharmaceutically acceptable salt of the present invention can be prepared by a conventional method known to those skilled in the art. The pharmaceutically acceptable salt of the present invention is not particularly limited as long as it is prepared using an acid that forms a non-toxic acid addition salt containing a pharmaceutically acceptable anion. For example, the pharmaceutically acceptable salt may include, but is not limited to, inorganic acid salts prepared with hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, hydroiodic acid, etc.; organic acid salts prepared with tartaric acid, formic acid, citric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, gluconic acid, benzoic acid, lactic acid, fumaric acid, maleic acid, etc.; and sulfonic acid salts prepared with methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, etc. In one embodiment of the present invention, the pharmaceutically acceptable salt may be hydrochloride. In the present invention, the compound according to any one of (1) to (5) above may have one or more asymmetric carbon centers, and thus may exist as an enantiomer mixture including a racemic mixture, a single enantiomer (optical isomer), a diastereomeric mixture, and a single diastereoisomer. Such isomers can be separated by resolution using conventional techniques, such as column chromatography or HPLC.Alternatively, it can be stereospecifically synthesized using optically pure starting materials and / or reagents of a known arrangement. Specifically, the stereoisomer may be an optical isomer. In the present invention, the "hydrate" refers to a compound according to any one of (1) to (5) or a pharmaceutically acceptable salt thereof and water are bound by non-covalent intermolecular forces, and may contain a stoichiometric or non-stoichiometric amount of water. In the present invention, the "solvate" refers to a compound according to any one of (1) to (5) or a pharmaceutically acceptable salt thereof and a solvent other than water are bound by non-covalent intermolecular forces, and may contain a solvent in a stoichiometric or non-stoichiometric amount. The compound according to any one of the above (1) to (5) of the present invention, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or a solvate thereof inhibits cell proliferation by inhibiting the activity of EZH1 and / or EZH2, and also has excellent absorption properties in the body and blood, and thus can be usefully used for the prevention or treatment of various diseases related to the activity of EZH1 and / or EZH2. That is, the compound according to any one of the above (1) to (5) of the present invention, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or a solvate thereof can be usefully used for the prevention or treatment of diseases related to the activity of EZH1 and / or EZH2.
[0180] 1,3 -Method for producing a benzodioxole derivative compound The present invention provides a method for producing a compound according to any one of (1) to (5), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The compound according to any one of (1) to (5) of the present invention, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof can be produced, for example, according to the method of the following reaction scheme 1, but is not limited thereto.
[0181] <Reaction Scheme 1> In the above reaction formula 1, R1 to R6 and V of Cl to C4 are each the same as defined in the compound item represented by the above chemical formula I.
[0182] [Step 1] Cross-coupling reaction This is a step of preparing the compound C3 by stirring the compound C4 in a solvent inert to the reaction, in the presence of a base, using a palladium catalyst or a nickel catalyst; and an equal or excess amount of a boronic acid, a boronic acid pinacol ester (in the case of Suzuki-Miyaura coupling), an organotin reagent (in the case of Stille coupling), or an alkene compound (in the case of Heck reaction) under heating conditions for 0.5 to 24 hours. Specifically, the compound C3 can be prepared by stirring at 60 to 120°C for 0.5 to 12 hours. The solvent is not particularly limited as long as it is inert to the reaction, but may include methanol, ethanol, tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane, water, N,N-dimethylformamide, dimethyl sulfoxide, benzene, toluene, xylene, or a mixture thereof. The palladium catalyst may include tetrakis(triphenylphosphine)palladium, [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium, tris(dibenzylideneacetone)dipalladium, palladium acetate, acetylacetonepalladium, or bis(triphenylphosphine)palladium dichloride. The nickel catalyst may include [i,r-bis(diphenylphosphino)ferrocene]nickel dichloride or bis(triphenylphosphine)nickel dichloride. The above base may be an organic base such as triethylamine, diisopropylethylamine, 1,8-diazabicyclo[5.4.di-7-undecene(DBU) or 1,5-diazabicyclo[4.3.di-5-nonene(DBN); or an inorganic base such as potassium bicarbonate, sodium bicarbonate, potassium carbonate, sodium carbonate, potassium hydroxide, sodium hydroxide, potassium phosphate, or sodium phosphate.
[0183] [Step 2] Hydrolysis reaction This is a step for producing compound C2 by stirring the compound C3 in a solvent using an equal or excess amount of an aqueous base solution under cooling or heating for 3 to 96 hours. Specifically, compound C2 can be produced by stirring at room temperature (10 to 25 °C) to 60 °C for 3 to 48 hours. The solvent is not particularly limited as long as it does not inhibit the reaction, but may be methanol, ethanol, tetrahydrofuran, dimethoxyethane, acetonitrile, or a mixture thereof. The base may be an inorganic base such as lithium hydroxide, sodium hydroxide, or potassium hydroxide.
[0184] [Step 3] Amidation reaction This is a step for producing compound C1 by stirring the compound C2 in an inert solvent for the reaction with an equal or excess amount of the corresponding amine and a condensing agent under cooling or heating for 1 to 24 hours. Specifically, compound C1 can be produced by stirring at room temperature to 120°C for 1 to 8 hours. The solvent is not particularly limited as long as it is inert to the reaction, but N,N-dimethylformamide, dimethylacetamide, dichloromethane, 1,2-dichloroethane, chloroform, tetrahydrofuran, 1,2-dimethoxyethane, acetonitrile, or a mixture thereof can be used. As the condensing agent, pentafluorophenyl trifluoroacetate, dicyclocarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI), 1,1'-carbonyldiimidazole, etc. can be used. In addition, an additive or base can be used in the reaction. As the additive, N-hydroxysuccinimide (HOSu), 1-hydroxybenzotriazole (HOBt), 1-hydroxy-7-azabenzotriazole (HOAt), etc. can be used. As the base, an organic base, such as triethylamine or diisopropylethylamine; or an inorganic base, such as potassium carbonate, sodium carbonate, potassium hydroxide, or sodium hydroxide, can be used.
[0185] 1,3 - Composition comprising a benzodioxole derivative compound, treatment method using the same, and use thereof The present invention provides a pharmaceutical composition comprising a compound according to any one of (1) to (5) above, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof as an active ingredient. The present invention provides a pharmaceutical composition for preventing or treating a disease related to EZH1 (Enhancer of zeste homo 1 og 1) or EZH2 (Enhancer of zeste homo 1 og 2) activity, comprising a compound according to any one of (1) to (5) above, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof as an active ingredient. In the present invention, "prevention" means a compound according to any one of (1) to (5) above, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof; Or it means any act of inhibiting or delaying the onset of a disease by administering a pharmaceutical composition containing it. In the present invention, "treatment" means any act of improving or beneficially changing the symptoms of a subject suspected of having or developing a disease by administering a compound according to any one of (1) to (5) of the present invention, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof; or a pharmaceutical composition containing it. In the present invention, "EZH1 or EZH2 activity-related disease" means a disease that can be prevented or treated by inhibiting the activity of one or more enzymes selected from EZH1 and EZH2. "Activity of one or more enzymes selected from EZH1 and EZH2" means an enzyme activity of EZH1 and / or EZH2 that introduces a methyl group to the 27th lysine of histone H3. In the present invention, the EZH1 or EZH2 activity-related disease may be a solid tumor in which cancer cells grow and form a mass.The above solid cancer may be at least one selected from rhabdoid tumor, melanoma, pancreatic cancer, colorectal cancer, adrenal cancer, prostate cancer, bladder cancer, lung cancer, breast cancer, ovarian cancer, liver cancer, brain cancer, stomach cancer, renal cancer, thyroid cancer, epithelioid sarcoma, and synovial sarcoma. In a specific embodiment of the present invention, the inhibitory activity of the compound according to any one of (1) to (5) of the present invention, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof against EZH1 and / or EZH2 and a tumor proliferation inhibitory activity were confirmed. The pharmaceutical composition of the present invention can inhibit the activity of at least one enzyme selected from EZH1 and EZH2, and thus can be usefully used for the prevention or treatment of various diseases related thereto. The pharmaceutical composition of the present invention may further comprise at least one pharmaceutically acceptable carrier in addition to the compound according to any one of (1) to (5), a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or a solvate thereof.Pharmaceutically acceptable carriers are those commonly used in the art, and specifically, may be, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, glycine, starch, gum tragacanth, gum acacia, calcium phosphate, calcium chloride, sodium chloride, alginic acid, sodium alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidine, polyethylene glycol, cellulose, water, ethanol, syrup, methylcellulose, methyl hydroxybenzonate, propyl hydroxybenzonate, talc, magnesium stearate, magnesium aluminum silicate, silica, orange essence, strawberry essence, vanilla essence, or mineral oil. The pharmaceutical composition of the present invention may further include, in addition to the above components, a binder, an isotonic agent, an adsorbent, a disintegrant, an antioxidant, a lubricant, a filler, a solubilizer, a solubilizing agent, a lubricant, a wetting agent, a sweetener, a flavoring agent, an emulsifier, a suspending agent, a preservative, a dispersing agent, or a stabilizer. In addition, the pharmaceutical composition of the present invention may be formulated in the form of oral dosage forms such as tablets, pills, powders, granules, capsules, suspensions, emulsions, liquids for internal use, emulsions, syrups, external preparations, suppositories, or sterile injections using pharmaceutically acceptable carriers and excipients, and may be manufactured in the form of unit doses or may be manufactured by inserting into multi-dose containers. The formulation may be manufactured by a conventional method used in formulation in the art or by a method described in Remington's Pharmaceutical Science (19. thed., 1995) and can be formulated into various preparations depending on each disease or component. The pharmaceutical composition of the present invention can be administered orally or parenterally depending on the intended method, and is preferably administered orally, but is not limited thereto. Non-limiting examples of dosage forms for oral administration include, but are not limited to, tablets, pills, powders, capsules, syrups, or emulsions. When the pharmaceutical composition of the present invention is in the form of oral administration, pharmaceutically acceptable carriers may include, but are not limited to, cellulose, calcium silicate, corn starch, lactose, sucrose, dextrose, calcium phosphate, stearic acid, magnesium stearate, calcium stearate, gelatin, talc, and the like. Non-limiting examples of dosage forms for parenteral administration include, but are not limited to, injections. When the pharmaceutical composition of the present invention is in the form of parenteral administration, pharmaceutically acceptable carriers may include, but are not limited to, water, saline, aqueous glucose solution, aqueous pseudo-saccharide solution, alcohol, glycol, ether, oil, fatty acid, fatty acid ester, glyceride, etc. The daily dosage of the compound according to any one of (1) to (5) of the present invention, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof may be about 0.1 to 2,000 (mg / day) for an adult weighing 70 kg, but is not limited thereto, and may be administered once or several times a day in divided doses. The dosage may vary depending on the patient's health condition, age, weight, sex, dosage form, and disease severity.The pharmaceutically effective amount and effective dosage of the pharmaceutical composition of the present invention may vary depending on the method of formulation of the pharmaceutical composition, the method of administration, the time of administration, and / or the route of administration, and may vary depending on various factors including the type and degree of the response to be achieved by administration of the pharmaceutical composition, the type, age, body weight, general health condition, symptoms or degree of the disease, sex, diet, excretion, drugs used simultaneously or simultaneously in the subject, other components of the composition, and similar factors well known in the medical field. A person having ordinary skill in the art can easily determine and prescribe an effective dosage for the desired treatment. The pharmaceutical composition of the present invention may be administered once a day or divided into several times. The pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. Taking all of the above factors into consideration, the amount that can obtain the maximum effect with the minimum amount without causing side effects can be administered, and this can be easily determined by a person having ordinary skill in the art to which the present invention pertains. The pharmaceutical composition of the present invention can exhibit excellent effects even when used alone, but can be additionally used in combination with various methods such as hormone therapy and drug therapy to increase therapeutic efficiency. The present invention provides a method for preventing or treating a disease related to EZH1 or EZH2 activity, comprising the step of administering to a subject a compound according to any one of (1) to (5), a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, or a pharmaceutical composition comprising the same. In the present invention, "administration" means introducing a predetermined substance to a subject by an appropriate method.In the present invention, "subject" means all animals, such as rats, mice, livestock, etc., including humans, that have developed or may develop a disease related to EZH1 or EZH2 activity, and specifically, may be mammals including humans, but is not limited thereto. The method for preventing or treating a disease related to EZH1 or EZH2 activity of the present invention may be to administer a therapeutically effective amount of a compound according to any one of (1) to (5), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The "therapeutically effective amount" in the present invention means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment and not causing side effects, and this can be determined by those skilled in the art based on factors including the patient's sex, age, weight, health condition, type of disease, severity, activity of the drug, sensitivity to the drug, administration method, administration time, administration route, excretion rate, treatment period, drugs used in combination or simultaneously, and other factors well known in the medical field. It is preferable that the specific therapeutically effective amount for a specific patient be applied differently depending on various factors including the type and degree of response to be achieved, the specific composition including whether other agents are used in some cases, the patient's age, body weight, general health, sex and diet, the time of administration, the route of administration and the secretion rate of the composition, the treatment period, drugs used together or simultaneously with the specific composition, and similar factors well known in the medical field. The method for preventing or treating a disease related to EZH1 or EZH2 activity of the present invention includes not only treating the disease itself before the onset of symptoms, but also inhibiting or avoiding the symptoms thereof by administering a compound according to any one of the above (1) to (5), a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, or a pharmaceutical composition comprising the same.In the management of a disease, the prophylactic or therapeutic dosage of a particular active ingredient will vary depending on the nature and severity of the disease or condition and the route by which the active ingredient is administered. The dosage and frequency of administration will vary depending on the age, weight, and response of the individual patient. Appropriate dosage regimens can be readily selected by those skilled in the art, taking these factors into account. In addition, the method for preventing or treating a disease associated with EZH1 or EZH2 activity of the present invention may further comprise administering a therapeutically effective amount of an additional active agent that is helpful in the prevention or treatment of the disease, together with the compound according to any one of (1) to (5), a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof. The additional active agent may exhibit a synergistic or additive effect with the compound according to any one of (1) to (5), a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof. The present invention provides a use of a compound according to any one of (1) to (5), a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, or a pharmaceutical composition comprising the same for the prevention or treatment of a disease associated with EZH1 or EZH2 activity. The present invention provides a use of a compound according to any one of (1) to (5), a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, or a pharmaceutical composition comprising the same for the manufacture of a medicament for the prevention or treatment of a disease associated with EZH1 or EZH2 activity. For the manufacture of a medicament, a compound according to any one of (1) to (5) of the present invention, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, or a pharmaceutically acceptable adjuvant, diluent, carrier, etc. may be mixed, and may be manufactured into a composite formulation with other active agents to have a synergistic effect.The matters mentioned in each item of the present invention, namely, 1,3-benzodioxole derivative compound, method for preparing the same, pharmaceutical composition comprising the same, method for treating using the same, and use thereof, apply equally unless they are contradictory to each other.
[0186]
Effect of the invention
[0187]
Mode for carrying out the invention
[0188] <Manufacturing Example> In the following manufacturing examples, the specific rotation was measured using a JASCO P-2000 Digital Polarimeter. Manufacturing Example 1. Synthesis of 2-(trans-4-(dimethylamino)cyclohexyl)-7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide and its hydrochloride salt, (Compound 1 and its hydrochloride salt)
[0189] <Reaction Formula 2>
[0190] [Step 1] Synthesis of methyl 2-(trans-4-aminocyclohexyl)-7-bromo-2,4-dimethylbenzo[d][1,3]dioxole-5-carboxylate hydrochloride To methyl 7-bromo-2-(trans-4-((tert-butoxycarbonyl)amino)cyclohexyl)-2,4-dimethylbenzo[d][l,3]dioxole-5-carboxylate (20 g, 41.3 mmole) was added 1 M aqueous hydrochloric acid solution (80 mL), the temperature was increased, and the mixture was stirred. Upon completion of the reaction, the internal temperature was cooled to room temperature, and isopropyl alcohol (80 mL) was added dropwise, followed by stirring. The resulting crystals were filtered and dried at an internal temperature of 60°C to obtain the title compound (17.2 g). [Step 2] Synthesis of methyl 7-bromo-2-(trans-4-(dimethylamino)cyclohexyl)-2,4-dimethylbenzo[d][1,3]dioxole-5-carboxylate Methanol (173 mL) was added to the compound (17 g, 41 mmole) obtained in the above [Step 1] and stirred at room temperature. Dimethylamine (23 mL) was added and stirred. A 35% formaldehyde aqueous solution (12 mL) was slowly added and stirred. After cooling, sodium triacetoxyborohydride (35 g) was slowly added and stirred at room temperature. Upon completion of the reaction, dichloromethane (173 mL) was added and washed with an aqueous sodium bicarbonate solution (173 mL). Afterwards, magnesium sulfate was added, filtered, and concentrated to obtain the title compound (16.8 g).
[0191] [Step 3] Methyl 2-(trans-4-(dimethylamino)cyclohexyl)-7-(6-
[0192] Synthesis of ((2S, 6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethylbenzo[d][1,3]dioxole-5-carboxylate Dioxane (160 mL) and purified water (80 mL) were added to the compound (16 g, 39 mmole) obtained in the above [Step 2]. Then, (2S, 6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine (16 g) was added, tetrakis(triphenylphosphine)palladium (4.5 g) was added, and sodium carbonate (12.3 g) was added, and the temperature was increased and stirred. Upon completion of the reaction, hexane was added, the precipitated solid was filtered using silica / Celite, and the filtrate was washed with purified water (160 mL). Magnesium sulfate was added, filtered, and concentrated to obtain the title compound (20 g).
[0193] [Step 4] Synthesis of 2-(trans-4-(dimethylamino)cyclohexyl)-7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethylbenzo[bi[1,3]dioxole-5-carboxylic acid Tetrahydrofuran (160 mL) and methanol (80 mL) were added to the compound (20 g, 38.2 mmole) obtained in the above [Step 3]. 2N aqueous sodium hydroxide solution (76 mL) was added, the temperature was increased, and the mixture was stirred. Upon completion of the reaction, 2N aqueous hydrochloric acid solution (57 mL) was added, and the mixture was concentrated. The resulting crystals were filtered, and ethyl acetate (400 mL) was added. Afterwards, purified water (200 mL) was added to wash, magnesium sulfate was added, filtered, and concentrated to obtain the title compound (19.2 g).
[0194] [Step 5] Synthesis of pentafluorophenyl 2-(trans-4-(dimethylamino)cyclohexyl)-7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethylbenzo[d][1,3]dioxole-5-carboxylate Dimethylformamide (95 mL) was added to the compound (19 g, 37.3 mmole) obtained in the above [Step 4], and triethylamine (21 mL) was added. Then, pentafluorophenyl trifluoroacetate (10 mL) was added dropwise and stirred at room temperature. When the reaction was completed, the next reaction was performed.
[0195] [Step 6] Synthesis of 2-(trans-4-(dimethylamino)cyclohexyl)-7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide,
[0196] (Compound 1)
[0197] Triethylamine (16 mL) was added to the reaction solution reacted in the above [Step 5]. Then, 3-(aminomethyl)-6-methyl-4-(methylthio)pyridin-2(1H)-one hydrochloride (9.2 g) was added and stirred at an internal temperature of 50°C. Upon completion of the reaction, the reactant was added dropwise to purified water (1,900 mL), and the resulting solid was filtered. The solid was dissolved in methylene chloride (380 mL), the aqueous layer was separated, magnesium sulfate was added, and the mixture was filtered and concentrated to obtain the title compound (25 g). P NMR (Chloroform-d): 8.53 (d, 1H), 7.68 (d, 1H), 7.20 (t, 1H), 7.05 (s, 1H), 6.53 (d, 1H), 5.91 (s, 1H), 4.58 (d, 2H), 3.97 (d, 2H), 3.66 (m, 2H), 2.47 (t, 2H), 2.42 (s, 3H), 2.25 (d, 9H), 2.13 (m, 4H), 1.95 (m, 4H), 1.78 (t, 1H), 1.54 (s, 3H), 1.22 (m, 10H) .
[0198] LC-MS (ESI, m / z) = 676.4 (M+H+)
[0199] [Step 7] Methyl 2-(trans-4-(dimethylamino)cyclohexyl)-7-(6-
[0200] Synthesis of ((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide hydrochloride, (hydrochloride of compound 1) 1M hydrochloric acid aqueous solution (130 mL) was added to the compound (25 g, 37 mmole) obtained in the above [Step 6], and the mixture was stirred while raising the temperature. Upon completion of the reaction, the mixture was concentrated, dissolved in methanol (50 mL), slowly added to ethyl acetate (200 mL), and stirred. The mixture was then filtered and dried at an internal temperature of 60°C to obtain the title compound (24 g). Manufacturing Example 2. 2-(trans-4-(dimethylamino)cyclohexyl)-7-(2-((2S,6R)-
[0201] 2,6-dimethylaminomorpholino)pyrimidin-5-yl)-2,4-dimethyl- N-((6-methyl- 4-
[0202] (Methylthio)-2-oxo-1,2 ■dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide synthesis, (compound 2) The same reaction as in Preparation Example 1 was performed except that (2S,6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine was used instead of (2S,6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)morpholine in [Step 3] of Preparation Example 1, to obtain the title compound (30 mg). P NMR (Chloroform-d): 8.56 (s, 2H), 7.10 (s, 1H), 7.00 (s, 1H), 5.92 (s, 1H), 4.57 (d, 2H), 4.56 (d, 2H), 3.58 (s, 2H), 2.58 (t, 2H) , 2.41 (s, 3H), 2.26 (s, 9H), 1.94 (s, 4H) , 1.78 (m, 1H) , 1.54 (s, 3H) , 1.19 (s, 9H) .
[0203] LC-MS (ESI, m / z) = 677.4 (M+H + ) Manufacturing Example 3. 7-(6-(4, 4-difluoropiperidin-1-yl)pyridin-3-yl)-2-(trans-
[0204] Synthesis of 4-(dimethylamino)cyclohexyl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[bi[1,3]dioxole-5-carboxamide,
[0205] (Compound 3) The same reaction as in Preparation Example 1 was carried out except that 2-(4,4-difluoropiperidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine was used instead of (2S,6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine in [Step 3] of Preparation Example 1, to obtain the title compound (25 mg). P NMR (020): 8.23 (s, 1H), 8.11 (s, 1H), 7.29 (d, 1H), 7.01 (s, 1H), 6.25 (s, 1H), 4.31 (s, 2H), 3.76 (m, 4H), 3.09 (m, 1H) , 2.71 (s, 3H) , 2.38 (s, 3H), 2.31 (m, 7H) , 2.12 (m, 8H) , 2.03 (s, 1H) , 1.65 (s, 3H) , 1.58 (m, 2H), 1.42 (m, 2H).
[0206] LC-MS (ESI, m / z) = 682.4 (M+H + ) Manufacturing example 4. Synthesis of 2-(trans-4-(dimethylamino)cyclohexyl)- 2, 4 ■dimethyl- N-((6-methyl-4-(methylthio)- 2 -oxo- 1 , 2 -dihydropyridin- 3 -yl)methyl)- 7-(2-(piperidin- 1-yl)pyrimidin- 5 -yl)benzo [d][l, 3]dioxole- 5 -carboxamide, (Compound 4)
[0207] In [Step 3] of Manufacturing Example 1, (2S,6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine was replaced with 2-(piperidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine, and the same reaction as in Manufacturing Example 1 was performed to obtain the title compound (26 mg). P NMR (Chloroform-d): 8.55 (s, 2H), 7.19 (t, 1H), 7.00 (s, 1H), 5.92
[0208] (s, 1H), 4.58 (d, 2H), 3.73 (t, 4H), 2.42 (s, 3H), 2.26 (d, 9H), 2.17 (s, 4)
[0209] H), 1.95 (d, 4H), 1.79 (t, 1H), 1.64 (d, 2H), 1.54 (s, 7H), 1.21 (m, 4H).
[0210] LC-MS (ESI, m / z) = 647.4 (M+H + ) Manufacturing Example 5. Synthesis of 2-(trans-4-(dimethylamino)cyclohexyl)- 2, 4 ■dimethyl- N-((6-methyl-4-(methylthio)- 2 -oxo- 1, 2 -dihydropyridin- 3 -yl)methyl)-7-(2-(pyrrolidin- 1-yl)pyrimidin- 5 -yl)benzo [d][l, 3]dioxole- 5 -carboxamide, (Compound 5) The same reaction as in Manufacturing Example 1 was performed except that 2-(pyrrolidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine was used instead of (2S,6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine in [Step 3] of Manufacturing Example 1, to obtain the title compound (70 mg). P NMR (Methanol-d3): 8.85 (s, 1H), 7.23 (s, 1H), 6.36 (m, 1H), 4.51 (s, 2H), 3.70 (s 3H), 3.20 (s, 1H), 2.75 (s, 6H), 2.54 (m, 4H) , 2.31 (s, 7H) , 2.10 (m, 8H), 2.00 (m, 1H) , 1.65 (s, 3H) , 1.60 (m, 2H) , 1.56 (m, 2H) .
[0211] LC-MS (ESI, m / z) = 633.4 (M+H + ) Manufacturing Example 6. 2-(trans-4-(dimethylamino)cyclohexyl)- 2, 4 ■Dimethyl- N- ((6-methyl- 4-(methylthio)- 2 -oxo- 1,2 -dihydropyridin- 3 -yl)methyl)- 7-(4-
[0212] Synthesis of (morpholinomethyl)phenyl)benzo[d][l,3]dioxole-5-carboxamide, (compound 6) The same reaction as in Manufacturing Example 1 was performed except that 4-(4-(4, 4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)morpholine was used instead of (2S,6R)-2,6-dimethyl-4-(5-(4, 4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine in [Step 3] of Manufacturing Example 1, to obtain the title compound (78 mg). P NMR (Chloroform-d): 7.53(m, 2H), 7.27 (m, 2H), 7.25 (s, 1H), 5.90 (s, 1H), 4.64 (m 2H), 3.80 (6m 6H), 3.04 (s, 1H), 2.45 (s, 3H) , 2.36 (s, 3H) ,
[0213] 2.33 (s, 8H), 2.00 (m, 7H), 1.64 (m, 5H), 1.55 (m, 5H). LC-MS (ESI, m / z) = 661.4 (M+H + ) Manufacturing example 7. Synthesis of 2-(trans-4-(dimethylamino)cyclohexyl)-2,4-dimethyl-7-(1-methyl-1H-indole-5-yl)-N-((6-methyl-4-(methylthio)-2-oxo-1,2 ■dihydropyridin-3-yl)methyl)benzo[d][l,3]dioxole-5-carboxamide, (Compound 7) The same reaction as in Manufacturing Example 1 was performed except that 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)indole was used instead of (2S,6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine in [Step 3] of Manufacturing Example 1, to obtain the title compound (67 mg). P NMR (Methanol-d3): 7.85 (s, 1H), 7.32 (d, 1H), 7.18 (d, 1H), 7.12 (s, 1H), 7.11 (d, 1H), 6.41 (d, 1H), 6.20 (s, 1H), 4.51 (s, 2H) , 3.75 (s, 3H), 2.47 (s, 3H), 2.24 (m, 12H) , 1.98 (dd, 4H) , 1.80 (t, 1H) , 1.58 (s, 3H) , 1.26 (m, 5H).
[0214] LC-MS (ESI, m / z) = 615.4 (M+H + ) Manufacturing Example 8. 7-(2-(4, 4 ■Difluoropiperidin-1-yl)pyrimidin-5-yl)-2-
[0215] Synthesis of (trans-4-(dimethylamino)cyclohexyl)-2,4-dimethyl- N-((6-methyl-4-(methylthio) ~2~ oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, (Compound 8) In [Step 3] of Manufacturing Example 1, (2S,6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine was replaced with 2-(4,4-difluoropiperidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine, and the same reaction as in Manufacturing Example 1 was carried out, to obtain the title compound (99 mg). P NMR (Chloroform-d): 8.59 (s, 2H), 7.17 (t, 1H), 7.04 (s, 1H),
[0216] 5.92(s, 1H), 4.57(d, 2H), 3.91(t, 4H), 2.42 (s, 3H), 2.28 (m, 9H), 2.17 (s,
[0217] 4H), 1.92 (m, 8H), 1.78 (t, 1H), 1.55 (s, 3H), 1.21 (m, 4H).
[0218] LC-MS (ESI, m / z) = 683.3 (M+H + ) Manufacturing Example 9. Synthesis of 2-(trans-4-(dimethylamino)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(4-morpholinophenyl)benzo[d][l,3]dioxole-5-carboxamide, (Compound 9)
[0219] The same reaction as in Manufacturing Example 1 was performed except that 4-(4-(4, 4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)morpholine was used instead of (2S,6R)-2,6-dimethyl-4-(5-(4, 4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine in [Step 3] of Manufacturing Example 1, to obtain the title compound (56 mg). P NMR (Chloroform-d): 7.55 (m, 2H), 7.53 (t, 1H), 7.25 (s, 1H), 6.79 (d, 2H), 5.93 (s, 3H), 4.62 (d, 2H), 3.82 (m, 4H), 3.08 (m, 4H) , 2.45 (s, 3H), 2.32 (m, 10H) , 2.14 (s, 3H) , 2.00 (m, 4H) , 1.99 (m, 1H) , 1.57 (s, 3H), 1.26 (m, 4H).
[0220] LC-MS (ESI, m / z) = 647.4 (M+H + ) Manufacturing Example 10. Synthesis of 2-(trans-4-(dimethylamino)cyclohexyl)-7-(4-fluorophenyl)-2,4 ■dimethyl-N-((6 ■methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo [bi[1,3]dioxole-5-carboxamide,
[0221] (Compound 10) The same reaction as in Manufacturing Example 1 was performed except that 2-(4-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolan was used instead of (2S,6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine in [Step 3] of Manufacturing Example 1, to obtain the title compound (78 mg). P NMR (Chloroform-d): 7.58 (m, 2H), 7.19 (t, 1H), 7.08 (s, 1H), 7.00 (t, 2H), 5.92 (s, 1H), 4.60 (d, 2H), 2.44 (s, 3H), 2.31 (s, 3H) , 2.25 (m, 10H), 2.09 (m, 4H), 1.96 (m, 4H) , 1.80 (t, 1H) , 1.57 (s, 3H) , 1.23 (m, 4H) .
[0222] LC-MS (ESI, m / z) = 580.3 (M+H + ) Manufacturing Example 11. Synthesis of 2-(trans-4-(dimethylamino)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(thiophene ~3~ yl)benzo[bi[1,3]dioxole-5-carboxamide, (Compound 11) In [Step 3] of Manufacturing Example 1, (2S,6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine was replaced with 4,4,5,5-tetramethyl-2-(thiophene-3-yl)-1,3,2-dioxaborolan, and the same reaction as in Manufacturing Example 1 was performed to obtain the title compound (30 mg). P NMR (Chloroform-d): 7.59 (d, 1H), 7.39 (m, 1H), 7.25 (m, 1H), 7.23
[0223] (m, 1H), 7.19 (s, 1H), 5.92 (s, 1H) , 4.60 (d, 2H) , 2.43 (s, 3H) , 2.29 (s, 3H), 2.24 (s, 6H), 2.14 (m, 4H) , 1.97 (t, 4H) , 1.80 (t, 1H) , 1.58 (s, 3H) ,
[0224] 1.23 (m, 4H).
[0225] LC-MS (ESI, m / z) = 568.3 (M+H + ) Manufacturing Example 12. 2-(trans-4-(dimethylamino)cyclohexyl)-7-(5-fluoro-2-methoxyphenyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridine-
[0226] Synthesis of 3-methylbenzo[bi[1,3]dioxole-5-carboxamide, (Compound 12) The same reaction as in Manufacturing Example 1 was performed except that 2-(5-fluoro-2-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine was used instead of (2S,6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine in [Step 3] of Manufacturing Example 1, to obtain the title compound (35 mg). P NMR (Chloroform-d): 7.02 (m, 1H), 6.98 (m, 2H), 6.92 (m, 1H), 6.79 (m, 1H), 5.91 (s, 1H), 4.58 (d, 2H), 3.68 (s, 3H), 2.44 (s, 3H), 2.32 (s, 2H), 2.25 (s, 6H), 2.13 (s, 4H), 1.94 (m, 3H), 1.79 (t, 1H), 1.53 (s, 3H), 1.20 (m, 4H).
[0227] LC-MS (ESI, m / z) = 610.3 (M+H +) Manufacturing Example 13. Synthesis of 2-(trans-4-(dimethylamino)cyclohexyl)-7-(3,5-dimethylisoxazol-4-yl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[bi[1,3]dioxole-5-carboxamide,
[0228] (Compound 13) The same reaction as in Manufacturing Example 1 was performed except that 3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole was used instead of (2S,6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine in [Step 3] of Manufacturing Example 1, to obtain the title compound (80 mg). P NMR (Chloroform-d): 7.01 (m, 1H), 6.74 (s, 1H), 5.97 (s, 1H), 4.57 (m, 2H), 2.45 (s, 3H), 2.28 (m, 5H), 2.25 (s, 6H), 2.19 (s, 3H) , 2.16 (s, 2H), 2.12 (m, 1H), 1.92 (d, 4H) , 1.76 (t, 1H) , 1.51 (s, 2H) , 1.18 (m, 4H) .
[0229] LC-MS (ESI, m / z) = 581.4 (M+H + ) Manufacturing Example 14. 7-(2, 6-difluoropyridine-3-yl)-2-(trans ~4~
[0230] (Dimethylamino)cyclohexyl)- 2, 4 ■Dimethyl- N- ((6 ■Methyl- 4- (methylthio)- 2 -oxo- 1,2 -dihydropyridin- 3 -yl)methyl)benzo [d][ 1,3]dioxole- 5 -synthesis of carboxamide,
[0231] (Compound 14) The same reaction as in Preparation Example 1 was performed except that 2,6-difluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine was used instead of (2S,6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine in [Step 3] of Preparation Example 1, to obtain the title compound (63 mg). P NMR (Methanol-d3): 8.15 (s, 1H), 7.05 (s, 2H), 6.42 (s, 1H), 4.52 (s, 2H), 2.82 (s, 1H), 2.32 (s, 6H), 2.26 (s, 3H), 2.13 (m, 5H) , 2.10 (m, 5H), 1.61 (s, 6H), 1.60 (s, 3H) , 1.55 (m, 2H) , 1.53 (m, 4H) .
[0232] LC-MS (ESI, m / z) = 599.0 (M+H + ) Manufacturing Example 15. Manufacturing of 7-(2-(2-oxa- 7-azaspiro [3.5]nonane- 7-yl)pyrimidin-5-yl)-2-(trans- 4-(dimethylamino)cyclohexyl)- 2,4-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2 ■dihydropyridin- 3-yl)methyl)benzo [ d] [ 1,3 ]dioxole- 5-carboxamide, (Compound 15) The same reaction as in Preparation Example 1 was performed except that 7-(5-(4, 4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)-2-oxa-7-azaspiro[3.5]nonane was used instead of (2S,6R)-2,6-dimethyl-4-(5-(4, 4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine in [Step 3] of Preparation Example 1, to obtain the title compound (63 mg). P NMR (Chloroform-d): 8.58 (s, 1H), 7.11 (m, 1H), 7.04 (d, 1H), 5.98 s, 1H), 4.61 (dd, 2H), 4.47 (s, 2H), 3.75 (s, 2H), 2.45 (m, 8H), 2.36 (s,
[0233] 3H), 2.35 (s, 3H), 2.29 (m, 5H), 1.94 (m, 2H), 1.90 (m, 2H), 1.80 (s, 1H),
[0234] 1.56 (m, 3H), 1.30 (m, 5H).
[0235] LC-MS (ESI, m / z) = 689.4 (M+H+) Preparation Example 16. 2-(trans-4-(dimethylamino)cyclohexyl)- 7-(6-(3, 5-dimethylpiperidin- 1-yl)pyridin- 3 -yl)- 2 , 4 ■Dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo-
[0236] Synthesis of 1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide,
[0237] (Compound 16) In [Step 3] of Manufacturing Example 1, the same reaction as Manufacturing Example 1 was performed except that 2-(3, 5-dimethylpiperidin-1-yl)-5-(4, 4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl)pyridine was used instead of (2S, 6R)-2, 6-dimethyl-4-(5-(4, 4,5,5-tetramethyl-1, 3, 2-dioxaborolan-2-yl)pyridin-2-yl)morpholine, to obtain the title compound (30 mg). P NMR (Chloroform-d): 8.52 (s, 1H), 7.67 (s, 1H), 7.25 (m, 1H), 7.06 s, 1H), 6.62 (m, 1H), 5.94 (s, 1H), 4.62 (d, 2H), 4.24 (d, 2H), 2.45 (s,
[0238] 3H), 2.39 (s, 6H), 2.30 (m, 5H) , 2.30 (s, 3H), 2.29 (m, 4H), 2.17 (m, 2H) ,
[0239] 1.57 (m, 2H), 1.56 (m, 3H), 1.28 (m, 4H), 0.94 (m, 6H).
[0240] LC-MS (ESI, m / z) = 675.1 (M+H+) Preparation Example 17. 2-(trans-4-(dimethylamino)cyclohexyl)- 2, 4 -dimethyl- N-
[0241] Synthesis of ((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(6-thiomorpholinopyridin-3-yl)benzo[d][l,3]dioxole-5-carboxamide,
[0242] (Compound 17) In [Step 3] of Manufacturing Example 1, the same reaction as Manufacturing Example 1 was performed except that 4-(5-(4, 4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)thiomorpholine was used instead of (2S,6R)-2,6-dimethyl-4-(5-(4, 4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine, to obtain the title compound (20 mg).
[0243] X H NMR (Chloroform-d): 8.52(s, 1H), 7.70(d, 1H), 7.27(d, 1H), 6.52(d,
[0244] 1H), 5.94(s, 1H), 4.61(m, 2H), 3.91(m, 4H), 2.61(s, 5H), 2.45(s, 3H), 2.39(m,
[0245] 6H), 2.31(s, 3H), 2.16(s, 3H), 2.15(m, 4H), 2.04(m, 1H), 2.01(s, 3H), 1.29(s,
[0246] 4H).
[0247] LC-MS (ESI, m / z) = 665.0 (M+H+) Preparation Example 18. 2-(trans-4-(dimethylamino)cyclohexyl)-7-(furan-3-yl)-
[0248] Synthesis of 2,4-dimethyl- N- ((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3-yl)methyl)benzo[bi[1,3]dioxole- 5-carboxamide, (Compound 18) The same reaction as in Manufacturing Example 1 was performed except that 2-(furan-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine was used instead of (2S,6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine in [Step 3] of Manufacturing Example 1, to obtain the title compound (73 mg). P NMR (Chloroform-d): 7.81 (s, 1H), 7.36 (t, 1H), 7.19 (t, 1H), 7.06 (s, 1H), 6.66 (s, 1H), 5.95 (s, 1H), 4.59 (m, 2H), 2.44 (s, 3H) , 2.24 (m, 9H), 2.18 (m, 4H), 1.95 (m, 4H) , 1.80 (t, 1H) , 1.58 (s, 3H) , 1.21 (m, 4H) .
[0249] LC-MS (ESI, m / z) = 552.3 (M+H + ) Manufacturing Example 19. 7-(5-chlorothiophene-2-yl)-2-(trans-4-
[0250] (Dimethylamino)cyclohexyl)- 2, 4 ■Synthesis of dimethyl- N- ((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3-yl)methyl)benzo[d][ 1,3]dioxole- 5 -carboxamide,
[0251] (Compound 19) In [Step 3] of Manufacturing Example 1, (2S,6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine was replaced with 2-(5-chlorothiophene-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolan, and the same reaction as in Manufacturing Example 1 was carried out, to obtain the title compound (93 mg). P NMR (Chloroform-d): 7.25 (m, 1H), 7.11 (d, 1H), 7.04 (s, 1H), 6.76
[0252] (d, 1H), 5.95 (s, 1H), 4.57 (t, 3H), 2.43 (t, 4H), 2.35 (s, 1H), 2.26 (m,
[0253] 14H), 2.19 (m, 7H), 1.98 (m, 5H) , 1.79 (t, 1H) , 1.59 (m, 5H) , 1.21 (m, 6H)
[0254] LC-MS (ESI, m / z) = 603.3 (M+H + ) Manufacturing Example 20. Synthesis of 7-(6-((2S,6R)- 2, 6 ■dimethylmorpholino)pyridin- 3 -yl)- 2,4-dimethyl- 2-(trans- 4-(methyl(2, 2, 2 -trifluoroethyl)amino)cyclohexyl)- N-((6-methyl- 4-(methylthio)- 2 -oxo- 1 ,2 -dihydropyridin ~3~ yl)methyl)benzo [d] [1,3]dioxole- 5 -carboxamide and its hydrochloride salt, (Compound 20 and its hydrochloride salt)
[0255] <Reaction Formula 3>
[0256]
[0257] [Step 1] Synthesis of methyl 7-bromo-2-(trans-4-(tert-butoxycarbonyl)(methyl)amino)cyclohexyl)- 2,4-dimethylbenzo[d][1,3]dioxole-5- larboxylate To methyl 7-bromo-2-(trans-4((tert-butoxycarbonyl)amino)cyclohexyl)- 2,4-dimethylbenzo[d][l,3]dioxole-5-carboxylate (15 g, 30.97 mmole) was added dimethylformamide (75 mL), followed by methyl iodide (16 mL), and the internal temperature was cooled to -5 °C or lower. Sodium hydride (3.372 g) was added, and the mixture was heated to room temperature and stirred. Upon completion of the reaction, ethyl acetate (300 mL) was added, and purified water (300 mL) was added to wash. Magnesium sulfate was added, filtered, and concentrated to obtain the title compound (16 g).
[0258] [Step 2] Synthesis of methyl-2-(trans-4-((tert-butoxycarbonyl)(methyl)amino)cyclohexyl)-7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethoxybenzo[bi[1,3]dioxole-5-carboxylate] Dioxane (150 mL) and purified water (75 mL) were added to the compound (15 g, 30.10 mmole) obtained in the above [Step 1]. Then, (2S,6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine (12.8 g) was added, followed by tetrakis(triphenylphosphine)palladium (3.58 g), sodium carbonate (13.1 g), and the temperature was raised while stirring. Upon completion of the reaction, hexane was added, the precipitated solid was filtered using silica / Celite, and the filtrate was washed with purified water (450 mL). Magnesium sulfate was added, filtered, and concentrated to obtain the title compound (18 g).
[0259] [Step 3] Synthesis of 2-(trans-4-((tert-butoxycarbonyl)(methyl)amino)cyclohexyl)-7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethylbenzo[bi[1,3]dioxole-5-carboxylic acid] Tetrahydrofuran (150 mL) and methanol (75 mL) were added to the compound (18 g, 29.6 mmole) obtained in the above [Step 2]. 2N sodium hydroxide aqueous solution (74 mL) was added, the temperature was increased, and the mixture was stirred. When the reaction was complete, 2N hydrochloric acid aqueous solution (74 mL) was added, and ethyl acetate (350 mL) was added. Afterwards, purified water (350 mL) was added to wash, magnesium sulfate was added, filtered, and concentrated to obtain the title compound (15.6 g).
[0260] [Step 4] Synthesis of pentafluorophenyl-2-(trans-4-((tert-butoxycarbonyl)(methyl)amino)cyclohexyl)-7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethylbenzo[1,3]dioxole-5-carboxylate Dimethylformamide (80 mL) was added to the compound obtained in [Step 3] (15.6 g, 26.3 mmole), and triethylamine (15 mL) was added. Then, pentafluorophenyl trifluoroacetate (7.1 mL) was added dropwise, and the mixture was stirred at room temperature. When the reaction was completed, the next reaction was performed.
[0261] [Step 5] Tert-Butyl (trans- 4- (7- (6- ((2S,6R)- 2,6-dimethylmorpholino)pyridin- 3 -yl )-2 , 4 -dimethyl- 5- ( ( (6 -methyl- 4- (methylthio)- 2 -oxo-
[0262] Synthesis of 1, 2-dihydropyridin-3-yl)methyl)carbamyl)benzo[d][1,3]dioxol-2-yl)cyclohexyl)(methyl)carbamate Triethylamine (11 mL) was added to the reaction solution reacted in the above [Step 4]. Then, 3-(aminomethyl)-6-methyl-4-(methylthio)pyridin-2(1H)-one hydrochloride (7.6 g) was added and stirred at an internal temperature of 50°C. Upon completion of the reaction, the reactant was added dropwise to purified water (936 mL) and the resulting solid was filtered. The solid was dissolved in methylene chloride (312 mL) to separate the aqueous layer, magnesium sulfate was added, filtered, and concentrated to obtain the title compound (20 g).
[0263] [Step 6] Synthesis of 7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl-methyl-2-(trans-4-(methylamino)cyclohexyl)benzo[d][1,3]dioxole-5-carboxylate hydrochloride To the compound obtained in the above [Step 5] (20 g, 26.2 mmole) was added a 1M aqueous hydrochloric acid solution (lOOmL), and the mixture was stirred while heating. Upon completion of the reaction, it was concentrated, dissolved in methanol (lOOmL), and slowly added dropwise to ethyl acetate (400 mL). Afterwards, it was filtered and dried at an internal temperature of 60°C to obtain the title compound. (21.6g) was obtained.
[0264] [Step 7] Synthesis of 7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethyl-2-(trans-4-(methyl (2,2,2-trifluoroethyl)amino)cyclohexyl)-N-((6-methyl—4-(methylthio)—2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, (Compound 20) Acetonitrile (238 mL) was added to the compound obtained in the above [Step 6] (21.6 g, 29.4 mmole), and sodium bicarbonate (20 g) was added. 2, 2, 2-trifluoroethyl trifluoromethanesulfonate (10.6 mL) was added dropwise, the temperature was raised, and the mixture was stirred. After the reaction was completed, the mixture was concentrated, ethyl acetate (432 mL) was added, and purified water (432 mL) was added and washed. Magnesium sulfate was added, filtered, and concentrated. Afterwards, the mixture was dissolved in isopropyl alcohol (130 mL), hexane (151 mL) was added dropwise, and the resulting crystals were filtered and dried at an internal temperature of 60 °C to obtain the title compound (21 g). P NMR (Chloroform-d): 8.54 (d, 1H), 7.70 (d, 1H), 7.22 (t, 1H), 7.07 (s, 1H), 6.56 (d, 1H), 5.91 (s, 1H), 4.60 (d, 2H), 4.01 (d, 2H) , 3.67 (m, 2H), 2.95 (m, 2H) , 2.51 (m, 2H) , 2.41 (m. 8H) , 2.30 (s, 3H) , 2.15 (s, 3H) , 1.99 (m, 2H), 1.88 (m, 2H) , 1.78 (m, 1H) , 1.56 (s, 3H) , 1.25 (m, 12H) .
[0265] LC-MS (ESI, m / z) = 745.4 (M+H + )
[0266] [Step 8] Synthesis of 7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethyl-2-(trans-4-(methyl (2,2,2-trifluoroethyl)amino)cyclohexyl)-N-((6-methyl— 4-(methylthio)— 2 -oxo- 1 , 2 -dihydropyridin- 3-yl)methyl)benzo[d][1,3]dioxole- 5 -carboxamide hydrochloride, (hydrochloride of Compound 20) 1M hydrochloric acid aqueous solution (105 mL) was added to the compound (21 g, 28.2 mmole) obtained in the above [Step ', and the temperature was increased and stirred. The internal temperature was cooled to room temperature, and isopropyl alcohol (105 mL) was added dropwise and stirred. The resulting crystals were filtered and dried at an internal temperature of 60°C to obtain the title compound (20 g). Manufacturing Example 21. Synthesis of 2, 4-dimethyl-2-(trans-4-(methyl (2,2,2-trifluoroethyl)amino)cyclohexyl)-N-((6 ■methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(2-(piperidin-1-yl)pyrimidin ~5~ yl)benzo [bi [1,3]dioxole-5-carboxamide, (Compound 21) The same reaction as in Preparation Example 20 was performed except that 2-(piperidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine was used instead of (2S,6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine in [Step 2] of Preparation Example 20, to obtain the title compound (78 mg). P NMR (DMS0-d6): 11.50 (s, 1H), 8.62 (d, 2H), 7.91 (m, 1H), 7.05 (s, 1H), 6.05 (s, 1H), 4.27 (m, 2H), 3.74 (m, 4H), 3.06 (m, 2H) , 2.47 (m, 4H) , 2.29 (s, 3H), 2.17 (m, 6H) , 1.85 (m. 3H) , 1.80 (s, 2H) , 1.60 (s, 2H) , 1.55 (s, 3H), 1.48 (m, 4H) , 1.17 (m, 4H) .
[0267] LC-MS (ESI, m / z) = 716.3 (M+H + ) Manufacturing Example 22. 7-(2-(dimethylamino)pyrimidin-5-yl)- 2, 4-dimethyl- 2-(trans-
[0268] 4-(methyl(2,2,2-trifluoroethyl)amino)cyclohexyl)- N-((6-methyl ~4~
[0269] (Methylthio)-2-oxo-1,2 ■dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide synthesis, (Compound 22) In [Step 2] of Manufacturing Example 20, the same reaction as Manufacturing Example 20 was performed except that N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine was used instead of (2S,6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine, to obtain the title compound (66 mg). iH NMR (DMS0-d6): 11.50 (s, 1H), 8.65 (d, 2H), 7.91 (m, 1H), 7.05 (s, 1H), 6.05 (s, IH), 3.08 (s, 6H), 3.06 (m, 2H), 2.46 (m, 4H) , 2.28 (s, 2H) , 2.17 (s, 3H), 2.13 (s, 3H) , 1.85 (m. 3H) , 1.80 (s, 2H) , 1.55 (s, 3H) , 1.18 (m, 4H) .
[0270] LC-MS (ESI, m / z) = 625.3 (M+H + ) Manufacturing Example 23. Synthesis of 7-(2-((2S,6R)-2,6-dimethylmorpholino)pyrimidin-5-yl)-2,4-dimethyl-2-(trans-4-(methyl (2,2,2-trifluoroethyl)amino)cyclohexyl)-N-((6-methyl-4-(methylthio)-2-oxo-1,2 ■dihydropyridin-3-yl)methyl)benzo[d][l,3]dioxole-5-carboxamide, (Compound 23) The same reaction as in Preparation Example 20 was performed except that (2S,6R)-2,6-dimethyl-4-(5-(4, 4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine was used instead of (2S,6R)-2,6-dimethyl— 4-(5-(4, 4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)morpholine in [Step 2] of Preparation Example 20, to obtain the title compound (50 mg). Blood NMR (Chloroform-d): 8.60 (s, 2H), 8.41(s, IH), 7.08 (s, IH), 7.03
[0271] (s, IH), 5.95 (s, IH), 4.60 (m, 2H), 4.54 (m, 3H), 3.63 (m, 3H), 2.92 (m, 2H), 2.62 (m, 3H), 2.44 (m, 3H), 2.43 (m, 7H), 2.29 (s, 3H) , 2.21 (m, 4H) ,
[0272] 1.80 (m, 1H), 1.55 (s, 3H), 1.20 (m, 7H).
[0273] LC-MS (ESI, m / z) = 745.4 (M+H+) Preparation Example 24. 7-(6-((2S , 6R)- 2 , 6 ■Dimethylmorpholino)pyridin- 3 -yl)-2 -
[0274] (trans-4-((2-methoxyethyl)(methyl)amino)cyclohexyl)- 2,4-dimethyl- N-((6-methyl-
[0275] Synthesis of 4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, (Compound 24) The same reaction as in Manufacturing Example 20 was performed except that 1-bromo-2-methoxyethane was used instead of 2,2,2-trifluoroethyl trifluoromethanesulfonate in step 20, to obtain the title compound (48 mg). P NMR (Chloroform-d): 8.50 (s, 1H), 7.72 (d, 1H), 7.15 (m, 1H), 7.07 s, 1H), 6.59 (d, 1H), 5.96 s, 1H), 4.62 (d, 2H), 4.04 (d, 2H), 3.70 (m,
[0276] 2H), 3.68 (t, 2H), 3.49 (s, 3H), 2.53 (s, 2H), 2.51 s, 3H), 2.45 (s, 3H),
[0277] 2.37 (s, 3H), 2.30 (s, 3H), 2.23 (m, 4H), 2.19 (m, 1H), 1.58 s, 3H), 1.26
[0278] (m, 10H).
[0279] LC-MS (ESI, m / z) = 720.5 (M+H + ) Manufacturing Example 25. 7-(2-((2S,6R)-2, 6-dimethylmorsolino)pyrimidin-5-yl)-2-
[0280] (trans-4-((2-methoxyethyl)(methyl)amino)cyclohexyl)- 2,4-dimethyl- N-((6-methyl-
[0281] Synthesis of 4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[bi[1,3]dioxole-5-carboxamide, (Compound 25) In [Step 2] of Manufacturing Example 20, (2S,6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine was used instead of (2S,6R)-2,6-dimethyl— 4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)morpholine, and in [Step 2], 1-bromo-2-methoxyethane was used instead of 2,2,2-trifluoroethyl trifluoromethanesulfonate, and the same reaction as in Manufacturing Example 20 was performed to obtain the title compound (27 mg). P NMR (DMS0-d6): 11.49 (s, 1H), 8.65 (s, 2H), 7.91 (t, 1H), 7.05 (s, 1H), 6.05 (s, 1H), 4.51 (d, 1H), 4.27 (d, 2H), 3.52 (m, 2H) , 3.30 (s, 2H) , 3.29 (s, 3H), 2.47 (m, 6H) , 2.46 (s, 1H) , 2.45 (s, 6H) , 2.40 (m, 2H) , 2.17 (m, 2H), 2.13 (s, 3H) , 1.13 (m, 4H) , 1.11 (m, 6H) .
[0282] LC-MS (ESI, m / z) = 721.4 (M+H + ) Manufacturing Example 26. Synthesis of 7-(2-(dimethylamino)pyrimidin-5-yl)-2-(trans-4-((2-methoxyethyl)(methyl)amino)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, (Compound 26) In [Step 2] of Manufacturing Example 20, (2S,6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine was replaced with N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine,
[0283] [The same reaction as in Preparation Example 20 was performed except that 1-bromo-2-methoxyethane was used instead of 2,2,2-trifluoroethyl trifluoromethanesulfonate in the step 1, to obtain the title compound (19 mg). P NMR (DMS0-d6): 11.49 (s, 1H), 8.63 (s, 2H), 7.91 (s, 1H), 7.05 (s, 1H), 6.05 (s, 1H), 4.27 (m, 2H), 3.29 (s, 3H), 3.12 (s, 6H) , 2.48 (s, 3H) , 2.47 (s, 1H), 2.46 (s, 3H) , 2.45 (s, 6H) , 2.41 (m, 2H) , 2.16 (m, 2H) , 2.13 (m, 2H), 1.55 (m, 3H) .
[0284] LC-MS (ESI, m / z) = 651.4 (M+H + ) Manufacturing Example 27. 7-(6-(4, 4-difluoropiperidin-1-yl)pyridin-3-yl)-2-
[0285] Synthesis of (trans-4-((2-methoxyethyl)(methyl)amino)cyclohexyl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[bi[1,3]dioxole-5-carboxamide, (Compound 27) In [Step 2] of Manufacturing Example 20, 2-(4,4-difluoropiperidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine was used instead of (2S,6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine, and 2,2,2-trifluoroethyl trifluoromethanesulfonate was used instead of 1-bromo-2-methoxyethane in [Step 2], to obtain the title compound (30 mg). P NMR (Chloroform-d): 8.50 (s, 1H), 7.67 (d, 1H), 7.29 (m, 1H), 6.57 (d, 1H), 5.89 (s, 1H), 4.58 (d, 2H), 3.65 (t, 3H), 3.39 (t, 2H) , 3.28 (s, 3H), 2.57 (t, 2H), 2.40 (s, 3H) , 2.38 (s, 1H) , 2.28 (s, 3H) , 2.24 (s, 3H) , 2.11(s, 3H), 1.95 (m, 2H) , 1.93 (s, 1H) , 1.54 (s, 3H) , 1.21 (t, 3H) .
[0286] LC-MS (ESI, m / z) = 727.0 (M+H + ) Manufacturing Example 28. 2-(trans-4-((2 ■methoxyethyl)(methyl)amino)cyclohexyl)-7-
[0287] Synthesis of (6-methoxypyridin-3-yl)-2,4-dimethyl ~N~((6~methyl-4-(methylthio)-2-oxo-1,2~dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, (Compound 28) In [Step 2] of Manufacturing Example 20, (2S,6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine was replaced with 2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine, and in [Step 2], 1-bromo-2-methoxyethane was replaced with 2,2,2-trifluoroethyl trifluoromethanesulfonate, and the same reaction as in Manufacturing Example 20 was performed to obtain the title compound (56 mg). P NMR (Chloroform-d): 4.60 (d, 2H), 3.89 (s, 3H), 3.42 (t, 2H), 3.31 (s, 3H), 2.61 (t, 2H), 2.43 (s, 3H), 2.30 (s, 1H), 2.27 (s, 3H) , 2.12 (s, 3H), 1.96 (m, 2H), 1.88 (m, 2H) , 1.76 (m, 1H) , 1.55 (s, 3H) , 1.22 (t, 3H) .
[0288] LC-MS (ESI, m / z) = 637.4 (M+H + ) Manufacturing Example 29. 7- (6- ((2S,6R)- 2, 6 ■ dimethylmorpholino) pyridin- 3 -yl)- 2-
[0289] (trans-4-(((S)-2-hydroxypropyl)(methyl)amino)cyclohexyl)-2,4-dimethyl-N-
[0290] Synthesis of ((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[bi[1,3]dioxole-5-carboxamide, (Compound 29)
[0291] The same reaction as in Preparation Example 20 was performed except that (S)-1-chloro-2-propanol was used instead of 2,2,2-trifluoroethyl trifluoromethanesulfonate in the step of Preparation Example 20, to obtain the title compound (34 mg). P NMR (Chloroform-d): 8.50 (d, 1H), 7.69 (d, 1H), 7.13 (m, 1H), 7.05 s, 1H), 6.58 (d, 1H), 5.94 (s, 1H), 4.57 s, 2H), 4.18 s, 1H), 4.01 (dd,
[0292] 2H), 3.69 (m, 2H), 2.65 (m, 4H), 2.50 (t, 2H), 2.44 (s, 3H), 2.26 (s, 3H),
[0293] 2.19 (s, 5H), 2.04 (m, 2H), 1.83 (t, 1H) , 1.55 (s, 3H), 1.40 (m, 4H), 1.24
[0294] (d, 8H), 1.16 (d, 3H).
[0295] LC-MS (ESI, m / z) = 720.5 (M+H + ) Manufacturing example 30. Synthesis of 7-(6-((2S,6R)- 2, 6 ■dimethylmorpholino)pyridin- 3 -yl)- 2,4-dimethyl- 2-(trans- 4-(methyl(2-propoxyethyl)amino)cyclohexyl)- N-((6-methyl- 4- (methylthio)- 2 -oxo- 1, 2 ■dihydropyridin- 3 -yl)methyl)benzo [ d] [ 1, 3 ]dioxole- 5-carboxamide, (Compound 30)
[0296] The same reaction as in Manufacturing Example 20 was performed except that 2-chloroethyl propyl ether was used instead of 2,2,2-trifluoroethyl trifluoromethanesulfonate in the step [to obtain the title compound (28 mg).] NMR (Chloroform-d): 8.50 (s, 1H), 7.70 (dd, 1H), 7.19 (t, 1H),
[0297] 7.06 (s, 1H), 6.54 (d, 1H), 5.92 (s, 1H), 4.59 (d, 2H), 3.98 (d, 2H), 3.79
[0298] (m, 2H), 3.51 (t, 2H), 3.35 (t, 2H), 2.69 (t, 2H), 2.50 (t, 3H), 2.43 (s,
[0299] 3H), 2.33 (s, 3H), 2.28 (s, 3H) , 2.14 (s, 3H) , 1.92 (m, 4H) , 1.79 (m, 1H) ,
[0300] 1.54 (m, 5H), 1.24 (d, 11H), 0.86 (t, 3H).
[0301] LC-MS (ESI, m / z) = 749.3 (M+H + ) Manufacturing Example 31. 2-(trans-4-((2,2-dimethoxyethyl)(methyl)amino)cyclohexyl)- 7-(6-((2S,6R)- 2,6-dimethylmorpholino)pyridin- 3 -yl)- 2, 4 -dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo-
[0302] Synthesis of 1,2-dihydropyridin-3-yl)methyl)benzo[d][l,3]dioxole-5-carboxamide,
[0303] (Compound 31)
[0304] The same reaction as in Manufacturing Example 20 was performed except that bromoacetaldehyde dimethyl acetal was used instead of 2,2,2-trifluoroethyl trifluoromethanesulfonate in the step [to obtain the title compound (53 mg).] NMR (Chloroform-d): 8.53 (s, 1H), 7.69 (d, 1H), 7.19 (m, 1H), 7.06
[0305] (d, 1H), 6.56 (m, 1H), 5.92 (s, 1H), 4.59 (s, 2H), 4.48 (s, 1H), 3.98 (d,
[0306] 2H), 3.67 (m, 2H) , 3.33 (d, 6H) , 2.58 (s, 2H) , 2.48 (t, 3H) , 2.42 (s, 3H) ,
[0307] 2.35 (s, 3H), 2.28 (d, 3H) , 2.14 (s, 3H) , 1.91 (d, 4H) , 1.78 (s, 1H) , 1.54
[0308] (d, 3H), 1.23 (m, 12H) .
[0309] LC-MS (ESI, m / z) = 750.5 (M+H + ) Manufacturing Example 32. 2-(trans-4-(((1,3 ■dioxolan- 2-yl)methyl)(methyl)amino)cyclohexyl)- 7-(6-((2S,6R)- 2,6-dimethylmorpholino)pyridin- 3 -yl)- 2, 4 ■dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo-
[0310] Synthesis of 1,2-dihydropyridin-3-yl)methyl)benzo[d][l,3]dioxole-5-carboxamide,
[0311] (Compound 32)
[0312] The same reaction as in Manufacturing Example 20 was performed except that 2-bromomethyl-1,3-dioxolane was used instead of 2,2,2-trifluoroethyl trifluoromethanesulfonate in the step 20, to obtain the title compound (40 mg). P NMR (Chloroform-d): 8.52 (d, 1H), 7.69 (m, 1H), 7.18 (t, 1H), 7.06
[0313] (s, 1H), 6.55 (d, 1H), 5.93 (s, 1H), 5.00 (t, 1H), 4.59 (d, 2H), 3.99 (m,
[0314] 3H), 3.82 (m, 1H) , 3.68 (m, 2H) , 2.71 (d, 1H) , 2.50 (m, 2H) , 2.43 (s, 5H) ,
[0315] 2.28 (s, 3H), 2.15 (s, 3H) , 1.97 (m, 4H) , 1.79 (d, 1H) , 1.54 (s, 3H) , 1.25
[0316] (m, 11H).
[0317] LC-MS (ESI, m / z) = 748.5 (M+H + ) Manufacturing Example 33. Synthesis of 7- (6- ((2S,6R)- 2, 6 ■dimethylmorpholino)pyridin- 3 -yl)- 2,4-dimethyl- N- ( (6 -methyl- 4- (methylthio)- 2 -oxo- 1 , 2 ■dihydropyridin- 3 -yl)methyl )-2- (1- (2 , 2 , 2 -trifluoroethyl)piperidin- 4 -yl )benzo [bi [ 1 , 3]dioxole- 5 -carboxamide and its hydrochloride salt, (Compound 33 and its hydrochloride salt)
[0318] <Reaction Formula 4>
[0319]
[0320] [Step 1] Synthesis of tert-butyl 4-(7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-5-(methoxycarbonyl)-2,4-dimethylbenzo[d][1,3]dioxol-2-yl)pyridine-1-carboxylate tert-butyl 4-(7-bromo-5-(methoxycarbonyl)-2,4-dimethylbenzo[d][1,3]dioxol-2-yl)piperidine-1-carboxylate (20g,
[0321] Dioxane (200 mL) was added to 44.2 mmole), and purified water (lOOmL) was added. Then, (2S, 6R)-2,6-dimethyl-4-(5-(4, 4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl)pyridin-2-yl)morpholine (18.3 g) was added, tetrakis(triphenylphosphine)palladium (5.11 g) was added, and sodium carbonate (14 g) was added, then the temperature was increased and the mixture was stirred. Upon completion of the reaction, hexane (200 mL) and purified water (lOOmL) were added, the precipitated solid was filtered using silica / Celite, and the filtrate was washed with purified water (200 mL). Magnesium sulfate was added, filtered, and concentrated to obtain the title compound (16 g).
[0322] [Step 2] Synthesis of 2-(1-(tert-butoxycarbonyl)piperidin-4-yl)-7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethylbenzo[bi[1,3]dioxole-5-carboxylic acid Tetrahydrofuran (128 mL) and purified water (64 mL) were added to the compound (16 g, 27.5 mmole) obtained in the above [Step 1]. 2N sodium hydroxide aqueous solution (69 mL) was added, the temperature was raised, and the mixture was stirred. Upon completion of the reaction, 2N hydrochloric acid aqueous solution (69 mL) was added, followed by ethyl acetate (128 mL). Afterwards, purified water was added twice (300 mL each) to wash, magnesium sulfate was added, filtered, and concentrated to obtain the title compound (14.2 g).
[0323] [Step 3] Synthesis of tert-butyl 4-(7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethyl-5-((pentafluorophenoxy)carbonyl)benzo[d][1,3]dioxol-2-yl)piperidine-1-carboxylate Dimethylformamide (70 mL) was added to the compound obtained in [Step 2] (14.2 g, 25.1 mmole), and triethylamine (14 mL) was added. Then, pentafluorophenyl trifluoroacetate (6.8 mL) was added dropwise, and the mixture was stirred at room temperature. Upon completion of the reaction, the next reaction was performed.
[0324] [Step 4] Synthesis of tert-butyl 4-(7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethyl-5-(((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)carbamoyl)benzo[d][1,3]dioxol-2-yl)piperidine-1-carboxylate Triethylamine (10 mL) was added to the reaction solution reacted in the above [Step 3]. Afterwards, 3-(aminomethyl)-6-methyl-4-(methylthio)pyridin-2(1H)-one hydrochloride (7.2 g) was added, and the mixture was stirred at an internal temperature of 50°C. Upon completion of the reaction, the reactant was added dropwise to purified water (710 mL), and the resulting solid was filtered. The solid was dissolved in methylene chloride (284 mL), the aqueous layer was separated, magnesium sulfate was added, and the resultant was filtered and concentrated to obtain the title compound (16.9 g).
[0325] [Step 5] Synthesis of 7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)2-(piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide hydrochloride To the compound (16.9 g, 23 mmole) obtained in the above [Step 4], 1 M hydrochloric acid (ethanol solution) (85 mL) was added, and the temperature was raised and stirred. Upon completion of the reaction, the reaction solution was added dropwise to ethyl acetate (338 mL), the resulting solid was filtered, and dried at an internal temperature of 60°C to obtain the title compound (15.4 g).
[0326] [Step 6] 7- (6- ((2S,6R)- 2, 6 -dimethylmorpholino)pyridin- 3 -yl)- 2,4-dimethyl- N- ( (6 -methyl- 4- (methylthio)- 2 -oxo- 1 , 2 -dihydro
[0327] Synthesis of (2,2,2-trifluoroethyl)piperidine-4-yl)benzo[d][1,3]dioxole-5-carboxamide, (Compound 33) Acetonitrile (308 mL) was added to the compound (15.4 g, 22 mmole) obtained in the above [Step 5], and sodium bicarbonate (15.5 g) was added. Trifluoroethyl trifluoromethanesulfonate (8.2 mL) was added dropwise, and the mixture was heated and stirred. After the reaction was completed, the mixture was concentrated, and ethyl acetate (308 mL) was added, and purified water was added.
[0328] (462 mL) was added and washed. Magnesium sulfate was added, filtered, and concentrated. Then, isopropyl alcohol (92 mL) was added and the temperature was raised to dissolve. Hexane (lOOmL) was added dropwise, and the resulting crystals were filtered and dried at an internal temperature of 60°C to obtain the title compound (11 g). P NMR (Chloroform-d): 8.42 (s, 1H), 7.60 (d, 1H), 7.33 (s, 1H), 6.98 (s, 1H), 6.46 (d, 1H), 5.82 (s, 1H), 4.47 (s, 2H), 3.89 (d, 2H) , 3.57 (s, 2H), 2.85 (m, 4H) , 2.32(m, 5H) , 2.20 (s, 5H) , 2.02 (s, 3H) , 1.72 (d, 3H) , 1.49 (s, 5H), 1.13 (d, 6H).
[0329] LC-MS (ESI, m / z) = 716.4 (M+H + )
[0330] [Step 7] Synthesis of 7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(2,2,2-trifluoroethyl)piperidine-4yl)benzo[d][1,3]dioxole-5-carboxamide hydrochloride, (hydrochloride of Compound 33) 1M hydrochloric acid aqueous solution (lOOmL) was added to the compound (11g, 14.8mmole) obtained in the above [Step 6], the temperature was increased, and the mixture was stirred. The internal temperature was cooled to room temperature, and ethyl acetate (230mL) was added dropwise and stirred. The resulting crystals were filtered and dried at an internal temperature of 60°C to obtain the title compound (11 g). Manufacturing Example 34. 2, 4 ■ Synthesis of dimethyl- N-( (6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3 -yl)methyl )-7- (6 ■ thiomorpholinopyridin- 3 -yl )-2-( 1- (2 , 2 , 2 -trifluoroethyl)piperidin- 4 -yl )benzo [d] [ 1 , 3 ]dioxole- 5 -carboxamide , (Compound 34) The same reaction as in Preparation Example 33 was performed except that 4-(5-(4, 4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)thiomorpholine was used instead of (2S,6R)-2,6-dimethyl-4-(5-(4, 4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine in [Step 1] of Preparation Example 33, to obtain the title compound (88 mg). P NMR (Chloroform-d): 8.55 (s, 1H), 7.76 (s, 1H), 7.13 (s, 1H), 6.56 (s, 1H), 5.94 (s, 1H), 4.61 (d, 2H), 3.95 (m, 4H), 3.01 (d, 2H), 2.96 (m, 2H), 2.65 (m, 4H), 2.46 (s, 3H), 2.33 (m, 5H), 2.18 (s, 3H), 1.82 (m, 3H), 1.59 (m, 5H).
[0331] LC-MS (ESI, m / z) = 704.3 (M+H + ) Manufacturing Example 35. 7-(2-(dimethylamino)pyrimidin-5-yl)- 2, 4 ■Dimethyl- N-((6-methyl-
[0332] Synthesis of 4-(methylthio)-2-oxo-1,2 ■dihydropyridin-3-yl)methyl)-2-(1-(2, 2,2-trifluoroethyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide,
[0333] (Compound 35) The same reaction as in Preparation Example 33 was performed except that N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine was used instead of (2S,6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine in [Step 1] of Preparation Example 33, to obtain the title compound (21 mg). P NMR (Chloroform-d): 8.64 (s, 1H), 7.28 (s, 1H), 7.07 (S, 1H), 5.94 (s, 1H), 4.61 (d, 2H), 3.19 (s, 6H), 2.96 (m, 2H), 2.94 (m, 2H) , 2.45 (s,
[0334] 3H), 2.31 (m, 5H), 2.29 (s, 3H), 1.81 1.79 (s, 6H).
[0335] LC-MS (ESI, m / z) = 647.3 (M+H + ) Manufacturing Example 36. 7- (6-methoxypyridin- 3-yl)- 2, 4 ■ Dimethyl- N- ((6-methyl- 4-
[0336] Synthesis of (methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(2,2,2~trifluoroethyl)piperidine-4-yl)benzo[d][1,3]dioxole-5-carboxamide,
[0337] (Compound 36) The same reaction as in Preparation Example 33 was performed except that 2-methoxy-5-(4, 4, 5, 5-tetramethyl-1,3, 2-dioxaborolan-2-yl)pyridine was used instead of (2S, 6R)-2, 6-dimethyl-4-(5-(4, 4, 5, 5-tetramethyl-1,3, 2-dioxaborolan-2-yl)pyridin-2-yl)morpholine in [Step 1] of Preparation Example 33, to obtain the title compound (20 mg). P NMR (Chloroform-d): 8.45 (s, 1H), 7.78 (d, 1H), 7.22 (s, 1H), 7.07 (s, 1H), 6.69 (d, 1H), 5.92 (s, 1H), 4.58 (d, 2H), 3.89 (d, 3H), 3.00 (d, 2H), 2.93 (m, 2H), 2.43 (s, 3H), 2.29 (m, 5H), 2.12 (s, 3H), 1.80 (m, 3H), 1.57 (m, 5H).
[0338] LC-MS (ESI, m / z) = 633.4 (M+H + ) Manufacturing Example 37. Synthesis of 7-(6-(3, 5-dimethylpiperidin-1-yl)pyridin-3-yl)-2, 4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1, 2 ■dihydropyridin-3-yl)methyl)-2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzo[d][1, 3]dioxole-5-carboxamide,
[0339] (Compound 37) The same reaction as in Preparation Example 33 was carried out except that 2-(3, 5-dimethylpiperidin-1-yl)-5-(4, 4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl)pyridine was used instead of (2S, 6R)-2, 6-dimethyl-4-(5-(4, 4,5,5-tetramethyl-1, 3, 2-dioxaborolan-2-yl)pyridine in [Step 1] of Preparation Example 33, and the title compound (47 mg) was obtained. P NMR (Chloroform-d): 8.51 (s, 1H), 7.68 (m, 1H), 7.25 (m, 1H), 7.08
[0340] (s, 1H), 6.60 (m, 1H), 5.92 (d, 1H), 4.60 (s, 2H), 4.20 (d, 2H), 2.99 (m,
[0341] 2H), 2.93 (m, 2H), 2.43 (d, 3H), 2.29 (d, 7H), 2.15 (d, 3H), 1.80 (s, 4H),
[0342] 1.56 (m, 7H), 1.24 (s, 1H), 0.93 (m, 7H), 0.79 (m, 1H).
[0343] LC-MS (ESI, m / z) = 714.5 (M+H + ) Manufacturing example 38. Synthesis of 7-(2-((2S,6R)- 2,6-dimethylmorpholino)pyrimidin-5-yl)- 2,4-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2 ■dihydropyridin- 3 -yl)methyl)-2-(1- (2,2,2-trifluoroethyl)piperidin- 4-yl)benzo [bi [1,3]dioxole- 5-carboxamide, (Compound 38) The same reaction as in Preparation Example 33 was performed except that (2S,6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine was used instead of (2S,6R)-2,6-dimethyl— 4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)morpholine in [Step 1] of Preparation Example 33, to obtain the title compound (37 mg). P NMR (Chloroform-d): 8.59 (s, 2H), 7.11 (t, 1H), 7.03 (s, 1H), 5.96 (s, 1H), 4.59 (d, 2H), 4.50 (dd, 2H), 3.61 (m, 2H), 3.00 (d, 2H) , 2.95 (m, 2H), 2.59 (t, 2H), 2.44 (s, 3H) , 2.28 (m, 5H) , 2.21 (s, 3H) , 1.79 (m, 3H) , 1.56 (s, 5H), 1.23 (d, 9H) .
[0344] LC-MS (ESI, m / z) = 717.4 (M+H + ) Manufacturing Example 39. Synthesis of 2, 4 -dimethyl- N- ((6 -methyl- 4- (methylthio) - 2 -oxo - 1,2- dihydropyridin- 3 -yl)methyl) -7- (2- (piperidin- 1-yl) pyrimidin- 5 -yl) -2- ( 1- (2 , 2 , 2- trifluoroethyl) piperidin- 4 -yl) benzo [bi [1,3] dioxole- 5 -carboxamide, (Compound 39) The same reaction as in Preparation Example 33 was performed except that 2-(piperidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine was used instead of (2S,6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine in [Step 1] of Preparation Example 33, to obtain the title compound (55 mg). P NMR (Chloroform-d): 8.57 (s, 2H), 7.23 (m, 1H), 7.03 (s, 1H), 5.94 (s, 1H), 4.58 (d, 2H), 3.75 (t, 4H), 2.99 (d, 2H), 2.93 (m, 2H) , 2.43 (s, 3H), 2.29 (m, 5H) , 2.19 (s, 3H) , 1.80 (m, 3H) , 1.65 (m, 2H) , 1.57 (s, 9H) .
[0345] LC-MS (ESI, m / z) = 687.3 (M+H + ) Manufacturing Example 40. 7-(6-((2S,6R)- 2, 6 -dimethylmorpholino)pyridin- 3 -yl)- 2-(1- ((S)- 2 -hydroxypropyl)piperidin- 4 -yl)-2 , 4 -dimethyl- N-((6 -methyl- 4-(methylthio)-
[0346] Synthesis of 2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[bi[1,3]dioxole-5-carboxamide, (Compound 40) The same reaction as in Manufacturing Example 33 was performed except that (S)-1-chloro-2-propanol was used instead of 2,2,2-trifluoroethyl trifluoromethanesulfonate in [Step 6] of Manufacturing Example 33, to obtain the title compound (66 mg). Blood NMR (Chloroform-d): 8.49 (t, 1H), 7.74 (d, 1H), 7.21 (s, 1H), 7.06(s, 1H), 6.59(d, 1H), 5.95(s, 1H), 4.58(s, 2H), 4.01(dd, 3H) , 3.68(m, 2H), 2.50 (t, 4H), 2.44 (s, 4H) , 2.28 (s, 3H) , 2.18 (s, 3H) , 1.88 (m, 4H) , 1.58 (s, 3H), 1.24 (d, 9H) , 1.13 (d, 3H) .
[0347] LC-MS (ESI, m / z) = 692.4 (M+H + ) Manufacturing Example 41. Synthesis of 2-(1-(2, 2-dimethoxyethyl)piperidin-4-yl)-7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2, 4 ■dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1, 2-dihydropyridin-3-yl)methyl)benzo[d][1, 3]dioxole-5-carboxamide,
[0348] (Compound 41)
[0349] The same reaction as in Manufacturing Example 33 was performed except that bromoacetaldehyde dimethyl acetal was used instead of 2,2,2-trifluoroethyl trifluoromethanesulfonate in [Step 6] of Manufacturing Example 33, to obtain the title compound (201 mg). P NMR (Chloroform-d): 8.50 (s, 1H), 7.67 (dd, 1H), 7.20 (t, 1H), 7.05(s, 1H), 6.53 (d, 1H), 5.92 (s, 1H), 4.59 (d, 2H), 4.51 (t, 1H) , 3.98- 4.00 (m, 2H), 3.66-3.67 (m, 2H) , 3.31 (s, 6H) , 3.06 (d, 2H) , 2.48-2.53 (m, 4H), 2.42 (s, 3H), 2.27 (s, 3H), 2.13 (s, 3H), 2.05 (t, 2H) , 1.76-1.80 (m, 3H), 1.64-1.66 (m, 2H) , 1.55(s, 3H) , 1.24 (d, 8H) .
[0350] LC-MS (ESI, m / z) = 722.4 (M+H + ) Manufacturing example 42. Synthesis of 2-(4-(dimethylamino)cyclohexyl)- 2, 4 ■dimethyl- N-((6-methyl- 4-(methylthio)- 2 -oxo- 1, 2 -dihydropyridin- 3 -yl)methyl)-7-(thiophene- 3-yl)benzo[bi[1,3]dioxole- 5 -carboxamide, (Compound 42) The same reaction as in Manufacturing Example 33 was performed except that 2-chloroethyl propyl ether was used instead of 2,2,2-trifluoroethyl trifluoromethanesulfonate in [Step 6] of Manufacturing Example 33, to obtain the title compound (220 mg). P NMR (Chloroform-d): 7.59 (d, 1H), 7.39 (m, 1H), 7.25 (m, 1H), 7.23 (m, 1H), 7.19 (s, 1H), 5.92 (s, 1H), 4.60 (d, 2H), 2.43 (s, 3H), 2.29 (s, 3H), 2.24 (s, 6H), 2.14 (m, 4H), 1.97 (t, 4H), 1.80 (t, 1H), 1.58 (s, 3H), 1.23 (m, 4H).
[0351] LC-MS (ESI, m / z) = 568.3 (M+H + ) Manufacturing Example 43. Preparation of 2- (4-(dimethylamino)cyclohexyl)- 7- (5 -fluoro- 2 -methoxyphenyl)- 2 , 4 -dimethyl - N- ( (6 -methyl- 4-(methylthio)- 2 -oxo- 1 , 2 -dihydropyridin- euyl) metal Ibenzo IdlU yo 1 daaepsol 3 5 k ] levoxamer J-type compound The same reaction as in Preparation Example 33 was performed except that 2-bromomethyl-1,3-dioxolane was used instead of 2,2,2-trifluoroethyl trifluoromethanesulfonate in [Step 6] of Preparation Example 33, to obtain the title compound (124 mg). P NMR (Chloroform-d): 7.02 (m, 1H), 6.98 (m, 2H), 6.92 (m, 1H), 6.79 (m, 1H), 5.91 s, 1H), 4.58 (d, 2H), 3.68 (s, 3H), 2.44 (s, 3H), 2.32 (s,
[0352] 2H), 2.25 (s, 6H), 2.13 (s, 4H), 1.94 (m, 3H), 1.79 (t, 1H), 1.53 (s, 3H),
[0353] 1.20 (m, 4H).
[0354] LC-MS (ESI, m / z) = 610.3 (M+H+) Preparation Example 44. Synthesis of stereoisomers of 7-(6-((2S,6R)- 2,6 -dimethylmorpholino)pyridin- 3 -yl)- 2,4-dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo- 1 , 2 -dihydropyridin- 3 -yl)methyl)-2-(1- (2 , 2 , 2 -trifluoroethyl)piperidin- 4 -yl)benzo [bi [1 , 3]dioxole- 5 -carboxamide, (Compound 44)
[0355] Except that stereospecific tert-butyl (R)-4-(7-bromo-5-(methoxycarbonyl)-2,4-dimethylbenzo[d][l,3]dioxol-2-yl)piperidine-1-carboxylate (3 g, 6.38 mmol) was used instead of tert-butyl 4-(7-bromo-5-(methoxycarbonyl)-2,4-dimethylbenzo[d][l,3]dioxol-2-yl)piperidine-1-carboxylate as the starting material in [Step 1], the steps of [Steps 1 to 6] of Preparation Example 33 were carried out in the same manner to obtain the title compound (3.3 g, 4.60 mmole). Tert-butyl (R)-4-(7-bromo-5-(methoxycarbonyl)-2,4-dimethylbenzo[d][1,3]dioxol-2-yl)piperidine-1- When the purity of the isomer was measured by liquid chromatography, it was measured at RT 6.01 min, had a chiral purity of 99.3%, and had a specific rotation [ Q ]D 25 = +4.0 (c=l, chloroform) was used.
[0356] - Detector: UV spectrophotometer (measurement wavelength 270 nm)
[0357] - Column: Chiralpak 0X-3 or equivalent (e.g. Chiralpak 0X-3, particle size 3iim, 4.6mm X 15cm)
[0358] - Column temperature: 25 °C
[0359] - Mobile phase: A mixture of hexane / ethanol (98:2, v / v).
[0360] - Flow rate: 1. OniL / min
[0361] - Analysis time: 15 minutes Blood NMR (DMS0-d6): 11.5 (s, 1H), 8.43 (s, 1H), 7.95 (t, 1H), 7.80 (s,
[0362] 1H), 7.02 (s, 1H), 6.90 (d, 1H) , 6.05 (s, 1H) , 4.27 (d, 2H) , 4.13 (d, 2H) ,
[0363] 3.53-3.59 (m, 2H) , 3.06-3.10 (m, 2H) , 2.92 (d, 2H) , 2.39-2.43 (m, 5H) , 2.38- 2.39 (m, 1H) , 2.24-2.30 (m, 2H) , 2.17 (s, 3H) , 2.13 (s, 3H) , 1.81-1.88 (m,
[0364] 1H), 1.67-1.73 (m, 2H) , 1.56 (s, 3H) , 1.32-1.40 (m, 2H) , 1.13 (s, 3H) , 1.12
[0365] (s, 3H).
[0366] LC-MS (ESI, m / z) = 716.8 (M+H + ) Specific rotation [ Q ]D 25 = -55.0000 (c=0.1, methanol) Manufacturing example 45. Synthesis of stereoisomer A of 7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzo[bi[1,3]dioxole-5-carboxamide, (Compound 45)
[0367] [Step 1] Except that stereospecific tert-butyl (S)-4-(7-bromo-5-(methoxycarbonyl)-2,4-dimethylbenzo[d][l,3]dioxol-2-yl)piperidine-1-carboxylate (3 g, 6.38 mmole) was used instead of tert-butyl 4-(7-bromo-5-(methoxycarbonyl)-2,4-dimethylbenzo[d][l,3]dioxol-2-yl)piperidine-1-carboxylate as the starting material, the same procedures as in [Steps 1 to 6] of Preparation Example 33 were carried out to obtain the title compound (3.2 g, 4.47 mmole). Tert-butyl (S)-4-(7-bromo-5-(methoxycarbonyl)-2,4-dimethylbenzo[d][1,3]dioxol-2-yl)piperidine-1-carboxylate( When the purity of the isomer was measured by liquid chromatography under the following conditions, it was measured at RT 5.24 min, had a chiral purity of 98.8%, and had a specific rotation [ Q ]D 25 = -3.6 (c=l, chloroform) was used.
[0368] - Detector: UV spectrophotometer (measurement wavelength 270 nm)
[0369] - Column: Chiralpak 0X-3 or equivalent (e.g. Chiralpak 0X-3, particle size 3iim, 4.6mm X 15cm)
[0370] - Column temperature: 25 °C
[0371] - Mobile phase: A mixture of hexane / ethanol (98:2, v / v).
[0372] - Flow rate: 1. OniL / min
[0373] - Analysis time: 15 minutes Blood NMR (DMS0-d6): 11.5 (s, 1H), 8.43 (s, 1H), 7.95 (t, 1H), 7.80 (s,
[0374] 1H), 7.02 (s, 1H), 6.90 (d, 1H) , 6.05 (s, 1H) , 4.27 (d, 2H) , 4.13 (d, 2H) ,
[0375] 3.53-3.59 (m, 2H) , 3.06-3.10 (m, 2H) , 2.92 (d, 2H) , 2.36-2.40 (m, 5H) , 2.34- 2.36 (m, 1H) , 2.22-2.30 (m, 2H) , 2.17 (s, 3H) , 2.13 (s, 3H) , 1.81-1.88 (m,
[0376] 1H), 1.67-1.73 (m, 2H) , 1.56 (s, 3H) , 1.32-1.40 (m, 2H) , 1.13 (s, 3H) , 1.12
[0377] (s, 3H)
[0378] LC-MS (ESI, m / z) = 716.8 (M+H + ) Specific rotation [ Q ]D 25 = +55.7000 (c=0.1, methanol) Preparation Example 46. 2- (1-(2, 2-difluoroethyl)piperidin- 4 -yl)- 7-(6- ((2S,6R)-
[0379] Synthesis of 2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[bi[1,3]dioxole-5-carboxamide, (Compound 46) The processes of [Steps 1 to 5] of the above Manufacturing Example 33 were carried out in the same manner to obtain 7- (6- ((2S,6R)- 2, 6 -dimethylmorpholino)pyridin- 3 -yl)- 2, 4 -dimethyl- N- ((6 -methyl- 4- (methylthio)- 2 -oxo- 1, 2 -dihydropyridin- 3 -yl)methyl) 2- (piperidin- 4-yl)benzo [d] [1,3] dioxole- 5 -carboxamide hydrochloride of [Step 5]. Acetonitrile (10 mL), sodium carbonate (0.43 g), and 2-iodo-1,1-difluoroethane (0.12 mL) were added to the obtained hydrochloride (0.5 g, 0.70 mmole), and the mixture was stirred at an internal temperature of 100°C for 24 hours. After cooling, dichloromethane (5 mL) was added, filtered, concentrated, and the layers were separated with dichloromethane (10 mL) and purified water (10 mL), and the larvae were dried over magnesium sulfate (MgS04) and concentrated. The crystals produced using ethanol (2 mL) and hexane (20 mL) were filtered, and dried at an internal temperature of 60°C to obtain the title compound (0.3 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.36 (s, 1H), 8.19 (t, 1H), 8.00 (s,
[0380] 1H), 7.23 (s, 1H), 7.09 (s, 1H), 6.61 (t, 1H) , 6.06 (s, 1H) , 4.26-4.28 (m, 4H), 3.62-3.64 (m, 4H) , 3.52-3.62 (m, 2H) , 3.06-3.07 (m, 2H) , 2.61-2.65 (m, 2H), 2.41 (s, 3H), 2.22 (s, 3H) , 2.14 (s, 3H) , 1.91-1.93 (m, 2H) , 1.88-1.91 (m, 3H), 1.60 (s, 3H), 1.14 (s, 3H) , 1.13 (s, 3H) .
[0381] LC-MS (ESI, m / z) = 698.4 (M+H +) Manufacturing Example 47. 2-(1-(2, 2-difluoroethyl)piperidin-4-yl)- 7-(6-((2S,6R)-
[0382] Synthesis of stereoisomers of 2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, (Compound 47)
[0383] [Step 1] Except that stereospecific tert-butyl (R)-4-(7-bromo-5-(methoxycarbonyl)-2,4-dimethylbenzo[d][l,3]dioxol-2-yl)piperidine-1-carboxylate (3 g, 6.38 mmole) was used instead of tert-butyl 4-(7-bromo-5-(methoxycarbonyl)-2,4-dimethylbenzo[d][l,3]dioxol-2-yl)piperidine-1-carboxylate, the reaction was carried out in the same manner as in Preparation Example 46 to obtain the title compound (0.2 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.44 (s, 1H), 7.94 (t, 1H), 7.79 (s, 1H), 7.02 (s, 1H), 6.90 (d, 1H), 6.04-6.05 (m, 2H), 4.26 (d, 2H) , 4.13 (d,
[0384] 2H), 3.55-3.56 (m, 2H) , 2.89-2.92 (m, 2H) , 2.60-2.69 (m, 2H) , 2.39 (s, 3H) ,
[0385] 2.36-2.38 (m, 2H) , 2.16 (s, 3H) , 2.13 (s, 3H) , 2.07-2.12 (m, 2H) , 1.80-1.86
[0386] (m, 1H), 1.65-1.72 (m, 2H), 1.56 (s, 3H), 1.35-1.40 (m, 2H), 1.13 (s, 3H),
[0387] 1.12 (s, 3H).
[0388] LC-MS (ESI, m / z) = 698.6 (M+H + ) Specific rotation [ ah) 25 = -58.1500 (c=0.1, methanol) Preparation Example 48. Synthesis of stereoisomer A of 2-(1-(2, 2 ■difluoroethyl)piperidin- 4 -yl)- 7-(6- ((2S,6R)- 2, 6 ■dimethylmorpholino)pyridin- 3 -yl)- 2, 4 ■dimethyl- N- ((6-methyl- 4-(methylthio)- 2-oxo- 1, 2 ■dihydropyridin- 3 -yl)methyl)benzo[ d] [ 1, 3 ]dioxole- 5 -carboxamide, (Compound 48) isomers
[0389]
[0390] [Step 1] Except that stereospecific tert-butyl (S)-4-(7-bromo-5-(methoxycarbonyl)-2,4-dimethylbenzo[d][l,3]dioxol-2-yl)piperidine-1-carboxylate (3 g, 6.38 mmole) was used instead of tert-butyl 4-(7-bromo-5-(methoxycarbonyl)-2,4-dimethylbenzo[d][l,3]dioxol-2-yl)piperidine-1-carboxylate, the reaction was carried out in the same manner as in Preparation Example 46 to obtain the title compound (0.2 g). P NMR (DMS0-d6): 11. 5(s, 1H), 8.44 (s, 1H), 7.94 (t, 1H), 7.79 (s, 1H), 7.02 (s, 1H), 6.90 (d, 1H), 6.04-6.05 (m, 2H), 4.26 (d, 2H) , 4.13 (d,
[0391] 2H), 3.57-3.58 (m, 2H) , 2.89-2.92 (m, 2H) , 2.60-2.69 (m, 2H) , 2.40 (s, 3H) ,
[0392] 2.36-2.38 (m, 2H) , 2.16 (s, 3H) , 2.13 (s, 3H) , 2.07-2.12 (m, 2H) , 1.80-1.86
[0393] (m, 1H), 1.65-1.72 (m, 2H), 1.56 (s, 3H), 1.35-1.40 (m, 2H), 1.13 (s, 3H),
[0394] 1.12 (s, 3H).
[0395] LC-MS (ESI, m / z) = 698.6 (M+H + ) Specific rotation [ Q ]D 25 = +65.5667 (c=0.1, methanol) Preparation example 49. Synthesis of stereoisomers of 7-(6-((2S,6R)- 2, 6 ■dimethylmorpholino)pyridin- 3 -yl)- 2-(1-ethylpiperidin- 4 -yl)- 2,4-dimethyl ~N~((6~methyl- 4-(methylthio)- 2 -oxo- 1,2~ dihydropyridin- 3 -yl)methyl)benzo [d] [1,3]dioxole- 5 -carboxamide, (Compound 49)
[0396] [Step 6] 2-iodo-1,1-difluoroethane instead of iodoethane
[0397] The reaction was carried out in the same manner as in Preparation Example 47 except that (0.1 mL) was used, and the title compound (0.1 g) was obtained. P NMR (DMS0-d6): 11.5 (s, 1H), 8.48 (s, 1H), 7.96 (t, 1H), 7.82 (d, 1H), 7.05 (s, 1H), 6.90 (d, 1H), 6.05 (s, 1H), 4.27 (d, 2H) , 4.14 (d, 2H) , 3.55-3.59 (m, 2H) , 3.40-3.47 (m, 2H) , 3.00-3.05 (m, 2H) , 2.80-2.86 (m, 2H) ,
[0398] 2.47 (s, 3H), 2.41-2.44 (m, 2H) , 2.18 (s, 3H), 2.12 (s, 3H), 1.87-1.99 (m,
[0399] 3H), 1.56-1.66 (m, 5H) , 1.12-1.13 (m, 6H) , 1.12 (s, 3H) .
[0400] LC-MS (ESI, m / z) = 662.6 (M+H + ) Specific rotation [ ah) 25 = -55.4000 (c=0.1, methanol) Preparation Example 50. Synthesis of stereoisomer A of 7-(6-((2S,6R)- 2, 6 ■dimethylmorpholino)pyridin- 3 -yl)- 2-(1-ethylpiperidin- 4 -yl)- 2, 4 ■dimethyl- N-((6 ■methyl- 4-(methylthio)- 2 -oxo- 1,2-dihydropyridin- 3 -yl)methyl)benzo [bi[1,3]dioxole- 5 -carboxamide, (Compound 50)
[0401] [Step 6] Iodoethane instead of 2-iodo-1,1-difluoroethane
[0402] The reaction was carried out in the same manner as in Manufacturing Example 48 except that (0.1 mL)was used, and the title compound (0.1 g) was obtained. P NMR (DMS0-d6): 11.5 (s, 1H), 8.49 (s, 1H), 7.96 (t, 1H), 7.82 (d,
[0403] 1H), 7.05 (s, 1H), 6.90 (d, 1H), 6.05 (s, 1H), 4.27 (d, 2H), 4.14 (d, 2H),
[0404] 3.55-3.57 (m, 2H) , 3.40-3.49 (m, 2H) , 3.00-3.06 (m, 2H) , 2.80-2.86 (m, 2H),
[0405] 2.47 (s, 3H), 2.41-2.43 (m, 2H) , 2.18 (s, 3H), 2.13 (s, 3H), 1.90-1.99 (m,
[0406] 3H), 1.55-1.65 (m, 5H) , 1.12-1.13 (m, 6H) , 1.12 (s, 3H).
[0407] LC-MS (ESI, m / z) = 662.6 (M+H + ) Specific rotation [ a > 25 = +67.8834 (c=0.1, methanol) Manufacturing example 51. Synthesis of stereoisomers of 7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2-(1-isopropylpiperidin-4-yl)-2,4-dimethyl-N-((6 ■methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][l,3]dioxole-5-carboxamide (Compound 51)
[0408] [Step 6] 2-iodo-1,1-difluoroethane instead of 2-iodopropane
[0409] The reaction was carried out in the same manner as in Preparation Example 47 except that (0.13 mL) was used, and the title compound (0.2 g) was obtained. P NMR (DMS0-d6): 11.5 (s, 1H), 8.46 (s, 1H), 7.95 (t, 1H), 7.81 (d,
[0410] 1H), 7.03 (s, 1H), 6.89 (d, 1H), 6.05 (s, 1H), 4.27 (d, 2H), 4.13 (d, 2H), 3.02-3.10 (m, 2H) , 2.41 (s, 3H) , 2.38-2.40 (m, 2H), 2.36-
[0411] 2.37 (m, 2H), 2.17 (s, 3H), 2.13 (s, 3H) , 2.00-2.10 (m, 2H) , 1.80-1.84 (m,
[0412] 2H), 1.58 (s, 3H), 1.45-1.48 (m, 2H) , 1.13 (s, 3H) , 1.12 (s, 3H), 1.02 (s,
[0413] 6H). LC-MS (ESI, m / z) = 676.6 (M+H + ) Specific rotation [ Q ]D 25 = -61.1000 (c=0.1, methanol) Manufacturing example 52. Synthesis of stereoisomer A of 7-(6-((2S,6R)- 2, 6 -dimethylmorpholino)pyridin- 3 -yl)- 2-(1-isopropylpiperidin- 4 -yl)-2 , 4 ■dimethyl- N-((6 ■methyl- 4-(methylthio)- 2 -oxo- 1 , 2-dihydropyridin- 3 -yl)methyl)benzo [bi[1,3]dioxole- 5 -carboxamide, (Compound 52)
[0414] [Step 6] The reaction was performed in the same manner as in Preparation Example 48, except that 2-iodopropane (0.13 mL) was used instead of 2-iodo-1,1-difluoroethane, to obtain the title compound (0.2 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.46 (s, 1H), 7.95 (t, 1H), 7.80 (d, 1H), 7.02 (s, 1H), 6.90 (d, 1H), 6.05 (s, 1H), 4.27 (d, 2H) , 4.14 (d, 2H) , 3.56-3.58 (m, 2H) , 2.83-2.88 (m, 2H) , 2.41 (s, 3H) , 2.38-2.40 (m, 2H) , 2.36-
[0415] 2.37 (m, 2H), 2.17 (s, 3H) , 2.13 (s, 3H) , 2.00-2.10 (m, 2H) , 1.72-1.81 (m, 2H), 1.57 (s, 3H), 1.38-1.43 (m, 2H) , 1.13 (s, 3H) , 1.12 (s, 3H) , 0.95 (s, 6H).
[0416] LC-MS (ESI, m / z) = 676.6 (M+H + ) Specific rotation [ Q ]D 25 = +67.5167 (c=0.1, methanol) Preparation Example 53. 2-(1-Cyclohexylpiperidine-4-yl)- 7-(6-((2S,6R)- 2,6-dimethylmorpholino)pyridin-3-yl)- 2,4-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo-
[0417] Synthesis of a stereoisomer of 1,2-dihydropyridin-3-yl)methyl)benzo[bi[1,3]dioxole-5-carboxamide, (Compound 53)
[0418] [Step 6] The reaction was carried out in the same manner as in Preparation Example 47 except that iodocyclohexane (0.17 mL) was used instead of 2-iodo-1,1-difluoroethane, to obtain the title compound (0.2 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.49 (s, 1H), 7.96 (t, 1H), 7.82 (d,
[0419] 1H), 7.05 (s, 1H), 6.90 (d, 1H), 6.05 (s, 1H), 4.27 (d, 2H), 4.14 (d, 2H),
[0420] 3.55-3.59 (m, 2H) , 3.38-3.41 (m, 2H), 3.10-3.12 (m, 2H) , 2.89-2.91 (m, 2H),
[0421] 2.41 (s, 3H), 2.36-2.40 (m, 4H) , 2.18 (s, 3H), 2.13 (s, 3H) , 1.87-1.95 (m,
[0422] 4H), 1.74-1.79 (m, 2H) , 1.60 (s, 3H), 1.54-1.58 (m, 2H) , 1.28-1.34 (m, 2H) ,
[0423] 1.20-1.26 (m, 2H), 1.13 (s, 3H) , 1.12 (s, 3H).
[0424] LC-MS (ESI, m / z) = 716.6 (M+H+) Specific rotation [ ah) 25 = -62.5333 (c=0.1, methanol) Preparation Example 54. 2-(1-cyclohexylpiperidine- 4-yl)- 7-(6-((2S,6R)- 2,6-dimethylmorpholino)pyridin- 3-yl)- 2,4 ■Dimethyl- N-((6-methyl- 4-(methylthio)- 2 -oxo-
[0425] Synthesis of stereoisomer A of 1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, (Compound 54) Stereoisomer A of
[0426]
[0427] [Step 6] The reaction was carried out in the same manner as in Preparation Example 48 except that iodocyclohexane (0.17 mL) was used instead of 2-iodo-1,1-difluoroethane, to obtain the title compound (0.2 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.49 (s, 1H), 7.96 (t, 1H), 7.82 (d,
[0428] 1H), 7.05 (s, 1H), 6.90 (d, 1H), 6.05 (s, 1H), 4.27 (d, 2H), 4.15 (d, 2H),
[0429] 3.54-3.58 (m, 2H) , 3.38-3.41 (m, 2H), 3.10-3.12 (m, 2H) , 2.93-3.60 (m, 2H) ,
[0430] 2.41 (s, 3H), 2.38-2.40 (m, 4H) , 2.19 (s, 3H), 2.13 (s, 3H) , 1.87-1.95 (m,
[0431] 4H), 1.74 - 1.79 (m, 2H), 1.60 (s, 3H), 1.56 - 1.58 (m, 2H), 1.28 - 1.34 (m, 2H),
[0432] 1.20 - 1.26 (m, 2H), 1.13 (s, 3H), 1.12 (s, 3H).
[0433] LC - MS (ESI, m / z) = 716.6 (M + H + ) Specific rotation [α) 25 = +67.3834 (c = 0.1, methanol) Preparation Example 55. Synthesis of the stereoisomer of 7 - (6 - ((2S,6R)-2,6 - dimethylmorpholino)pyridin - 3 - yl)-2,4 - dimethyl - N - ((6 - methyl - 4 - (methylthio)-2 - oxo - 1,2 - dihydropyridin - 3 - yl)methyl)-2 - (1 - phenethylpiperidin - 4 - yl)benzo[b][1,3]dioxole - 5 - carboxamide, (Compound 55)
[0434] [Step 6] The reaction was carried out in the same manner as in Preparation Example 47 except that iodocyclohexane (0.17 mL) was used instead of 2 - iodo - 1,1 - difluoroethane, and the title compound (0.2 g) was obtained. 1H NMR (DMSO - d6): 11.5 (s, 1H), 8.46 (s, 1H), 7.95 (t, 1H), 7.81 (d,
[0435] 1H), 7.20-7.30 (m, 2H), 7.10-7.20 (m, 3H), 7.03 (s, 1H), 6.90 (d, 1H), 6.05 (s, 1H), 4.27 (d, 2H), 4.14 (d, 2H), 3.53-3.58 (m, 2H) , 3.01-3.10 (m, 2H) , 2.70-2.97 (m, 2H) , 2.41 (s, 3H) , 2.38-2.40 (m, 2H) , 2.17 (s, 3H), 2.13 (s, 3H), 1.93-1.95 (m, 2H) , 1.87-1.91 (m, 2H) , 1.81-1.85 (m, 2H) , 1.70-1.81 (m, 2H), 1.58 (s, 3H), 1.38-1.48 (m, 2H) , 1.13 (s, 3H) , 1.12 (s, 3H) .
[0436] LC-MS (ESI, m / z) = 738.6 (M+H + ) Specific rotation [ ah) 25 = -82.3667 (c=0.1, methanol) Preparation Example 56. Synthesis of stereoisomer A of 7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-phenethylpiperidin-4-yl)benzo[d][l,3]dioxole-5-carboxamide, (Compound 56)
[0437] [Step 6] The reaction was carried out in the same manner as in Preparation Example 48 except that iodocyclohexane (0.17 mL) was used instead of 2-iodo-1,1-difluoroethane, to obtain the title compound (0.2 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.45 (s, 1H), 7.95 (t, 1H), 7.81 (d,
[0438] 1H), 7.21-7.22 (m, 2H), 7.03-7.18 (m, 3H), 7.02 (s, 1H), 6.91 (d, 1H), 6.05 (s, 1H), 4.27 (d, 2H), 4.14 (d, 2H), 3.56-3.57 (m, 2H) , 2.92-2.99 (m, 2H) ,
[0439] 2.66-2.69 (m, 2H) , 2.41 (s, 3H) , 2.38-2.40 (m, 2H) , 2.17 (s, 3H), 2.13 (s, 3H), 1.87-1.91 (m, 2H) , 1.85-1.87 (m, 2H) , 1.81-1.85 (m, 2H) , 1.70-1.81 (m, 2H), 1.58 (s, 3H), 1.38-1.48 (m, 2H) , 1.13 (s, 3H) , 1.12 (s, 3H) .
[0440] LC-MS (ESI, m / z) = 738.6 (M+H + ) Specific rotation [ Q ]D 25 = +78.3167 (c=0.1, methanol) Preparation Example 57. 7-(6-((2S,6R)- 2,6 -dimethylmorpholino)pyridin- 3 -yl)- 2,4-dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo- 1 , 2 -dihydropyridin- 3 -yl)methyl)-2-(1-
[0441] Synthesis of stereoisomers of (4,4,4-trifluorobutyl)piperidin-4-yl)benzo[bi[1,3]dioxole-5-carboxamide, (Compound 57)
[0442] [Step 6] The reaction was performed in the same manner as in Preparation Example 47 except that 1,1,1-trifluoro-4-iodobutane (0.17 mL) was used instead of 2-iodo-1,1-difluoroethane, to obtain the title compound (0.2 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.44 (s, 1H), 7.95 (t, 1H), 7.80 (d, 1H), 7.03 (s, 1H), 6.89 (d, 1H), 6.05 (s, 1H), 4.27 (d) ,2H), 4.14 (d, 2H) , 3.55-3.58 (m, 2H) , 2.82-2.89 (m, 2H) , 2.41 (s, 3H) , 2.34-2.41 (m, 3H) , 2.28- 3.34 (m, 2H), 2.18-2.28 (m, 2H) , 2.17 (s, 3H) , 2.13 (s, 3H) , 1.80-1.90 (m,
[0443] 2H), 1.68-1.74 (m, 2H), 1.58-1.63 (m, 2H), 1.57 (s, 3H), 1.30-1.41 (m, 2H), 1.13 (s, 3H), 1.12 (s, 3H).
[0444] LC-MS (ESI, m / z) = 744.7 (M+H + ) Specific rotation [ Q ]D 25 = -57.7500 (c=0.1, methanol) Preparation Example 58. 7- (6- ((2S,6R)- 2, 6 ■dimethylmorpholino)pyridin- 3 -yl)- 2,4-dimethyl- N- ( (6 -methyl- 4- (methylthio)- 2 -oxo- 1 , 2 -dihydropyridin- 3 -yl)methyl )-2- (1-
[0445] Synthesis of stereoisomer A of (4,4,4-trifluorobutyl)piperidin-4-yl)benzo[bi[1,3]dioxole-5-carboxamide, (Compound 58)
[0446] [Step 6] The reaction was carried out in the same manner as in Preparation Example 48 except that 1,1,1-trifluoro-4-iodobutane (0.17 mL) was used instead of 2-iodo-1,1-difluoroethane, to obtain the title compound (0.2 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.44 (s, 1H), 7.95 (t, 1H), 7.80 (d, 1H), 7.03 (s, 1H), 6.89 (d, 1H), 6.05 (s, 1H), 4.27 (d, 2H), 4.13 (d, 2H),
[0447] 3.56-3.57 (m, 2H) , 2.82-2.89 (m, 2H) , 2.41 (s, 3H) , 2.35-2.41 (m, 3H) , 2.28- 3.34 (m, 2H), 2.17-2.28 (m, 2H) , 2.17 (s, 3H), 2.13 (s, 3H), 1.80-1.90 (m,
[0448] 2H), 1.68-1.74 (m, 2H), 1.57-1.63 (m, 2H), 1.56 (s, 3H), 1.30-1.41 (m, 2H),
[0449] 1.13 s, 3H), 1.12 (s, 3H).
[0450] LC-MS (ESI, m / z) = 744.6 (M+H + ) Specific rotation [ a > 25 = +76.4834 (c=0.1, methanol) Preparation Example 59. 7-(6-((2S,6R)- 2, 6 -dimethylmorpholino)pyridin- 3 -yl)- 2, 4 -dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo- 1 , 2 ■dihydropyridin- 3 -yl)methyl)- 2-( 1-
[0451] Synthesis of stereoisomer B of (2, 2, 2-trifluoroacetyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide, (Compound 59)
[0452] [Step 6] The reaction was carried out in the same manner as in Preparation Example 47 except that phenyl trifluoroacetate (0.15 mL) was used instead of 2-iodo-1,1-difluoroethane, to obtain the title compound (0.2 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.44 (s, 1H), 7.95 (t, 1H), 7.80 (d,
[0453] 1H), 7.04 (s, 1H), 6.88 (d, 1H), 6.05 (s, 1H), 4.36 (d, 1H), 4.27 (d, 2H),
[0454] 4.13 (d, 2H), 3.88 (d, 1H), 3.55-3.57 (m, 2H), 3.21 (t, 1H), 2.83 (t, 1H),
[0455] 2.41 s, 3H), 2.32-2.38 (m, 2H) , 2.21-2.30 (m, 1H) , 2.17 (s, 3H), 2.13 (s,
[0456] 3H), 1.88-1.95 (m, 2H) . 1.57 (s, 3H) , 1.27-1.34 (m, 2H) 1.13 (s, 3H) . 1.12
[0457] (s, 3H).
[0458] LC-MS (ESI, m / z) = 730.5 (M+H + ) Specific rotation [ ah) 25 = -91.4000 (c=0.1, methanol) Preparation Example 60. 7- (6- ((2S,6R)- 2, 6 ■Dimethylmorpholino)pyridin- 3 -yl)- 2,4-dimethyl- N- ( (6 -methyl- 4-(methylthio)- 2 -oxo- 1 , 2 ■Dihydropyridin- 3 -yl)methyl )-2-( 1-
[0459] Synthesis of stereoisomer A of (2, 2, 2-trifluoroacetyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide, (compound 60) Stereoisomer A of
[0460]
[0461] [Step 6] The reaction was carried out in the same manner as in Preparation Example 48 except that phenyl trifluoroacetate (0.15 mL) was used instead of 2-iodo-1,1-difluoroethane, to obtain the title compound (0.2 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.44 (s, 1H), 7.95 (t, 1H), 7.81 (d,
[0462] 1H), 7.04 (s, 1H), 6.89 (d, 1H), 6.05 (s, 1H), 4.35 (d, 1H), 4.27 (d, 2H),
[0463] 4.14 (d, 2H), 3.89 (d, 1H), 3.55-3.58 (m, 2H), 3.21 (t, 1H), 2.83 (t, 1H),
[0464] 2.41 s, 3H), 2.32-2.38 (m, 2H) , 2.21-2.30 (m, 1H), 2.17 (s, 3H), 2.13 (s,
[0465] 3H), 1.88-1.95 (m, 2H) . 1.57 (s, 3H) , 1.27-1.35 (m, 2H) 1.13 (s, 3H) . 1.12
[0466] (s, 3H).
[0467] LC-MS (ESI, m / z) = 730.5 (M+H + ) Specific rotation [ Q ]D 25 = +66.5167 (c=0.1, methanol) Preparation Example 61. Synthesis of 2, 4 -dimethyl- N- ((6 -methyl- 4- (methylthio)- 2 -oxo- 1,2- dihydropyridin- 3 -yl)methyl)-7- (6 -morpholinopyridin- 3 -yl)-2- ( 1- (2 , 2 , 2- trifluoro )piperidin- 4 -yl)benzo [bi [1,3]dioxole- 5 -carboxamide,
[0468] (Compound 61) Except that 4-(5-(4, 4, 5, 5-tetramethyl- 1,3, 2-dioxaborolan- 2 -yl)pyridin- 2 -yl)morpholine was used instead of (2S, 6R)-2, 6-dimethyl- 4-(5-(4, 4, 5, 5-tetramethyl- 1,3, 2-dioxaborolan- 2 -yl)pyridin- 2 -yl)morpholine (intermediate 1) in [Step 1] of the above Manufacturing Example 33, the same procedures as in [Steps 1 to 5] were carried out to obtain 2, 4-dimethyl- N-((6-methyl- 4-(methylthio)- 2 -oxo- 1, 2-dihydropyridin- 3 -yl)methyl)- 7-(6-morpholinopyridin- 3 -yl)- 2-(Piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide hydrochloride was obtained. Acetonitrile (10 mL), sodium carbonate (0.43 g), and trifluoroethyl trifluoromethanesulfonate (0.20 mL) were added to the obtained hydrochloride (0.5 g, 0.70 mmole), and the mixture was stirred at an internal temperature of 100°C for 24 hours. After cooling, dichloromethane (5 mL) was added, filtered, and concentrated. The resulting crystals were filtered using ethanol (2 mL) and hexane (20 mL), and dried at an internal temperature of 60°C to obtain the title compound (0.3 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.44 (d, 1H), 7.95 (t, 1H), 7.82 (d, 1H), 7.04 (s, 1H), 6.89 (d, 1H), 6.04 (s, 1H), 4.26 (d, 2H) , 3.62-3.64 (m, 4H), 3.43-3.45 (m, 4H) , 3.02-3.12 (m, 2H) , 2.91-2.98 (m, 2H) , 2.41 (s, 3H) , 2.20-2.28 (m, 2H) , 2.26 (s, 3H) , 2.22 (s, 3H) , 1.81-1.88 (m, 1H) , 1.68-1.72 (m, 2H), 1.56 (s, 3H) , 1.35-1.40 (m, 2H) . LC-MS (ESI, m / z) = 688.4 (M+H +) Manufacturing Example 62. Synthesis of 2, 4-dimethyl- N-( (6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3 -yl)methyl )-7- (6-morpholinopyridin- 3 -yl )-2-( 1-(2 , 2 , 2-trifluoro)piperidin- 4 -yl)benzo [bi [1,3]dioxole- 5 -carboxamide stereoisomer, (Compound 62)
[0469] [Step 1] Except that stereospecific tert-butyl (R)-4-(7-bromo-5-(methoxycarbonyl)-2,4-dimethylbenzo[d][l,3]dioxol-2-yl)piperidine-1-carboxylate (3 g, 6.38 mmole) was used instead of tert-butyl 4-(7-bromo-5-(methoxycarbonyl)-2,4-dimethylbenzo[d][l,3]dioxol-2-yl)piperidine-1-carboxylate as the starting material, the reaction was carried out in the same manner as in Preparation Example 61 to obtain the title compound (0.3 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.45 (d, 1H), 7.95 (t, 1H), 7.81 (d, 1H), 7.03 (s, 1H), 6.89 (d, 1H), 6.04 (s, 1H), 4.26 (d, 2H) , 3.65-3.66 (m, 4H), 3.44-3.45 (m, 4H) , 3.06-3.12 (m, 2H) , 2.90-2.98 (m, 2H) , 2.40 (s, 3H) , 2.20-2.28 (m, 2H) , 2.26 (s, 3H) , 2.22 (s, 3H) , 1.81-1.88 (m, 1H) , 1.68-1.72 (m, 2H), 1.56 (s, 3H) , 1.35-1.40 (m, 2H) .
[0470] LC-MS (ESI, m / z) = 688.5 (M+H + ) Specific rotation [ Q ]D 25= -52.9667 (c=0.1, methanol) Preparation Example 63. 2, 4 ■Synthesis of stereoisomer A of dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3 -yl)methyl)-7-(6-morpholinopyridin- 3 -yl)-2-( 1-(2, 2, 2-trifluoro)piperidin- 4 -yl)benzo [bi[1,3]dioxole- 5-carboxamide, (Compound 63)
[0471] [Step 1] Except that stereospecific tert-butyl (S)-4-(7-bromo-5-(methoxycarbonyl)-2,4-dimethylbenzo[d][l,3]dioxol-2-yl)piperidine-1-carboxylate (3 g, 6.38 mmole) was used instead of tert-butyl 4-(7-bromo-5-(methoxycarbonyl)-2,4-dimethylbenzo[d][l,3]dioxol-2-yl)piperidine-1-carboxylate as the starting material, the reaction was carried out in the same manner as in Preparation Example 61 to obtain the title compound (0.3 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.45 (d, 1H), 7.95 (t, 1H), 7.81 (d, 1H), 7.03 (s, 1H), 6.89 (d, 1H), 6.04 (s, 1H), 4.26 (d, 2H) , 3.65-3.67 (m, 4H), 3.44-3.46 (m, 4H) , 3.10-3.12 (m, 2H) , 2.91-2.94 (m, 2H) , 2.42 (s, 3H) , 2.39-2.40 (m, 2H) , 2.26 (s, 3H) , 2.22 (s, 3H) , 1.81-1.88 (m, 1H) , 1.68-1.72 (m, 2H), 1.56 (s, 3H) , 1.35-1.40 (m, 2H) .
[0472] LC-MS (ESI, m / z) = 688.5 (M+H + ) Specific rotation [ ah) 25= +73.2333 (c=0.1, methanol) Preparation example 64. Synthesis of 2-(1-(2, 2 ■difluoroethyl)piperidin-4-yl)- 2, 4 ■dimethyl- N-((6-methyl-4-(methylthio)-2-oxo- 1, 2-dihydropyridin-3-yl)methyl)-7-(6-morpholinopyridin-3-yl)benzo[d][1,3]dioxole-5-carboxamide stereoisomer (compound 64) isomers
[0473]
[0474] [Step 6] The reaction was performed in the same manner as in Preparation Example 62, except that 2-iodo-1,1-difluoroethane (0.12 mL) was used instead of 2,2,2-trifluoroethyl trifluoromethanesulfonate, to obtain the title compound (0.2 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.45 (d, 1H), 7.95 (t, 1H), 7.81 (d, 1H), 7.03 (s, 1H), 6.89 (d, 1H), 6.04-6.05 (m, 2H), 4.26 (d, 2H) , 3.57-3.66 (m, 4H), 3.45-3.46 (m, 4H) , 2.88-2.89 (m, 2H) , 2.64-2.65 (m, 2H) , 2.40 (s, 3H), 2.17 (s, 3H), 2.13 (s, 3H) , 2.06-2.09 (m, 2H) , 1.82-1.84 (m, 1H) , 1.60- 1.62 (m, 2H), 1.57 (s, 3H) , 1.32-1.40 (m, 2H) .
[0475] LC-MS (ESI, m / z) = 670.5 (M+H + ) Specific rotation [ Q ]D 25 = -61.8334 (c=0.1, methanol) Manufacturing example 65. 2-(1-(2, 2 ■difluoroethyl)piperidin- 4 -yl)- 2, 4 ■dimethyl- N-
[0476] Stereoisomers of ((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(6-morpholinopyridin-3-yl)benzo[d][1,3]dioxole-5-carboxamide
[0477] Synthesis of A, (Compound 65)
[0478] [Step 6] The reaction was performed in the same manner as in Preparation Example 63, except that 2-iodo-1,1-difluoroethane (0.12 mL) was used instead of 2,2,2-trifluoroethyl trifluoromethanesulfonate, to obtain the title compound (0.2 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.46 (d, 1H), 7.95 (t, 1H), 7.81 (d, 1H), 7.03 (s, 1H), 6.89 (d, 1H), 6.04-6.05 (m, 2H), 4.26 (d, 2H), 3.66-3.68 (m, 4H), 3.44-3.46 (m, 4H), 2.89-2.92 (m, 2H), 2.61-2.65 (m, 2H), 2.40 (s, 3H), 2.17 (s, 3H), 2.13 (s, 3H) , 2.05-2.09 (m, 2H) , 1.80-1.85 (m, 1H) , 1.68- 1.70 (m, 2H), 1.57 (s, 3H) , 1.30-1.38 (m, 2H) .
[0479] LC-MS (ESI, m / z) = 670.5 (M+H + ) Specific rotation [ Q ]D 25 = +57.7334 (c=0.1, methanol) Manufacturing example 66. 2-(1-Ethylpiperidin- 4 -yl)- 2, 4 ■Dimethyl- N-((6 -methyl- 4 -
[0480] Synthesis of a stereoisomer of (methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(6-morpholinopyridin-3-yl)benzo[bi[1,3]dioxole-5-carboxamide, (Compound 66)
[0481] [Step 6] The reaction was carried out in the same manner as in Preparation Example 62, except that iodoethane (0.1 mL) was used instead of 2,2,2-trifluoroethyl trifluoromethanesulfonate, to obtain the title compound (0.1 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.45 (s, 1H), 7.95 (t, 1H), 7.82 (d, 1H), 7.03 (s, 1H), 6.89 (d, 1H), 6.04 (s, 1H), 4.26 (d, 2H) , 3.66-3.68 (m, 4H), 3.44-3.46 (m, 4H) , 2.88-2.89 (m, 2H) , 2.40 (s, 3H) , 2.22-2.28 (m, 2H) , 2.17(s, 3H), 2.13 (s, 3H) , 1.74-1.90 (m, 3H) , 1.69-1.71 (m, 2H) , 1.56 (s, 3H), 1.32-1.37 (m, 2H) , 0.93 (t, 3H) .
[0482] LC-MS (ESI, m / z) = 634.6 (M+H + ) Manufacturing example 67. Synthesis of stereoisomer A of 2-(1-ethylpiperidin-4-yl)-2, 4 ■dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(6-morpholinopyridin-3-yl)benzo[bi[1,3]dioxole-5-carboxamide, (Compound 67)
[0483] [Step 6] The reaction was carried out in the same manner as in Preparation Example 63 except that iodoethane (0.1 mL) was used instead of 2,2,2-trifluoroethyl trifluoromethanesulfonate, to obtain the title compound (0.1 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.46 (s, 1H), 7.95 (t, 1H), 7.82 (d, 1H), 7.03 (s, 1H), 6.89 (d, 1H), 6.05 (s, 1H) 4.26 (d, 2H) , 3.66-3.67 (m, 4H), 3.45-3.46 (m, 4H) , 2.95-2.98 (m, 2H) , 2.44 (s, 3H) , 2.32-2.40 (m, 2H) , 2.17(s, 3H), 2.13 (s, 3H) , 1.83-1.89 (m, 3H) , 1.71-1.79 (m, 2H) , 1.57 (s, 3H), 1.37-1.41 (m, 2H) , 0.97 (t, 3H) .
[0484] LC-MS (ESI, m / z) = 634.6 (M+H + ) Manufacturing Example 68. Synthesis of 2, 4 -dimethyl- N-( (6 -methyl- 4-(methylthio)- 2 -oxo- 1,2-dihydropyridin- 3 -yl)methyl )-7- (2 -morpholinopyrimidin- 5 -yl )-2-( 1- (2 , 2 , 2-trifluoro)piperidin- 4 -yl)benzo [d] [ 1,3]dioxole- 5 -carboxamide ,
[0485] (Compound 68) Except that 4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine was used instead of (2S,6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)morpholine (intermediate 1) in [Step 1] of the above Manufacturing Example 33, the processes of [Steps 1 to 5] were carried out in the same manner to obtain 2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(2-morpholinopyridine-5 -2-(piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide hydrochloride was obtained. Acetonitrile (10 mL), sodium carbonate (0.43 g), and trifluoroethyl trifluoromethanesulfonate (0.20 mL) were added to the obtained hydrochloride (0.5 g, 0.70 mmole), and the mixture was stirred at an internal temperature of 100°C for 24 hours. After cooling, dichloromethane (5 mL) was added, filtered, and concentrated. The resulting crystals were filtered using ethanol (2 mL) and hexane (20 mL), and dried at an internal temperature of 60°C to obtain the title compound (0.3 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.66 (s, 2H), 7.90 (t, 1H), 7.06 (s, 1H), 6.04 (s, 1H), 4.26 (d, 2H), 3.65-3.69 (m, 4H), 3.62-3.64 (m, 4H), 3.07- 3.10 (m, 2H), 2.90-2.92 (m, 2H), 2.40 (s, 3H), 2.22-2.28 (m, 2H), 2.19 (s, 3H), 2.12 (s, 3H), 1.81-1.87 (m, 1H) , 1.68-1.72 (m, 2H) , 1.56 (s, 3H) , 1.35- 1.38 (m, 2H).
[0486] LC-MS (ESI, m / z) = 689.5 (M+H+ ) Manufacturing example 69. Synthesis of 2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(2-morpholinopyrimidin-5-yl)-2-(1-(2,2,2-trifluoro)piperidin-4-yl)benzo[bi[1,3]dioxole-5-carboxamide stereoisomer, (Compound 69)
[0487] [Step 1] Except that stereospecific tert-butyl (R)-4-(7-bromo-5-(methoxycarbonyl)-2,4-dimethylbenzo[d][l,3]dioxol-2-yl)piperidine-1-carboxylate (3 g, 6.38 mmole) was used instead of tert-butyl 4-(7-bromo-5-(methoxycarbonyl)-2,4-dimethylbenzo[d][l,3]dioxol-2-yl)piperidine-1-carboxylate as the starting material, the reaction was carried out in the same manner as in Preparation Example 68 to obtain the title compound (0.3 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.67 (s, 2H), 7.90 (t, 1H), 7.07 (s, 1H), 6.04 (s, 1H), 4.26 (d, 2H), 3.68-3.70 (m, 4H), 3.63-3.64 (m, 4H), 3.08- 3.10 (m, 2H), 2.91-2.92 (m, 2H), 2.40 (s, 3H), 2.22-2.28 (m, 2H), 2.19 (s, 3H), 2.12 (s, 3H), 1.81-1.88 (m, 1H) , 1.68-1.71 (m, 2H) , 1.56 (s, 3H) , 1.35- 1.38 (m, 2H).
[0488] LC-MS (ESI, m / z) = 689.5 (M+H + ) Specific rotation [ ah) 25= -50.8167 (c=0.1, methanol) Preparation Example 70. Synthesis of stereoisomer A of 2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(2-morpholinopyrimidin-5-yl)-2-(1-(2,2,2-trifluoro)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide, (Compound 70) Stereoisomer A of
[0489]
[0490] [Step 1] Except that stereospecific tert-butyl (S)-4-(7-bromo-5-(methoxycarbonyl)-2,4-dimethylbenzo[d][l,3]dioxol-2-yl)piperidine-1-carboxylate (3 g, 6.38 mmole) was used instead of tert-butyl 4-(7-bromo-5-(methoxycarbonyl)-2,4-dimethylbenzo[d][l,3]dioxol-2-yl)piperidine-1-carboxylate as the starting material, the reaction was carried out in the same manner as in Preparation Example 68 to obtain the title compound (0.3 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.67 (s, 2H), 7.90 (t, 1H), 7.06 (s, 1H), 6.04 (s, 1H), 4.26 (d, 2H), 3.68-3.70 (m, 4H), 3.63-3.64 (m, 4H), 3.08- 3.12 (m, 2H), 2.92-2.98 (m, 2H), 2.40 (s, 3H), 2.20-2.30 (m, 2H), 2.16 (s, 3H), 2.12 (s, 3H), 1.80-1.86 (m, 1H) , 1.64-1.72 (m, 2H) , 1.56 (s, 3H) , 1.34— 1.36 (m, 2H).
[0491] LC-MS (ESI, m / z) = 689.5 (M+H + ) Specific rotation [ Q ]D 25= +62.5000 (c = 0.1, methanol) Preparation Example 71. 2-(1-(2,2-difluoroethyl)piperidin-4-yl)-2,4-dimethyl-N-
[0492] Synthesis of the stereoisomers of ((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(2-morpholinopyrimidin-5-yl)benzo[d][1,3]dioxole-5-carboxamide, (Compound 71)
[0493]
[0494] [Step 6] The reaction was carried out in the same manner as in Preparation Example 69 except that 2-iodo-1,1-difluoroethane (0.12 mL) was used instead of 2,2,2-trifluoroethyl trifluoromethanesulfonate to obtain the title compound (Compound 71) (0.2 g). 1H NMR (DMSO-d6): 11.5 (s, 1H), 8.67 (s, 2H), 7.91 (t, 1H), 7.06 (s,
[0495] 1H), 6.04 - 6.05 (m, 2H), 4.27 (d, 2H), 3.68 - 3.70 (m, 4H), 3.63 - 3.64 (m, 4H),
[0496] 2.89 - 2.91 (m, 2H), 2.62 - 2.65 (m, 2H), 2.40 (s, 3H), 2.17 (s, 3H), 2.13 (s,
[0497] 3H), 2.07 - 2.09 (m, 2H), 1.81 - 1.86 (m, 1H), 1.68 - 1.73 (m, 2H), 1.57 (s, 3H),
[0498] 1.32 - 1.40 (m, 2H).
[0499] LC-MS (ESI, m / z) = 671.5 (M + H + ) Specific rotation [α]D 25= -66.4167 (c=0.1, methanol) Manufacturing example 72. 2-(1-(2, 2 ■difluoroethyl)piperidin- 4 -yl)- 2, 4 ■dimethyl- N-
[0500] Stereoisomers of ((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(2-morpholinopyrimidin-5-yl)benzo[d][1,3]dioxole-5-carboxamide
[0501] Synthesis of A, (Compound 72)
[0502] [Step 6] The reaction was performed in the same manner as in Preparation Example 70, except that 2-iodo-1,1-difluoroethane (0.12 mL) was used instead of 2,2,2-trifluoroethyl trifluoromethanesulfonate, to obtain the title compound (0.2 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.67 (s, 2H), 7.91 (t, 1H), 7.06 (s, 1H), 6.05-6.06 (m, 2H), 4.27 (d, 2H), 3.68-3.70 (m, 4H) , 3.63-3.64 (m, 4H) , 2.87-2.90 (m, 2H) , 2.62-2.65 (m, 1H) , 2.40 (s, 3H) , 2.17 (s, 3H), 2.13 (s, 3H), 2.07-2.09 (m, 1H) , 1.68-1.73 (m, 2H) , 1.57 (s, 3H) , 1.32-1.40 (m, 2H) .
[0503] LC-MS (ESI, m / z) = 671.5 (M+H + ) Specific rotation [ Q ]D 25 = +55.1000 (c=0.1, methanol) Preparation Example 73. 2-(1-Ethylpiperidin- 4 -yl)- 2, 4 -dimethyl- N-((6 -methyl- 4- (methylthio)- 2 -oxo- 1, 2 -dihydropyridin- 3 -yl)methyl)-7-(2 -morpholinopyrimidine-
[0504] Synthesis of stereoisomer B of 5-day benzo[d][1,3]dioxole-5-carboxamide, (compound)
[0505] 73)
[0506] [Step 6] The reaction was carried out in the same manner as in Preparation Example 69 except that iodoethane (0.1 mL) was used instead of 2,2,2-trifluoroethyl trifluoromethanesulfonate, to obtain the title compound (0.1 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.70 (s, 2H), 7.92 (t, 1H), 7.10 (s,
[0507] 1H), 6.05 (s, 1H), 4,27 (d, 2H) , 3.70-3.72 (m, 4H) , 3.63-3.65 (m, 4H) , 3.40- 3.51 (m, 2H), 3.25-3.27 (m, 2H) , 3.01-3.05 (m, 2H) , 2.82-2.88 (m, 2H), 2.41 (s, 3H), 2.20 (s, 3H), 2.13 (s, 3H) , 1.92-2.00 (m, 2H) , 1.61 (s, 3H) , 1.54— 1.57 (m, 1H), 1.14-1.16 (t, 3H) .
[0508] LC-MS (ESI, m / z) = 635.6 (M+H + ) Specific rotation [ Q ]D 25 = -48.7834 (c=0.1, methanol) Preparation Example 74. Synthesis of stereoisomer A of 2-(1-ethylpiperidin-4-yl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(2-morpholinopyrimidin-5-yl)benzo[bi[1,3]dioxole-5-carboxamide, (Compound 74)
[0509] [Step 6] The reaction was carried out in the same manner as in Preparation Example 70 except that iodoethane (0.1 mL) was used instead of 2,2,2-trifluoroethyl trifluoromethanesulfonate, to obtain the title compound (0.1 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.71 (s, 2H), 7.92 (t, 1H), 7.10 (s,
[0510] 1H), 6.06 (s, 1H), 4,27 (d, 2H) , 3.70-3.72 (m, 4H) , 3.63-3.65 (m, 4H) , 3.40-
[0511] 3.51 (m, 2H), 3.25-3.29 (m, 2H) , 3.01-3.05 (m, 2H) , 2.82-2.88 (m, 2H), 2.41 (s, 3H), 2.19 (s, 3H), 2.13 (s, 3H) , 1.90-1.98 (m, 2H) , 1.60 (s, 3H) , 1.53-
[0512] 1.59 (m, 1H), 1.15-1.20 (t, 3H) . LC-MS (ESI, m / z) = 635.6 (M+H + ) Specific rotation [Q]D 25 = +56.6834 (c=0.1, methanol) Manufacturing example 75. Synthesis of 7-(2-(4-ethylpiperazin-1-yl)pyrimidin-5-yl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzo[bi[1,3]dioxole-5-carboxamide, (Compound 75) In [Step 1] of the above Manufacturing Example 33, (2S,6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine (Intermediate 1) was used instead of 2-(4-ethylpiperazin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine, and the same procedures of [Steps 1 to 5] were carried out to obtain 7-(2-(4-ethylpiperazin-1-yl)pyrimidin-5-yl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2 -Oxo- 1,2-dihydropyridin- 3-yl)methyl)- 2- (pyridin- 4-yl)benzo[d][1,3]dioxole- 5-carboxamide hydrochloride was obtained. The obtained hydrochloride (0.5 g, 0.70 mmole) was added with acetonitrile (10 mL), sodium carbonate (0.43 g) and trifluoroethyl trifluoromethanesulfonate.
[0513] (0.20 mL) was added and stirred at an internal temperature of 100°C for 24 hours. Cooled, dichloromethane (5 mL) was added, filtered, concentrated, and then ethanol (2 mL) and hexane were added.
[0514] The resulting crystals were filtered using (20 mL) and dried at an internal temperature of 60°C to obtain the title compound (0.2 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.65 (s, 2H), 7.91 (t, 1H), 7.05 (s, 1H), 6.05 (s, 1H), 4.27 (d, 2H), 3.66-3.70 (m, 4H), 3.06-3.12 (m, 2H) , 2.91- 2.93 (m, 2H), 2.40 (s, 3H) , 2.36-2.40 (m, 4H) , 2.30-2.34 (m, 2H) , 2.22-2.28 (m, 2H), 2.17 (s, 3H) , 2.13 (s, 3H) , 1.82-1.87 (m, 1H) , 1.68-1.70 (m, 2H) , 1.56 (s, 3H), 1.34-1.38 (m, 2H) , 1.00 (t, 3H) .
[0515] LC-MS (ESI, m / z) = 716.4 (M+H + ) Manufacturing example 76. Synthesis of 7-(2-(4-ethylpiperazin-1-yl)pyrimidin-5-yl)- 2, 4 ■dimethyl- N-((6-methyl- 4-(methylthio)- 2 -oxo- 1 , 2 ■dihydropyridin- 3 -yl)methyl )-2-( 1-(2 , 2, 2-trifluoroethyl)piperidin- 4 -yl)benzo [d] [1,3]dioxole- 5 -carboxamide stereoisomer, (Compound 76) isomers
[0516]
[0517] [Step 1] Except that stereospecific tert-butyl (R)-4-(7-bromo-5-(methoxycarbonyl)-2,4-dimethylbenzo[d][l,3]dioxol-2-yl)piperidine-1-carboxylate (3 g, 6.38 mmole) was used instead of tert-butyl 4-(7-bromo-5-(methoxycarbonyl)-2,4-dimethylbenzo[d][l,3]dioxol-2-yl)piperidine-1-carboxylate as the starting material, the reaction was carried out in the same manner as in Preparation Example 75 to obtain the title compound (0.2 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.64 (s, 2H), 7.92 (s, 1H), 7.05 (s, 1H), 6.05 (s, 1H), 4.27 (d, 2H), 3.75-3.70 (m, 4H), 3.06-3.10 (m, 2H) , 2.91- 2.93 (m, 2H), 2.41 (s, 3H) , 2.36-2.40 (m, 4H) , 2.30-2.34 (m, 2H) , 2.21-2.28 (m, 2H), 2.17 (s, 3H) , 2.13 (s, 3H) , 1.82-1.87 (m, 1H) , 1.68-1.70 (m, 2H) , 1.56 (s, 3H), 1.35-1.38 (m, 2H) , 1.00 (t, 3H) .
[0518] LC-MS (ESI, m / z) = 716.6 (M+H + ) Manufacturing Example 77. 7-(2-(4-ethylpiperazin-1-yl)pyrimidin-5-yl)-2,4-dimethyl-N-
[0519] Synthesis of stereoisomer A of ((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(2, 2, 2~trifluoroethyl)piperidin-4-yl)benzo[d][1, 3]dioxole-5-carboxamide, (Compound 77)
[0520]
[0521] [Step 1] Except that stereospecific tert-butyl (S)-4-(7-bromo-5-(methoxycarbonyl)-2,4-dimethylbenzo[d][l,3]dioxol-2-yl)piperidine-1-carboxylate (3 g, 6.38 mmole) was used instead of tert-butyl 4-(7-bromo-5-(methoxycarbonyl)-2,4-dimethylbenzo[d][l,3]dioxol-2-yl)piperidine-1-carboxylate as the starting material, the reaction was carried out in the same manner as in Preparation Example 75 to obtain the title compound (0.2 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.64 (s, 2H), 7.92 (s, 1H), 7.06 (s,
[0522] 1H), 6.05 (s, 1H), 4.27 (d, 2H) , 3.73-3.74 (m, 4H) , 3.06-3.12 (m, 2H) , 2.91- 2.93 (m, 2H), 2.41 (s, 3H) , 2.34-2.43 (m, 4H) , 2.26-2.34 (m, 2H) , 2.20-2.26 (m, 2H), 2.17 (s, 3H) , 2.13 (s, 3H) , 1.82-1.87 (m, 1H) , 1.68-1.70 (m, 2H) , 1.56 (s, 3H), 1.35-1.39 (m, 2H) , 1.01 (t, 3H) . LC-MS (ESI, m / z) = 716.6 (M+H + ) Manufacturing example 78. Synthesis of 7-(2-(ethyl (methyl)amino)pyridin-5-yl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzo[bi[1,3]dioxole-5-carboxamide, (Compound 78) Except that N-ethyl- N-methyl- 5-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan- 2-yl)pyrimidin- 2-amine was used instead of (2S,6R)- 2,6-dimethyl- 4- (5- (4,4,5,5-tetramethyl- 1,3,2-dioxaborolan- 2-yl)pyridin- 2-yl)morpholine (intermediate 1) in [Step 1] of the above Manufacturing Example 33, the same procedures of [Steps 1 to 5] were carried out to obtain 7- (2- (ethyl (methyl) amino) pyrimidin- 5 -yl)- 2,4-dimethyl- N- ( (6 -methyl- 4-
[0523] (Methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide hydrochloride was obtained. Acetonitrile (10 mL), sodium carbonate (0.43 g), and trifluoroethyl trifluoromethanesulfonate (0.20 mL) were added to the obtained hydrochloride (0.5 g, 0.73 mmole), and the mixture was stirred at an internal temperature of 100°C for 24 hours. After cooling, dichloromethane (5 mL) was added, filtered, and concentrated. The resulting crystals were filtered using ethanol (2 mL) and hexane (20 mL), and dried at an internal temperature of 60°C to obtain the title compound (0.3 g). P NMR (DMS0-d6): 11.5(s, 1H), 8.62(s, 2H), 7.90 (d, 1H), 7.05 (s, 1H), 6.05 (s, 1H), 4.26 (d, 2H), 3.62-3.63 (m, 2H), 3.06-3.10 (m, 5H) , 2.91- 2.92 (m, 2H), 2.40 (s, 3H) , 2.24-2.28 (m, 2H) , 2.17 (s, 3H) , 2.13 (s, 3H) , 1.83-1.88 (m, 1H), 1.69-1.72 (m, 2H) , 1.56 (s, 3H) , 1.36-1.38 (m, 2H), 1.07 (t, 3H).
[0524] LC-MS (ESI, m / z) = 661.5 (M+H + ) Manufacturing example 79. Synthesis of stereoisomers of 7-(2-(ethyl(methyl)amino)pyridin-5-yl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide, (Compound 79)
[0525] [Step 1] Except that stereospecific tert-butyl (R)-4-(7-bromo-5-(methoxycarbonyl)-2,4-dimethylbenzo[d][l,3]dioxol-2-yl)piperidine-1-carboxylate (3 g, 6.38 mmole) was used instead of tert-butyl 4-(7-bromo-5-(methoxycarbonyl)-2,4-dimethylbenzo[d][l,3]dioxol-2-yl)piperidine-1-carboxylate as the starting material, the reaction was carried out in the same manner as in Preparation Example 78 to obtain the title compound (0.3 g). P NMR (DMS0-d6): 11.5(s, 1H), 8.62(s, 2H), 7.90 (t, 1H), 7.05 (s, 1H), 6.05 (s, 1H), 4.26 (d, 2H), 3.62-3.65 (m, 2H), 3.06-3.10 (m, 5H) , 2.91- 2.92 (m, 2H), 2.40 (s, 3H) , 2.24-2.28 (m, 2H) , 2.17 (s, 3H) , 2.13 (s, 3H) , 1.82-1.84 (m, 1H), 1.69-1.70 (m, 2H) , 1.56 (s, 3H) , 1.36-1.40 (m, 2H), 1.07 (t, 3H).
[0526] LC-MS (ESI, m / z) = 661.5 (M+H + ) Specific rotation [ ah) 25= -49.3500 (c=0.1, methanol) Preparation example 80. Synthesis of stereoisomer A of 7-(2-(ethyl (methyl)amino)pyridin- 5 -yl)- 2, 4 ■dimethyl- N- ((6-methyl— 4-(methylthio)- 2 -oxo- 1 , 2 ■dihydropyridin- 3 -yl)methyl )-2-( 1-(2 ,2,2-trifluoroethyl)piperidin- 4 -yl)benzo [d] [1,3]dioxole- 5 -carboxamide, (Compound 80) Stereoisomers
[0527] [Step 1] Except that stereospecific tert-butyl (S)-4-(7-bromo-5-(methoxycarbonyl)-2,4-dimethylbenzo[d][l,3]dioxol-2-yl)piperidine-1-carboxylate (3 g, 6.38 mmole) was used instead of tert-butyl 4-(7-bromo-5-(methoxycarbonyl)-2,4-dimethylbenzo[d][l,3]dioxol-2-yl)piperidine-1-carboxylate as the starting material, the reaction was carried out in the same manner as in Preparation Example 78 to obtain the title compound (0.3 g). P NMR (DMS0-d6): 11.5(s, 1H), 8.62(s, 2H), 7.90 (t, 1H), 7.05 (s, 1H), 6.05 (s, 1H), 4.26 (d, 2H), 3.62-3.65 (m, 2H), 3.06-3.12 (m, 5H) , 2.91- 2.92 (m, 2H), 2.41 (s, 3H) , 2.24-2.28 (m, 2H) , 2.17 (s, 3H) , 2.13 (s, 3H) , 1.83-1.88 (m, 1H), 1.69-1.72 (m, 2H) , 1.56 (s, 3H) , 1.36-1.38 (m, 2H), 1.07 (t, 3H).
[0528] LC-MS (ESI, m / z) = 661.5 (M+H + ) Specific rotation [ Q ]D 25= +63.2167 (c=0.1, methanol) Manufacturing example 81. 2-(l-(2, 2-difluoroethyl)piperidin-4-yl)-7-(2-
[0529] (Ethyl (methyl) amino) pyrimidin -5 -yl) - 2, 4 ■ Dimethyl- N- ((6 -methyl- 4- (methylthio) - 2 -oxo-
[0530] Synthesis of stereoisomers of 1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide (Compound 81)
[0531] [Step 6] Instead of 2,2,2-trifluoroethyl trifluoromethanesulfonate
[0532] 2 - Same as the above manufacturing example except that iodo-1,1-difluoroethane (0.13 mL) was used
[0533] The reaction was carried out in the same manner as in 79, and the title compound (0.2 g) was obtained. P NMR (DMS0-d6): 11.5 (s, 1H), 8.63 (s, 2H), 7.90 (t, 1H), 7.04 (s,
[0534] 1H), 6.04-6.05 (m, 2H), 4.26 (d, 2H), 3.61-3.64 (m, 2H), 3.07 (s, 3H), 2.91-
[0535] 2.92 (m, 2H), 2.62-2.65 (m, 2H), 2.40 (s, 3H), 2.17 (s, 3H), 2.13 (s, 3H),
[0536] 2.06 (t, 2H), 1.80-1.81 (m, 1H), 1.68-1.69 (m, 2H), 1.56 (s, 3H), 1.35-1.36
[0537] (m, 2H), 1.08 (t, 3H).
[0538] LC-MS (ESI, m / z) = 643.5 (M+H+) Specific rotation [ ah) 25= -52.7667 (c=0.1, methanol) Manufacturing example 82. 2-(1-(2, 2 ■difluoroethyl)piperidine- 4 -yl)- 7-(2-
[0539] (Ethyl (methyl) amino) pyrimidin -5 -yl) - 2, 4 ■ Dimethyl- N- ((6 -methyl- 4- (methylthio) - 2 -oxo-
[0540] Synthesis of stereoisomer A of 1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide (Compound 82)
[0541] In [Step 6] instead of 2, 2, 2-trifluoroethyl trifluoromethanesulfonate
[0542] 2 - Same as the above manufacturing example except that iodo-1,1-difluoroethane (0.13 mL) was used
[0543] The reaction was carried out in the same manner as in 80, and the title compound (0.2 g) was obtained. P NMR (DMS0-d6): 11.5 (s, 1H), 8.62 (s, 2H), 7.91 (t, 1H), 7.05 (s,
[0544] 1H), 6.04-6.05 (m, 2H), 4.26 (d, 2H), 3.62-3.65 (m, 2H), 3.08 (s, 3H), 2.89-
[0545] 2.92 (m, 2H), 2.62-2.78 (m, 2H), 2.41 (s, 3H), 2.17 (s, 3H), 2.13 (s, 3H),
[0546] 2.06 (t, 2H), 1.81-1.86 (m, 1H), 1.68-1.69 (m, 2H), 1.57 (s, 3H), 1.35-1.39
[0547] (m, 2H), 1.07 (t, 3H).
[0548] LC-MS (ESI, m / z) = 643.5 (M+H+) Specific rotation [ ah) 25= +62.1000 (c=0.1, methanol) Manufacturing example 83. 7-(2-(ethyl(methyl)amino)pyrimidin-5-yl)- 2-(1-ethylpiperidine-
[0549] 4 - 1) - 2 , 4 - dimethyl - N - ( 6 - methyl - 4- (methylthio) - 2 - oxo - 1 , 2 - dihydropyridin - 3 - methyl tal 〉 benzo UHlO 1 dioxol * carboxamide of — 』 body — up! body — of — J%
[0550] (Compound 83)
[0551] [Step 6] The reaction was performed in the same manner as in Preparation Example 79, except that iodoethane (0.12 mL) was used instead of 2,2,2-trifluoroethyl trifluoromethanesulfonate, to obtain the title compound (0.1 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.63 (s, 2H), 7.92 (t, 1H), 7.08 (s, 1H), 6.06 (s, 1H), 4.28 (d, 2H), 3.61-3.64 (m, 2H), 3.40-3.47 (m, 2H), 3.08 (s, 3H), 2.96-3.05 (m,2H), 2.61-2.90 (m, 2H), 2.41 (s, 3H), 2.19 (s, 3H), 2.13 (s, 3H), 1.91-1.96 (m, 3H) , 1.60 (s, 3H), 1.55-1.57 (m, 2H), 1.14 (t, 3H), 1.07 (t, 3H).
[0552] LC-MS (ESI, m / z) = 607.5 (M+H + ) Manufacturing Example 84. Synthesis of stereoisomer A of 7-(2-(ethyl(methyl)amino)pyrimidin-5-yl)- 2-(1-ethylpiperidin- 4-yl)- 2,4-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3-yl)methyl)benzo [d][l,3]dioxole- 5-carboxamide.
[0553] (Compound 84)
[0554] [Step 6] The reaction was carried out in the same manner as in Preparation Example 80, except that iodoethane (0.12 mL) was used instead of 2,2,2-trifluoroethyl trifluoromethanesulfonate, to obtain the title compound (0.1 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.63 (s, 2H), 7.92 (t, 1H), 7.08 (s, 1H), 6.06 (s, 1H), 4.27 (d, 2H), 3.63-3.66 (m, 2H), 3.43-3.55 (m, 2H), 3.08 (s, 3H), 3.03-3.06 (m,2H), 2.80-2.96 (m, 2H), 2.41 (s, 3H), 2.21 (s, 3H), 2.13 (s, 3H), 1.93-2.00 (m, 3H) , 1.60 (s, 3H), 1.28-1.32 (m, 2H), 1.11-1.28 (m, 3H), 1.07 (t, 3H).
[0555] LC-MS (ESI, m / z) = 607.5 (M+H + ) Manufacturing Example 85. Synthesis of 7-(6-(ethyl (methyl)amino)pyridin-3-yl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(2,2,2-trifluoro)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide,
[0556] (Compound 85) In [Step 1] of the above Preparation Example 33, (2S,6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine (Intermediate 1) was replaced with N-ethyl-N-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine, but the same procedures as in [Step 1 to 5] were carried out to obtain 7-(6-(ethyl(methyl)amino)pyridin-3-yl)-2,4-dimethyl-N-((6-methyl-4-
[0557] (Methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide hydrochloride was obtained. Acetonitrile (10 mL), sodium carbonate (0.43 g), and 2,2,2-trifluoroethyl trifluoromethanesulfonate (0.20 mL) were added to the obtained hydrochloride (0.5 g, 0.73 mmole), and the mixture was stirred at an internal temperature of 100°C for 24 hours. After cooling, dichloromethane (5 mL) was added, filtered, and concentrated. The resulting crystals were filtered using ethanol (2 mL) and hexane (20 mL), and dried at an internal temperature of 60°C to obtain the title compound (0.3 g). P NMR (DMS0-d6): 11.6 (s, 1H), 8.41 (s, 1H), 7.92 (t, 1H), 7.76 (d, 1H), 7.01 (s, 1H), 6.65 (d, 1H), 6.03 (s, 1H), 4.25 (d, 2H) , 3.51-3.53 (m, 2H), 3.05-3.11 (m, 2H) , 2.96 (s, 3H) , 2.91-2.93 (m, 2H) , 2.41 (s, 3H), 2.26- 2.28 (m, 2H), 2.16 (s, 3H) , 2.13 (s, 3H) , 1.82-1.86 (m, 1H) , 1.69-1.71 (m, 2H), 1.56 (s, 3H), 1.36-1.41 (m, 2H) , 1.04 (t, 3H) .
[0558] LC-MS (ESI, m / z) = 660.5 (M+H + ) Manufacturing example 86. Synthesis of 7-(6-(ethyl(methyl)amino)pyridin-3-yl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo- 1,2 ■dihydropyridin-3-yl)methyl)-2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzo[bi[1,3]dioxole-5-carboxamide stereoisomer, (Compound 86)
[0559] [Step 1] Except that stereospecific tert-butyl (R)-4-(7-bromo-5-(methoxycarbonyl)-2,4-dimethylbenzo[d][l,3]dioxol-2-yl)piperidine-1-carboxylate (3 g, 6.38 mmole) was used instead of tert-butyl 4-(7-bromo-5-(methoxycarbonyl)-2,4-dimethylbenzo[d][l,3]dioxol-2-yl)piperidine-1-carboxylate as the starting material, the reaction was carried out in the same manner as in Preparation Example 85 to obtain the title compound (0.3 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.41 (s, 1H), 7.93 (t, 1H), 7.76 (d,
[0560] 1H), 7.01 (s, 1H), 6.65 (d, 1H), 6.04 (s, 1H), 4.26 (d, 2H), 3.52-3.55 (m,
[0561] 2H), 3.06-3.12 (m, 2H) , 2.96 (s, 3H) , 2.91-2.93 (m, 2H) , 2.41 (s, 3H) , 2.27-
[0562] 2.29 (m, 2H), 2.16 (s, 3H) , 2.13 (s, 3H) , 1.82-1.86 (m, 1H) , 1.69-1.71 (m,
[0563] 2H), 1.56 (s, 3H), 1.36-1.41 (m, 2H), 1.04 (t, 3H).
[0564] LC-MS (ESI, m / z) = 660.5 (M+H + ) Specific rotation [ ah) 25= -61.9834 (c=0.1, methanol) Preparation Example 87. Synthesis of stereoisomer A of 7-(6-(ethyl(methyl)amino)pyridin-3-yl)- 2, 4 ■dimethyl- N-((6-methyl- 4-(methylthio)- 2 -oxo- 1 ,2 -dihydropyridin- 3 -yl)methyl)~2~(!~(2 ,2 ,2~ trifluoroethyl)piperidin- 4 -yl)benzo [d] [1,3]dioxole- 5 -carboxamide, (Compound 87) [Step 1] Except that stereospecific tert-butyl (S)-4-(7-bromo-5-(methoxycarbonyl)-2,4-dimethylbenzo[d][l,3]dioxol-2-yl)piperidine-1-carboxylate (3 g, 6.38 mmole) was used instead of tert-butyl 4-(7-bromo-5-(methoxycarbonyl)-2,4-dimethylbenzo[d][l,3]dioxol-2-yl)piperidine-1-carboxylate as the starting material, the reaction was carried out in the same manner as in Preparation Example 85 to obtain the title compound (0.3 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.41 (s, 1H), 7.93 (t, 1H), 7.76 (d,
[0565] 1H), 7.01 (s, 1H), 6.65 (d, 1H), 6.05 (s, 1H), 4.26 (d, 2H), 3.51-3.56 (m,
[0566] 2H), 3.08-3.12 (m, 2H) , 2.97 (s, 3H) , 2.91-2.94 (m, 2H) , 2.41 (s, 3H) , 2.26-
[0567] 2.28 (m, 2H), 2.16 (s, 3H) , 2.13 (s, 3H) , 1.82-1.87 (m, 1H) , 1.69-1.73 (m,
[0568] 2H), 1.56 (s, 3H), 1.36-1.41 (m, 2H), 1.03 (t, 3H).
[0569] LC-MS (ESI, m / z) = 660.5 (M+H + ) Manufacturing Example 88. 2-(1-(2, 2 ■difluoroethyl)piperidin- 4 -yl)- 7-(6-
[0570] (Ethyl (methyl) amino) pyridin-3 -yl)- 2, 4 ■ Dimethyl- N- ((6 ■ Methyl- 4- (methylthio)- 2 -oxo-
[0571] Synthesis of stereoisomers of 1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide (Compound 88) Stereoisomer B of
[0572]
[0573] [Step 6] The reaction was carried out in the same manner as in Preparation Example 86 except that 2-iodo-1,1-difluoroethane (0.13 mL) was used instead of 2,2,2-trifluoroethyl trifluoromethanesulfonate, to obtain the title compound (0.2 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.40 (s, 1H), 7.94 (t, 1H), 7.74 (d, 1H), 7.01 (s, 1H), 6.66 (d, 1H), 5.95-6.07 (m, 3H), 4.26 (d, 2H), 3.52-3.55
[0574] (m, 2H) 2.97 (s, 3H) , 2.90-2.92 (m, 2H) , 2.62-2.67 (m, 2H) , 2.41 (s, 3H) ,
[0575] 2.16 (s, 3H), 2.13 (s, 3H) , 2.07-2.10 (m, 2H) . 1.80-1.84 (m, 1H) , 1.68-1.71
[0576] (m, 2H), 1.56 (s, 3H), 1.35-1.42 (m, 2H), 1.04 (t, 3H).
[0577] LC-MS (ESI, m / z) = 642.5 (M+H + ) Manufacturing example 89. Synthesis of stereoisomers of 7-(6-(ethyl(methyl)amino)pyridin-3-yl)-2-(1-ethylpiperidine-4~yl)-2,4 ■dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2 ■dihydropyridin-3-yl)methyl)benzo[d][l,3]dioxole-5-carboxamide,
[0578] (Compound 89) Stereoisomer B of
[0579]
[0580] [Step 6] The reaction was carried out in the same manner as in Preparation Example 86 except that iodoethane (0.12 mL) was used instead of 2,2,2-trifluoroethyl trifluoromethanesulfonate, to obtain the title compound (0.1 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.46 (s, 1H), 7.95 (t, 1H), 7.77 (d, 1H), 7.03 (s, 1H), 6.65 (d, 1H), 6.05 (s, 1H), 4.26 (d, 2H), 3.54-3.56 (m,
[0581] 2H), 3.47-3.49 (m, 2H) , 3.01-3.04 (m, 2H) , 2.97 (s, 3H) , 2.84-2.90 (m, 2H) ,
[0582] 2.41 (s, 3H), 2.19-2.20 (m, 1H) , 2.18 (s, 3H) , 2.13 (s, 3H) , 1.94-2.01 (m,
[0583] 2H), 1.60-1.65 (m, 5H), 1.16 (t, 3H), 1.04 (t, 3H).
[0584] LC-MS (ESI, m / z) = 606.5 (M+H +) Manufacturing example 90. 2, 4 ■Synthesis of dimethyl- N- ((6-methyl- 4- (methylthio)- 2-oxo- 1,2- dihydropyridin- 3 -yl) methyl) ~ 7~ (4~ (piperidin- 1-yl) phenyl) ~ 2~ ( ! ~ (2 , 2 , 2~ trifluoroethyl) piperidin- 4 -yl) benzo [d] [1,3] dioxole- 5 - carboxamide, (compound 90)
[0585] In the above Preparation Example 33 [Step 1], (2S,6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine (Intermediate 1) was replaced with 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidine, and the same procedures of [Steps 1 to 5] were carried out to obtain 2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(4-(piperidin-1-yl)phenyl)- 2-(Piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide hydrochloride was obtained. Acetonitrile (10 mL), sodium carbonate (0.43 g), and 2,2,2-trifluoroethyl trifluoromethanesulfonate (0.20 mL) were added to the obtained hydrochloride (0.5 g, 0.73 mmole), and the mixture was stirred at an internal temperature of 100°C for 24 hours. After cooling, dichloromethane (5 mL) was added, filtered, and concentrated. After filtering, the resulting crystals were filtered using ethanol (2 mL) and hexane (20 mL), and dried at an internal temperature of 60°C to obtain the title compound (0.3 g). P NMR (DMS0-d6): 11.5 (s, 1H), 7.95 (t, 1H), 7.50 (d, 2H), 7.01 (s, 1H), 6.91 (d, 2H), 6.04 (s, 1H), 4.26 (d, 2H), 3.14-3.16 (m, 4H) , 3.04-3.14 (m, 2H), 2.91-2.96 (m, 2H) , 2.41 (s, 3H) , 2.20-2.28 (m, 2H) , 2.16 (s, 3H) ,
[0586] 2.13 (s, 3H), 1.82-1.86 (m, 1H) , 1.66-1.73 (m, 2H) , 1.55-1.58 (m, 4H), 1.55 (s, 3H) , 1.49-1.54 (m, 2H) , 1.35-1.40 (m, 2H) .
[0587] LC-MS (ESI, m / z) = 685.5 (M+H + ) Manufacturing example 91. 2, 4 ■Synthesis of dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3 -yl)methyl)-7-(6-(piperidin- 1-yl)pyridin- 3 -yl)-2-( 1-(2, 2, 2-trifluoroethyl)piperidin- 4 -yl)benzo [d] [1,3]dioxole- 5 -carboxamide, (Compound 91) In [Step 1] of the above Manufacturing Example 33, 2, 6-dimethyl- 4- (5- (4, 4, 5, 5-tetramethyl- 1,3, 2-dioxaborolan- 2-yl)pyridin- 2-yl)morpholine (Intermediate 1) was replaced with 2- (piperidin- 1-yl)-5- (4, 4, 5, 5-tetraamyl- 1,3, 2-dioxaborolan- 2-yl)pyridine, and the same procedures of [Steps 1 to 5] were carried out to obtain 2, 4-dimethyl- N- ( (6-methyl- 4- (methylthio)- 2-oxo- 1, 2-dihydropyridin- 3-yl)methyl)- 7- (6- (piperidin- 1-(piperidin-3-yl)-2-(piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide hydrochloride was obtained. The obtained hydrochloride (0.5 g, 0.73 mmole) was added with acetonitrile (10 mL), sodium carbonate (0.43 g) and 2,2,2-trifluoroethyl trifluoromethanesulfonate.
[0588] (0.20 mL) was added and stirred at an internal temperature of 100°C for 24 hours. After cooling, dichloromethane (5 mL) was added, filtered, concentrated, and then ethanol (2 mL) and hexane were added.
[0589] The resulting crystals were filtered using (20 mL) and dried at an internal temperature of 60 °C to obtain the title compound (0.3 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.40 (s, 1H), 7.94 (t, 1H), 7.81 (d,
[0590] 1H), 7.02 (s, 1H), 6.89 (d, 1H), 6.05 (d, 1H), 4.26 (d, 2H), 3.51-3.54 (m,
[0591] 4H), 3.09 (d, 2H), 2.93 (d, 2H), 2.41 s, 3H), 2.22-2.30 (m, 2H), 2.16 s,
[0592] 3H), 2.13 (s, 3H), 1.80-1.90 (m, 1H), 1.69-1.71 (d, 2H), 1.56-1.57 (m, 2H),
[0593] 1.56 s, 3H), 1.51-1.52 (m, 4H), 1.34-1.40 (m, 2H).
[0594] LC-MS (ESI, m / z) = 686.4 (M+H+) Preparation Example 92. 2, 4 ■Dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3 -yl)methyl)-7-(2 ■Thiomorpholinopyrimidin- 5 -yl)-2-( 1-(2, 2, 2-trifluoroethyl)piperidin- 4 -yl)benzo [d] [1,3]dioxole- 5 -carboxamide Synthesis, (Compound 92) In [Step 1] of the above Manufacturing Example 33, (2S,6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine (Intermediate 1) was replaced with 4-
[0595] The same steps as in [Steps 1 to 5] were carried out except that (5-(4, 4, 5, 5 -tetramethyl- 1,3, 2 -dioxaborolan- 2 -yl)pyrimidin-2 -yl)thiomorpholine was used. [Step
[0596] 5] 2,4-dimethyl- N- ( (6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3-yl )methyl )- 2-(piperidin- 4 -yl )- 7- (6-thiomorpholinopyridin- 3-yl )benzo [d] [1,3]dioxole- 5 -carboxamide hydrochloride was obtained. To the obtained hydrochloride (0.5 g, 0.73 mmole) were added acetonitrile (lOmL), sodium carbonate (0.43 g) and 2,2,2-trifluoroethyl trifluoromethanesulfonate (0.20 mL), and the mixture was stirred at an internal temperature of 100°C for 24 hours. After cooling, dichloromethane (5 mL) was added, filtered, concentrated, and the resulting crystals were filtered using ethanol (2 mL) and hexane (20 mL), and dried at an internal temperature of 60°C to obtain the title compound (0.3 g). P NMR (DMS0-d6): 11.5 (s. 1H), 8.70 (s, 2H), 7.91 (t, 1H), 7.06 (s, 1H), 6.04 (s, 1H), 4.24-4.28 (m, 2H), 4.06-4.08 (m, 4H) , 3.08-3.10 (m, 2H) , 2.88-2.95 (m, 2H) , 2.58-2.60 (m, 4H) 2.41 (s. 3H) , 2.21-2.30 (m, 2H) , 2.17 (s, 3H), 2.13 (s, 3H), 1.78-1.88 (m, 1H) , 1.65-1.71 (m, 2H) , 1.56 (s, 3H) , 1.34-1.38 (m, 2H) .
[0597] LC-MS (ESI, m / z) = 705.8 (M+H +) Manufacturing Example 93. Synthesis of 2',2'-difluoro-2,7-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)-[4,5'-bibenzo[bi[1,3]dioxole]-6-carboxamide, (Compound 93)
[0598] In the above Manufacturing Example 33 [Step 1], (2S,6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine (Intermediate 1) was replaced with 2-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolan, and the same procedures as in [Steps 1 to 5] were carried out to obtain 2',2'-difluoro-2,7-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)- 2-(Piperidin-4-yl)-[4,5'-bibenzo[d][1,3]dioxole-6-carboxamide hydrochloride was obtained. Acetonitrile (10 mL), sodium carbonate (0.43 g), and 2,2,2-trifluoroethyl trifluoromethanesulfonate (0.20 mL) were added to the obtained hydrochloride (0.5 g, 0.73 mmole), and the mixture was stirred at an internal temperature of 100°C for 24 hours. After cooling, dichloromethane (5 mL) was added, filtered, and concentrated. The resulting crystals were filtered using ethanol (2 mL) and hexane (20 mL), and dried at an internal temperature of 60°C to obtain the title compound (0.3 g). P NMR (DMS0-d6): 11.5 (s, 1H), 7.95 (t, 1H), 7.67 (s, 1H), 7.49-7.51 (m, 1H), 7.46-7.47 (m, 1H), 7.07 (s, 1H), 6.05 (s, 1H) , 4.27 (d, 2H) , 3.06- 3.12 (m, 2H), 2.89-2.95 (m, 2H) , 2.41 (s, 3H) , 2.25-2.31 (m, 2H) , 2.19 (s, 3H), 2.13 (s, 3H), 1.83-1.88 (m, 1H) , 1.69-1.71 (m, 2H) , 1.58 (s, 3H) , 1.35 - 1.40 (m, 2H) .
[0599] LC-MS (ESI, m / z) = 682.7 (M+H + ) Manufacturing Example 94. 2, 7 ■Dimethyl- N-( (6 -methyl- 4-(methylthio)- 2 -oxo- 1,2-dihydropyridin- 3 -yl)methyl )~2~( !~(2 , 2 , 2 -trifluoroethyl)piperidin- 4 -yl )~
[0600] Synthesis of [4,5'-bibenzo[d][l, 3]dioxole]-6-carboxamide, (Compound 94) In [Step 1] of the above Manufacturing Example 33, (2S,6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine (intermediate 1) was used instead of 2-(benzo[d][1,3]dioxol-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolan, and the same procedures of [Steps 1 to 5] were carried out to obtain 2,7-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(piperidine-4 -1)-[4,5'-bibenzo[d][1,3]dioxole]-6-carboxamide hydrochloride was obtained. Acetonitrile (10 mL), sodium carbonate (0.43 g), and 2,2,2-trifluoroethyl trifluoromethanesulfonate (0.20 mL) were added to the obtained hydrochloride (0.5 g, 0.73 mmole), and the mixture was stirred at an internal temperature of 100°C for 24 hours. After cooling, dichloromethane (5 mL) was added, filtered, and concentrated. The resulting crystals were filtered using ethanol (2 mL) and hexane (20 mL), and dried at an internal temperature of 60°C to obtain the title compound (0.3 g). P NMR (DMS0-d6): 11.5 (s, 1H), 7.96 (t, 1H), 7.21 (s, 1H), 7.19-7.20 (m, 1H), 7.01 (s, 1H), 6.97-6.98 (m, 1H), 6.04 (s, 1H) , 6.01 (s, 2H) , 4.26 (d, 2H), 3.06-3.13 (m, 2H) , 2.91-2.94 (m, 2H) , 2.41 (s, 3H) , 2.21-2.30 (m, 2H), 2.17 (s, 3H), 2.13 (s, 3H), 1.82-1.87 (m, 1H) , 1.68-1.72 (m, 2H) , 1.56 (s, 3H), 1.32-1.38 (m, 2H) .
[0601] LC-MS (ESI, m / z) = 646.7 (M+H+ ) Manufacturing Example 95. 2— (1—(2, 2—difluoroethyl)piperidine 1 4 —yl) 1 2 ,7 —dimethyl- N~
[0602] ((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)- [4,5 1 ~ Synthesis of bibenzo[d][1,3]dioxole]-6-carboxamide, (Compound 95) 2,7-dimethyl- N- ((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3-yl)methyl)- 2- (piperidin- 4-yl)- [4,5'-bibenzo [d] [l, 3]dioxole]- 6-carboxamide hydrochloride (0.5 g, 0.73 mmole) obtained through the same process as [Steps 1 to 5] of the above Manufacturing Example 94 was added acetonitrile (10 mL), sodium carbonate (0.43 g) and 2-iodo- 1,1-difluoroethane (0.09 mL), and stirred at an internal temperature of 100°C for 24 hours. After cooling, dichloromethane (5 mL) was added, filtered, concentrated and then ethanol
[0603] The resulting crystals were filtered using (2 mL) and hexane (20 mL), and dried at an internal temperature of 60°C to obtain the title compound (0.3 g). P NMR (DMS0-d6): 11.5 (s, 1H), 7.96 (t, 1H), 7.21 (s, 1H), 7.19-7.20 (m, 1H), 7.01 (s, 1H), 6.97-6.98 (m, 1H), 6.04 (s, 1H) , 6.01 (t, 1H) , 4.26 (d, 2H), 2.89-2.92 (m, 2H) , 2.61-2.68 (m, 2H) , 2.46 (s, 3H) , 2.17 (s, 3H) , 2.13 (s, 3H), 2.05-2.10 (m, 2H), 1.83-1.84 (m, 1H) , 1.67-1.70 (m, 2H), 1.57 (s, 3H), 1.34-1.39 (m, 2H) .
[0604] LC-MS (ESI, m / z) = 628.5 (M+H + ) Manufacturing example 96. Synthesis of 7-(benzofuran-5-yl)-2, 4 ■dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1!, 2 —dihydropyridin-1 3 —yl)methyl)~2~(!~(2 , 2 , 2 —trifluoroethyl)piperidine~ 4 -yl)benzo[d][1,3]dioxole-5-carboxamide, (compound 96) In the above Manufacturing Example 33 [Step 1], 2-(benzofuran-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine (intermediate 1) was used instead of 2-(benzofuran-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolan, except that the steps 1 to 5 were carried out in the same manner to obtain 7-(benzofuran-5-yl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(piperidine- 4-day) Benzo[d][1,3]dioxole-5-carboxamide hydrochloride was obtained. The obtained hydrochloride (0.5 g, 0.73 mmole) was added with acetonitrile (10 mL), sodium carbonate (0.43 g) and 2,2,2-trifluoroethyl trifluoromethanesulfonate.
[0605] (0.20 mL) was added and stirred at an internal temperature of 100°C for 24 hours. After cooling, dichloromethane (5 mL) was added, filtered, concentrated, and then ethanol (2 mL) and hexane were added.
[0606] The resulting crystals were filtered using (20 mL) and dried at an internal temperature of 60 °C to obtain the title compound (0.3 g). P NMR (DMS0-d6): 11.5 s, 1H), 7.99 (s, 2H), 7.91 s, 1H), 7.61-7.63 (m, 1H), 7.60-7.61 (m, 1H), 7.09 (s, 1H), 6.99 (s, 1H),
[0607] 6.04 s, 1H), 4.27 (d, 2H), 3.06-3.10 (m, 2H), 2.92-2.94 (m, 2H), 2.41 (s,
[0608] 3H), 2.26-2.30 (m, 2H) , 2.19 (s, 3H) , 2.13 s, 3H), 1.84-1.89 (m, 2H), 1.71-
[0609] 1.74 (m, 2H), 1.58 (s, 3H) , 1.38-1.41 (m, 2H) .
[0610] LC-MS (ESI, m / z) = 642.6 (M+H + ) Manufacturing example 97. Synthesis of 7-(benzofuran- 5-yl)- 2- (1-(2, 2-difluoroethyl)piperidine- 4~ yl)- 2, 4 ■dimethyl- N- ((6-methyl- 4- (methylthio)- 2 -oxo- 1, 2 ■dihydropyridin- 3-yl)methyl)benzo[d][l, 3]dioxole- 5 -carboxamide, (Compound 97) 7 - obtained through the same process as [Steps 1 to 5] of the above manufacturing example 96
[0611] (Benzofuran-5-yl)-2,4-dimethyl- N- ((6-methyl-4-(methylthio)-2-oxo- 1,2-dihydropyridin-3-yl)methyl)- 2-(piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide hydrochloride (0.5 g, 0.73 mmole) was added acetonitrile (10 mL), sodium carbonate (0.43 g) and 2-iodo-1,1-difluoroethane (0.09 mL), stirred at an internal temperature of 100°C for 24 hours, cooled, dichloromethane (5 mL) was added, filtered, concentrated, and the resulting crystals were filtered using ethanol (2 mL) and hexane (20 mL), dried at an internal temperature of 60°C to obtain the title compound. (0.3g) was obtained. Blood NMR (DMS0-d6): 11.5 (s, 1H), 7.99 (s, 2H), 7.90 (s, 1H), 7.62-7.63 (m, 1H), 7.60-7.61 (m, 1H), 7.08 (s, 1H), 6.99 (s, 1H), 5.94-6.06 (m, 2H), 4.27 (d, 2H), 2.91 (d, 2H), 2.60-2.67 (m, 2H), 2.41 (s, 3H), 2.19 (s, 3H), 2.13 (s, 3H), 2.06-2.10 (m, 2H) , 1.83-1.87 (m, 1H) , 1.69-1.72 (m, 2H), 1.58 (s, 3H), 1.33-1.41 (m, 2H) .
[0612] LC-MS (ESI, m / z) = 624.6 (M+H + ) Manufacturing example 98. Synthesis of 7-(6-(butyl (methyl)amino)pyridin-3-yl)-2, 4 ■dimethyl- N-((6-methyl— 4-(methylthio)-2-oxo- 1 , 2 ■dihydropyridin-3-yl)methyl )-2-( 1-(2 , 2, 2-trifluoroethyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide, (Compound 98) Except that N-butyl-N-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine (intermediate 1) was used instead of (2S,6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine in [Step 1] of the above Manufacturing Example 33, the processes of [Steps 1 to 5] were carried out in the same manner as in [Step
[0613] 5] 7- (6- (butyl (methyl) amino) pyridin- 3 -yl)- 2, 4 - dimethyl- N- ((6 - methyl- 4-
[0614] (Methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide hydrochloride was obtained. To the obtained hydrochloride (0.5 g, 0.73 mmole) was added acetonitrile (10 mL), sodium carbonate (0.43 g) and 2,2,2-trifluoroethyl trifluoromethanesulfonate.
[0615] (0.20 mL) was added and stirred at an internal temperature of 100°C for 24 hours. After cooling, dichloromethane (5 mL) was added, filtered, concentrated, and the resulting crystals were filtered using ethanol (2 mL) and hexane (20 mL), and dried at an internal temperature of 60°C to obtain the title compound.
[0616] (0.3g) was obtained. P NMR (DMS0-d6): 11.5 (s, 1H), 8.40 (s, 1H), 7.93 (t, 1H), 7.74 (d,
[0617] 1H), 7.01 (s, 1H), 6.64 (d, 1H), 6.05 s, 1H), 4.26 (d, 2H), 3.48 (t, 2H),
[0618] 3.06-3.12 (m, 2H), 2.97 (s, 3H), 2.94 (d, 2H), 2.41 s, 3H), 2.27 (t, 2H),
[0619] 2.17 (s, 3H), 2.13 (s, 3H), 1.84 (t, 1H), 1.70 (d, 2H), 1.56 (s, 3H), 1.46—
[0620] 1.50 (m, 2H), 1.32-1.43 (m, 2H), 1.24-1.28 (m, 2H), 0.88 (t, 3H).
[0621] LC-MS (ESI, m / z) = 688.8 (M+H+) Preparation Example 99. Synthesis of 7- (6-(butyl (methyl)amino)pyridin- 3 -yl)- 2, 4 ■dimethyl- N- ((6 - methyl— 4—(methylthio)— 2 -oxo- 1 , 2 -dihydropyridin- 3 -yl)methyl )-2-(1-(2 , 2, 2-trifluoroethyl)piperidin- 4 -yl)benzo[bi[1,3]dioxole- 5 -carboxamide,
[0622] (Compound 99) Except that N-butyl-N-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine was used instead of (2S,6R)-2,6-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine (intermediate 1) in [Step 1] of the above Manufacturing Example 33, the same procedures of [Steps 1 to 5] were carried out to obtain 7-(2-(butyl(methyl)amino)pyrimidin-5-yl)-2,4-dimethyl-N-((6-methyl-4-
[0623] (Methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide hydrochloride was obtained. Acetonitrile (10 mL), sodium carbonate (0.43 g) and 2,2,2-trifluoroethyl trifluoromethanesulfonate (0.20 mL) were added to the obtained hydrochloride (0.5 g, 0.73 mmole), and the mixture was stirred at an internal temperature of 100°C for 24 hours. After cooling, dichloromethane (5 mL) was added, filtered, and concentrated. The resulting crystals were filtered using ethanol (2 mL) and hexane (20 mL), and dried at an internal temperature of 60°C to obtain the title compound (0.3 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.62 (s, 2H), 7.90 (t, 1H), 7.05 (s,
[0624] 1H), 6.05 (s, 1H), 4.26 (d, 2H), 3.58 (t, 2H), 3.06-3.10 (m, 5H), 2.92 (d,
[0625] 2H), 2.41 (s, 3H), 2.27 (t, 2H) , 2.18 (s, 3H) , 2.13 (s, 3H) , 1.85 (t, 1H) , 1.70 (d, 2H) , 1.57 (s, 3H) , 1.49-1.53 (m, 2H) , 1.30-1.41 (m, 2H) , 1.24-1.29 (m, 2H) , 0.88 (t, 3H) .
[0626] LC-MS (ESI, m / z) = 689.8 (M+H + ) Manufacturing Example 100. 2-(trans-4-aminocyclohexyl)-7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-
[0627] Synthesis of 1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide hydrochloride, (Compound 100)
[0628] <Reaction Formula 5>
[0629] [Step 1] 2-((trans-4-((tert-butoxycarbonyl)amino)cyclohexyl)-7-
[0630] Synthesis of (6-((2S,6R)-2,6-dimethoxymorpholino)pyridin-3-yl)-2,4-dimethylbenzo[d][1,3]dioxole-5-carboxylic acid Dioxane (50 mL) was added to methyl 7-bromo-2-((trans-4-((tert-butoxycarbonyl)amino)cyclohexyl)- 2 , 4-dimethylbenzo[d][1 , 3]dioxole-5-carboxylate (10 g, 20.64 mmole), and purified water (25 mL) was added. Then, (2S, 6R)-2, 6-dimethyl-4-(5-(4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl)pyridin-2-yl)morpholine (8.54 g) was added, tetrakis(triphenylphosphine)palladium (0.48 g) was added, and sodium carbonate (4.37 g) was added, followed by stirring at 90°C for 4 hours. Upon completion of the reaction, ethyl acetate (50 mL) was added, and the precipitated solid was filtered using Celite and washed with ethyl acetate (25 mL). After concentration under reduced pressure, ethyl acetate (80 mL) and purified water (80 mL) were added, and the mixture was stirred for 30 minutes. The reaction solution was allowed to settle, the layers were separated, and anhydrous sodium sulfate and activated carbon were added to the organic layer and stirred for 1 hour. The reaction solution was filtered and concentrated to obtain the resulting methyl 2-(trans-4-((tert-butoxycarbonyl)amino)cyclohexyl)-7-(6-((2S,6R)-2,6-dimethoxymorpholino)pyridin-3-yl)-2,4-dimethylbenzo[d][1,3]dioxole-5-carboxylate intermediate, which was then subjected to the next reaction without a separate purification process. The obtained intermediate was dissolved in tetrahydrofuran (72 mL) and methanol (36 mL), and 2N aqueous sodium hydroxide solution (46.5 mL) was injected and stirred under reflux for 4 hours. The reactant was concentrated under reduced pressure, and ethyl acetate (70 mL) and purified water (30 mL) were added to the residue, and the pH was adjusted to 4.0 with 20% hydrochloric acid aqueous solution (13 mL).After the reaction mixture was allowed to settle, the layers were separated, and anhydrous sodium sulfate and activated carbon were added to the organic layer, followed by stirring for 1 hour. The reaction mixture was filtered and washed with dichloromethane (20 mL). The filtered organic material was concentrated under reduced pressure, and acetonitrile (90 mL) was added to the residue, stirred under reflux for 2 hours, and cooled. The resulting solid was filtered, washed with acetonitrile (30 mL), and dried under reduced pressure to obtain the title compound 2-(trans-4-((tert-butoxycarbonyl)amino)cyclohexyl)-7-(6-((2S,6R)-2,6-dimethoxymorpholino)pyridin-3-yl)-2,4-dimethylbenzo[d][1,3]dioxole-5-carboxylic acid (9.9 g, 17.01 mmol).
[0631] [Step 2] Synthesis of tert-butyl (trans-4-(7-(6-((2S,6R)-2,6-dimethoxymorpholino)pyridin-3-yl)-2,4-dimethyl-5-(((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)carbamoyl)benzo[bi[1,3]dioxol-2-yl)cyclohexyl)carbamate Dimethylformamide (18 mL) and triethylamine (9.5 mL) were added to the compound obtained in [Step 1] (9.9 g, 17.01 mmole). Then, pentafluorophenyl trifluoroacetate (3.04 mL) was added dropwise and stirred at room temperature for 3 hours. Triethylamine (4.73 mL) was added to the reaction solution, followed by 3-(aminomethyl)-6-methyl-4-(methylthio)pyridin-2(1H)-one hydrochloride (4.5 g), and stirred at an internal temperature of 50°C. Upon completion of the reaction, the solution was concentrated under reduced pressure, and the concentrated residue was dissolved in dichloromethane (40 mL) and purified water (40 mL), separated from the water vapor, and purified water (30 mL) was injected into the organic layer, adjusted to pH 3.5 with a 20% hydrochloric acid solution, and the organic layer was separated by layer separation. Anhydrous sodium sulfate and activated carbon were injected into the separated organic layer, and stirred for 1 hour. The reaction solution was filtered, washed with dichloromethane (15 mL), and concentrated to proceed with [Step 3] reaction without a separate purification process.
[0632] [Step 3] Synthesis of 2-(trans-4-aminocyclohexyl)-7-(6-((2S,6R)-2,6-dimethoxymorpholino)pyridin-3-yl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxyamide hydrochloride 1M hydrochloric acid (ethanol solution) (lOOmL) was added to the compound obtained in the above [Step 2], and the mixture was heated to 70°C and stirred. When the reaction was completed, the reaction solution was added dropwise to ethyl acetate (338mL), the resulting solid was filtered, and dried at an internal temperature of 60°C to obtain the title compound (11.0g (16.98mmol). P NMR (DMS0-d6): 11.5 (s, 1H), 8.44 (s, 1H), 8.16 (br. s, 2H), 7.95 (t, 1H), 7.81 (d, 1H), 7.03 (s, 1H), 6.89 (d, 1H), 6.05 (s, 1H), 4.26 (d,
[0633] 2H), 4.14 (d, 2H), 3.55-3.57 (m, 2H), 2.89-2.93 (m, 1H), 2.41 (s, 3H), 2.34-
[0634] 2.39 (m, 2H), 2.17 (s, 3H) , 2.13 (s, 3H) , 1.95-2.01 (m, 2H) , 1.81-1.90 (m,
[0635] 3H), 1.55 (s, 3H), 1.28-1.39 (m, 2H) , 1.18-1.28 (m, 2H) , 1.13 (s, 3H) , 1.11
[0636] (s, 3H).
[0637] LC-MS (ESI, m / z) = 648.6 (M+H + ) Manufacturing Example 101. 7-(6-((2S,6R)- 2, 6 ■Dimethylmorpholino)pidirin- 3 -yl)- 2-
[0638] (trans-4-(3-hydroxyazetidine-1-yl)cyclohexyl)-2,4-dimethyl ~N~((6-methyl ~4~ (methylthio)-2-oxo- 1,2 ■dihydropyridin-3-yl)methyl)benzo [ d] [ 1,3 ]dioxole-5-carboxamide synthesis, (Compound 101) <Reaction Scheme 6> Dichloromethane and purified water were added to the compound (8 g, 12.3 mmole) obtained in [Step 3] of the above Preparation Example 100. 2N sodium hydroxide aqueous solution was added to adjust the pH to 7 to 8, the layers were separated, and the oil layer was dried over sodium sulfate. Filtration and concentration were performed, and ethanol was added, followed by addition of (R)-epichlorohydrin and heating. Upon completion of the reaction, cooling was performed, calcium carbonate was added, the temperature was increased to proceed with the reaction, cooling, filtering, and layer separation with dichloromethane and purified water. The oil layer was dried over sodium sulfate, filtered, concentrated, purified by column chromatography, and recrystallized with dichloromethane and ethyl acetate to obtain the title compound (5.4 g, 7.7 mmole). P NMR (DMS0-d6): 11.5 (s, 1H), 8.43 (s, 1H), 7.94 (t, 1H), 7.79 (d,
[0639] 1H), 7.02 (s, 1H), 6.89 (d, 1H) , 6.05 (s, 1H) , 5.25 (br. s, 1H) , 4.27 (d,
[0640] 2H), 4.14 (d, 2H), 4.09-4.13 (m, 1H), 3.51-3.60 (m, 2H), 3.40-3.51 (m, 2H),
[0641] 2.68-2.74 (m, 3H) , 2.41 (s, 3H) , 2.36-2.40 (m, 2H) , 2.15 (s, 3H), 2.13 (s,
[0642] 3H), 1.78-1.87 (m, 3H) , 1.73-1.75 (m, 2H) , 1.54 (s, 3H) , 1.28-1.21 (m, 2H) , 1.13 (s, 3H), 1.12 (s, 3H), 0.87-0.81 (m, 2H) .
[0643] LC-MS (ESI, m / z) = 704.6 (M+H +) Manufacturing Example 102. 7- (6- ((2S,6R)- 2, 6 -dimethylmorsolino)pyridin- 3 -yl)- 2,4-dimethyl- N- ( (6 -methyl- 4- (methylthio)- 2 -oxo- 1 , 2 -dihydropyridin- 3 -yl)methyl )-2 -
[0644] Synthesis of (trans-4-(3-(2,2,2-trifluoroethyl)azetidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-carboxamide, (Compound 102)
[0645] <Reaction Formula 7> Dimethylformamide (20 mL) was added to the compound (300 mg, 0.42 mmole) obtained in the above Preparation Example 101. Cesium carbonate (347 mg) and 2, 2, 2-trifluoroethyl trifluoromethanesulfonate (99 mg) were added, stirred at 90 °C for 15 hours, and distilled. The layers were separated with dichloromethane and purified water, dried over anhydrous sodium sulfate, filtered, washed, and then distilled under reduced pressure. The title compound (135 mg) was obtained by purification by column chromatography. P NMR (DMS0-d6): 11.5 (s, 1H), 8.42 (s, 1H), 8.09 (t, 1H), 7.76 (d, 1H), 7.01 (s, 1H), 6.90 (d, 1H), 6.89 (s, 1H), 4.88-4.92 (m, 2H) , 4.38-4.39 (m, 2H), 4.30-4.31 (m, 1H) , 4.20-4.30 (m, 2H) , 4.13-4.15 (m, 2H) , 3.55-3.57 (m, 3H), 2.60-2.66 (m, 2H) , 2.36-2.43 (m, 2H) , 2.35 (s, 3H) , 2.16 (s, 3H) ,
[0646] 1.79-1.81 (m, 7H), 1.55 (s, 3H) , 1.13 (s, 3H) , 1.12 (s, 6H) , 1.01-1.08 (m,
[0647] 2H). LC-MS (ESI, m / z) = 786.6 (M+H + ) Manufacturing Example 103. Synthesis of 2-(trans-4-(3-(2,2-difluoroethoxy)azetidin-1-yl)cyclohexyl)-7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, (Compound 103) Instead of 2, 2, 2-trifluoroethyl trifluoromethanesulfonate in Manufacturing Example 102
[0648] 2—Preparation example above except that iodo—!,!—difluoroethane (0.04 mL) was used
[0649] The compound (300 mg, 0.43 mmole) obtained in 101 was used in the same manner as in Preparation Example 102 to obtain the title compound (71 mg, 0.09 mmole). P NMR (DMS0-d6): 11.5 (s, 1H), 8.42 (s, 1H), 8.06 (t, 1H), 7.77-7.79
[0650] (m, 1H), 7.01 (s, 1H), 6.90 (d, 1H), 6.85 (s, 1H), 6.33 (t, 1H), 6.05 (s,
[0651] 1H), 4.50-4.51 (m, 2H), 4.30-4.38 (m, 3H), 4.13-4.15 (m, 2H), 4.06-4.07 (m,
[0652] 1H), 3.55-3.57 (m, 2H), 3.43-3.45 (m, 2H), 2.60-2.66 (m, 2H), 2.45-2.47 (m,
[0653] 2H), 2.36-2.43 (m, 2H), 2.35 (s, 3H), 2.15 (s, 3H), 1.79-1.81 (m, 1H), 1.75-
[0654] 1.78 (m, 4H), 1.72-1.75 (m, 2H), 1.54 (s, 3H), 1.13 (s, 3H), 1.12 (s, 6H), 0.83-0.86 (m, 2H).
[0655] LC-MS (ESI, m / z) = 768.7 (M+H + ) Manufacturing Example 104. Synthesis of 2-(trans-4-(3-(2,2-difluoroethoxy)azetidine ~1~ yl)cyclohexyl)-7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, (Compound 104) The compound obtained in Preparation Example 101 (300 mg, 0.43 mmole) was used in the same manner as in Preparation Example 102, except that 1,1,1-trifluoro-4-iodobutane (0.06 mL) was used instead of 2,2,2-trifluoroethyl trifluoromethanesulfonate in Preparation Example 102, to obtain the title compound (71 mg, 0.09 mmole). P NMR (DMS0-d6): 11.6 (s, 1H), 8.44 (s, 1H), 7.93 (t, 1H), 7.78-7.81 (m, 1H), 7.01 (d, 1H), 6.89 (d, 1H), 6.78 (s, 1H), 4.36-4.39 (m, 2H) , 4.29-
[0656] 4.30 (m, 2H), 4.26-4.29 (m, 2H), 4.13-4.15 (m, 2H), 3.95-3.97 (m, 2H), 3.55-
[0657] 3.57 (m, 3H), 2.60-2.66 (m, 4H), 2.43-2.46 (m, 3H), 2.35-2.38 (m, 2H), 2.43
[0658] (s, 3H), 2.15 (s, 3H), 1.78-1.87 (m, 4H), 1.76-1.77 (m, 1H), 1.55 (s, 3H),
[0659] 1.13 (s, 3H), 1.12 (s, 6H), 1.01-1.08 (m, 2H). LC-MS (ESI, m / z) = 814.7 (M+H+) Preparation Example 105. 7-(6-((2S,6R)- 2, 6 -dimethylmorpholino)pyridin- 3 -yl)- 2-
[0660] Synthesis of (trans-4-(3-isopropoxyazetidine-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2 ■dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, (Compound 105) The reaction was carried out in the same manner as in Preparation Example 102 using the compound (300 mg, 0.43 mmole) obtained in Preparation Example 101, except that 2-iodopropane (0.04 mL) was used instead of 2, 2, 2-trifluoroethyl trifluoromethanesulfonate in Preparation Example 102, to obtain the title compound (56 mg, 0.08 mmole). P NMR (DMS0-d6): 11.5 (s, 1H), 8.42 (s, 1H), 8.00 (t, 1H), 7.77 (d, 1H), 7.00 (s, 1H), 6.90 (d, 1H), 6.72 (s, 1H), 5.20-5.23 (m, 2H) , 4.34 (d, 2H), 4.30-4.31 (m, 1H) , 4.14 (d, 2H) , 4.06-4.08 (m, 1H) , 3.56-3.57 (m, 2H) , 2.43-2.46 (m, 3H) , 2.34-2.42 (m, 2H) , 2.30 (s, 3H) , 2.16 (s, 3H) , 1.79-1.87 (m, 1H), 1.78-1.87 (m, 4H) , 1.72-1.74 (m, 2H) , 1.54 (s, 3H) , 1.23 (s, 3H) , 1.22 (s, 3H), 1.13 (s, 3H), 1.12 (s, 6H), 0.83-0.86 (m, 2H). LC-MS (ESI, m / z) = 746.7 (M+H + ) Manufacturing Example 106. 7-(6-((2S,6R)-2, 6-dimethylmorpholino)pyridin-3-yl)-2-
[0661] (trans-4-(3-methoxyazetidine-1-yl)cyclohexyl)- 2,4-dimethyl- N-((6-methyl-4-
[0662] Synthesis of (methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, (Compound 106) The reaction was carried out in the same manner as in Preparation Example 102 using the compound (300 mg, 0.43 mmole) obtained in Preparation Example 101, except that iodomethane (0.03 mL) was used instead of 2, 2, 2-trifluoroethyl trifluoromethanesulfonate in Preparation Example 102, to obtain the title compound (10 mg, 0.02 mmole). P NMR (DMS0-d6): 11.5 (s. 1H), 8.43 (s, 1H), 7.94 (t, 1H), 7.80 (d, 1H), 7.02 (s, 1H), 6.89 (d, 1H), 6.05 (s, 1H), 4.24-4.27 (d, 2H), 4.14 (d, 2H), 3.45-3.60 (m, 2H), 3.36-3.37 (m, 1H), 2.86-2.90 (m, 2H), 2.61-2.64 (m,
[0663] 2H), 2.58-2.59 (m, 1H) , 2.41 (s, 3H) , 2.34-2.39 (m, 2H) , 2.28-2.33 (m, 2H) ,
[0664] 2.18 (s, 3H), 2.16 (s, 3H) , 2.13 (s, 3H) , 1.84-1.89 (m, 2H) , 1.72-1.82 (m,
[0665] 3H), 1.55 (s, 3H), 1.14-1.20 (m, 2H), 1.13 (s, 3H), 1.12 (s, 3H). LC-MS (ESI, m / z) = 718.5 (M+H + ) Manufacturing Example 107. Synthesis of stereoisomers of 7-(6-((2S,6R)- 2, 6 ■dimethylmorpholino)pyridin- 3 -yl)- 2, 4 - dimethyl- 2-(trans- 4-(methyl(2, 2, 2 -trifluoroethyl)amino)cyclohexyl)- N-((6-methyl- 4-(methylthio)- 2 -oxo- 1 ,2 -dihydropyridin ~3~ yl)methyl)benzo [d] [l,3]dioxole- 5 -carboxamide,
[0666] (Compound 107) In [Step 1] of the above Manufacturing Example 20, the starting material methyl-7-bromo-2-(trans-4-
[0667] The same reaction was carried out from [Step 1] to [Step 20] except that stereospecific methyl-(R)-7-bromo-2-(trans-4-((tert-butoxycarbonyl)amino)cyclohexyl)-2,4-dimethylbenzo[d][1,3]dioxole-5-carboxylate (0.5 g, 1.03 mmole) was used instead of ((tert-butoxycarbonyl)amino)cyclohexyl)-2,4-dimethylbenzo[d][1,3]dioxole-5-carboxylate, to obtain the title compound (0.2 g, 0.27 mmole). P NMR (DMS0-d6): 11.5 (s, 1H), 8.29 (d, 2H), 8.09 (s, 1H), 7.51 (d,
[0668] 1H), 7.15 (s, 1H), 6.12 (s, 1H), 4.36 (d, 2H), 4.29 s, 2H), 4.12-4.13 (m,
[0669] 1H), 3.63-3.64 (m, 2H), 3.23-3.24 (m, 1H), 2.76-2.78 (m, 6H), 2.75 (s, 3H),
[0670] 2.42 s, 3H), 2.22 (s, 3H), 2.17-2.21 (m, 2H), 1.98 s, 3H), 1.59 (s, 3H),
[0671] 1.56-1.58 (m, 2H), 1.21-1.41 (m, 2H), 1.14 (s, 3H), 1.13 s, 3H).
[0672] LC-MS (ESI, m / z) = 744.8 (M+H +) Manufacturing Example 108. Synthesis of stereoisomer A of 7-(6-((2S,6R)- 2, 6 ■dimethylmorpholino)pyridin- 3 -yl)- 2,4-dimethyl- 2-(trans- 4-(methyl(2, 2, 2 -trifluoroethyl)amino)cyclohexyl)- N-((6-methyl- 4-(methylthio)- 2 -oxo- 1 ,2 -dihydropyridin ~3~ yl)methyl)benzo [d][l, 3]dioxole- 5 -carboxamide, (Compound 108) Stereoisomers of A
[0673] In [Step 1] of the above Manufacturing Example 20, the starting material methyl-7-bromo-2-(trans-4-
[0674] The same procedure as in Preparation Example 20 except that stereospecific methyl- (S)-7-bromo-2- (trans-4- ((tert-butoxycarbonyl)amino)cyclohexyl)-2,4-dimethylbenzo[d][1,3]dioxole-5-carboxylate (0.5 g, 1.03 mmole) was used instead of ((tert-butoxycarbonyl)amino)cyclohexyl)-2,4-dimethylbenzo[d][1,3]dioxole-5-carboxylate.
[0675] 1] to [The same reaction was performed from step 1 to [to obtain the title compound (0.2 g, 0.27 mmol). P NMR (DMS0-d6): 11.5 (s, 1H), 8.29 (d, 2H), 8.09 (s, 1H), 7.50 (d,
[0676] 1H), 7.15 (s, 1H), 6.12 (s, 1H), 4.36 (d, 2H), 4.29 s, 2H), 4.12-4.13 (m,
[0677] 1H), 3.64-3.67 (m, 2H), 3.21-3.23 (m, 1H), 2.76-2.75 (m, 6H), 2.43 (s, 3H),
[0678] 2.20 s, 3H), 2.19 (s, 3H), 2.16-2.18 (m, 2H), 1.97 s, 3H), 1.59 (s, 3H),
[0679] 1.42-1.58 (m, 2H), 1.21-1.32 (m, 2H), 1.14 (s, 3H), 1.13 s, 3H).
[0680] LC-MS (ESI, m / z) = 744.8 (M+H + ) Manufacturing Example 109. Synthesis of 2-(trans-4-((2,2-difluoroethyl(methyl)amino)cyclohexyl)-7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, (Compound 109) Compound obtained through the same reaction as [Steps 1 to 6] of the above manufacturing example 20
[0681] (0.5g, 0.68mmole) was used to carry out the reaction of step [, but in step [
[0682] The reaction was carried out using 2-iodo-1,1-difluoroethane (0.12 ml) instead of 2, 2, 2-trifluoroethyl trifluoromethanesulfonate, and the title compound (0.2 g) was obtained. P NMR (DMS0-d6): 11.5 (s, 1H), 8.44 (s, 1H), 7.94 (t, 1H), 7.80 (d,
[0683] 1H), 7.02 (s, 1H), 6.89 (d, 1H), 6.04 (s, 1H), 5.91 (t, 1H), 4.27 (d, 2H),
[0684] 4.13 (d, 2H), 3.52-3.57 (m, 2H), 2.66-2.73 (m, 2H), 2.41 (s, 3H), 2.36-2.40
[0685] (m, 2H), 2.30-2.36 (m, 1H), 2.22 s, 3H), 2.16 s, 3H), 2.13 s, 3H), 1.85-
[0686] 1.88 (m, 2H), 1.76-1.85 (m, 1H), 1.68-1.72 (m, 2H), 1.54 (s, 3H), 1.14-1.18
[0687] (m, 4H), 1.13 (s, 3H), 1.12 s, 3H).
[0688] LC-MS (ESI, m / z) = 726.6 (M+H + ) Manufacturing Example 110. 7-(6-((2S,6R)- 2, 6 ■Dimethylmorpholino)pyridin- 3 -yl)- 2 -
[0689] Synthesis of (trans-4-(isopropyl(methyl)amino)cyclohexyl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, (Compound 110) The compound (0.5 g, 0.68 mmole) obtained through the same reaction as in [Steps 1 to 6] of the above Preparation Example 20 was used to carry out the reaction of [Step group], but 2-iodopropane (0.14 ml) was used instead of 2,2,2-trifluoroethyl trifluoromethanesulfonate in the [Step group], and the title compound (0.1 g) was obtained. P NMR (DMS0-d6): 11.5 (s, 1H), 8.44 (s, 1H), 7.94 (t, 1H), 7.81 (d,
[0690] 1H), 7.02 (s, 1H), 6.89 (d, 1H) , 6.05 (s, 1H) , 4.27 (d, 2H) , 4.14 (d, 2H) ,
[0691] 3.54-3.59 (m, 2H) , 2.86-2.90 (m, 1H) , 2.41 (s, 3H) , 2.28-2.40 (m, 2H) , 2.32- 2.40 (m, 1H4), 2.16 (s, 3H), 2.13 (s, 3H) , 2.05 (s, 3H) , 1.84-1.88 (m, 2H) ,
[0692] 1.72-1.84 (m, 3H), 1.54 (s, 3H) , 1.14-1.23 (m, 4H) , 1.13 (s, 3H), 1.12 (s,
[0693] 3H), 0.90 (s, 3H), 0.89 (s, 3H) .
[0694] LC-MS (ESI, m / z) = 704.7 (M+H + ) Manufacturing Example 111. 7- (6- ((2S,6R)- 2, 6 ■ dimethylmorpholino) pyridin- 3 -yl)- 2 -
[0695] (trans-4-(ethyl(methyl)amino)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-
[0696] Synthesis of (methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, (Compound 111) The compound (0.5 g, 0.68 mmole) obtained through the same reaction as [Step 1 to 6] of the above Preparation Example 20 was used to carry out the reaction of [Step 1], but 2-iodoethane (0.1 mL) was used instead of 2,2,2-trifluoroethyl trifluoromethanesulfonate in [Step 1], and the title compound (0.1 g) was obtained. P NMR (DMS0-d6): 11.5 (s, 1H), 8.46 (s, 1H), 7.94 (t, 1H), 7.81 (d,
[0697] 1H), 7.04 (s, 1H), 6.89 (d, 1H) , 6.05 (s, 1H) , 4.26 (d, 2H) , 4.14 (d, 2H) ,
[0698] 3.53-4.57 (m, 2H), 2.62 (d, 3H), 2.41 (s, 3H), 2.36-2.40 (m, 2H), 2.34-2.36 (m, 1H), 2.17 (s, 3H), 2.13 (s, 3H), 1.87-1.1.97 (m, 3H) , 1.57 (s ,3H),1.43—
[0699] 1.52 (m, 2H), 1.20-1.25 (m, 2H) , 1.16-1.20 (m, 4H) , 1.13 (s, 3H), 1.12 (s,
[0700] 3H), 0.83 (t, 3H).
[0701] LC-MS (ESI, m / z) = 690.6 (M+H + ) Manufacturing Example 112. Synthesis of 7- (6- ((2S,6R)- 2, 6 -dimethylmorpholino)pyridin- 3 -yl)- 2,4-dimethyl- 2- (trans- 4- (methyl (phenethyl)amino)cyclohexyl)- N- ((6 -methyl- 4- (methylthio)- 2 -oxo- 1 , 2 ■dihydropyridin- 3 -yl)methyl)benzo [ d] [ 1 , 3 ]dioxole- 5-carboxamide, (Compound 112)
[0702] The compound (0.5 g, 0.68 mmole) obtained through the same reaction as in [Steps 1 to 6] of the above Preparation Example 20 was used to carry out the reaction of [Step 1], but 2-iodoethylbenzene (0.20 mL) was used instead of 2,2,2-trifluoroethyl trifluoromethanesulfonate in [Step 1], thereby obtaining the title compound (0.2 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.43 (s, 1H), 7.94 (t, 1H), 7.80 (d, 1H), 7.18-7.22 (m, 2H), 7.15-7.18 (m, 3H), 7.01 (s, 1H) , 6.90 (d, 1H) , 6.05 (s, 1H), 4.27 (d, 2H), 4.14 (d, 2H) , 3.54-2.59 (m, 2H) , 2.51-2.63 (m, 2H) ,
[0703] 2.45 (s, 3H), 2.41 (s, 3H) , 2.36-2.40 (m, 2H) , 2.34-2.36 (m, 1H) , 2.18-2.22
[0704] (m, 2H), 2.16 (s, 3H) , 2.13 (s, 3H) , 1.81-1.88 (m, 2H) , 1.70-1.78 (m, 3H) ,
[0705] 1.54 (s, 3H), 1.16-1.29 (m, 4H) , 1.13 (s, 3H) , 1.12 (s, 3H) .
[0706] LC-MS (ESI, m / z) = 766.7 (M+H + ) Manufacturing Example 113. 7-(6-((2S,6R)- 2, 6 ■Dimethylmorpholino)pyridin- 3 -yl)- 2,4-dimethyl- 2-(trans- 4-(methyl(phenethyl)amino)cyclohexyl)- N-(( 6 -methyl- 4-
[0707] (Methylthio)-2-oxo-1,2 ■dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide synthesis, (Compound 113)
[0708] The compound (0.5 g, 0.68 mmole) obtained through the same reaction as in [Steps 1 to 6] of the above Preparation Example 20 was used to carry out the reaction of [Step group], but instead of 2, 2, 2-trifluoroethyl trifluoromethanesulfonate in [Step group], the reaction was carried out using 1,1,1-trifluoro 4-iodobutane (0.17 mL), thereby obtaining the title compound (0.2 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.45 (s, 1H), 7.94 (t, 1H), 7.81 (d, 1H), 7.03 (s, 1H), 6.89 (d, 1H), 6.05 (s, 1H), 4.27 (d, 2H) , 4.14 (d, 2H) , 3.53-3.57 (m, 2H) , 2.41 (s, 3H) , 2.34-2.41 (m, 4H) , 2.31-2.34 (m, 1H), 2.17 (s, 3H), 2.13 (s, 3H), 1.89-1.95 (m, 3H) , 1.67-1.80 (m, 4H) , 1.66-1.68 (m, 1H), 1.61-1.65 (m, 2H), 1.57 (s, 3H) , 1.42-1.48 (m, 2H) , 1.20-1.34 (m, 4H) , 1.13 (s, 3H), 1.12 (s, 3H).
[0709] LC-MS (ESI, m / z) = 772.7 (M+H + ) Manufacturing Example 114. 2-(trans-4-(cyclohexyl(methyl)amino)cyclohexyl)-7-
[0710] (6-((2S,6R)- 2, 6 ■Dimethylmorpholino)pyridin- 3 -yl)- 2, 4 ■Dimethyl- N-((6 ■Methyl- 4-
[0711] Synthesis of (methylthio)-2-oxo-1,2 ■dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, (Compound 114)
[0712] The compound (0.5 g, 0.68 mmole) obtained through the same reaction as in [Steps 1 to 6] of the above Preparation Example 20 was used to carry out the reaction of [Step group], but cyclohexyl iodide (0.18 mL) was used instead of 2,2,2-trifluoroethyl trifluoromethanesulfonate in [Step group], thereby obtaining the title compound (0.05 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.45 (s, 1H), 7.95 (t, 1H), 7.82 (d, 1H), 7.01 (s, 1H), 6.90 (d, 1H), 6.05 (s, 1H), 4.27 (d, 2H) , 4.14 (d, 2H) ,
[0713] 3.54-3.58 (m, 2H) , 3.38-3.41 (m, 2H) , 3.10-3.12 (m, 2H) , 2.93-3.60 (m, 2H) ,
[0714] 2.41 (s, 3H), 2.34-2.41 (m, 2H) , 2.31-2.34 (m, 1H) , 2.17 (s, 3H), 2.13 (s, 3H), 1.89-1.95 (s, 3H), 1.67-1.80 (m, 4H) , 1.66-1.68 (m, 1H) , 1.61-1.65 (m,
[0715] 2H), 1.57 (s, 3H), 1.55-1.56 (m, 2H) , 1.42-1.48 (m, 2H) , 1.28-1.34 (m, 2H) ,
[0716] 1.13 (s, 3H), 1.12 (s, 3H).
[0717] LC-MS (ESI, m / z) = 744.7 (M+H + ) Manufacturing Example 115. 7- (6- ((2S,6R)- 2, 6 ■dimethylmorpholino)pyridin- 3 -yl)- 2, 4 - dimethyl- N- ( (6 -methyl- 4- (methylthio)- 2 -oxo- 1 , 2 - dihydropyridin- 3 -yl)methyl )-2-
[0718] Synthesis of (trans-4-(2,2,2-trifluoro-N-methylacetamido)cyclohexyl)benzo[d][1,3]dioxole-5-carboxamide,
[0719] (Compound 115) The compound (0.5 g, 0.68 mmole) obtained through the same reaction as in [Step 1 to 6] of the above Preparation Example 20 was used to carry out the reaction of [Step 1], but phenyl trifluoroacetate (0.20 mL) was used instead of 2,2,2-trifluoroethyl trifluoromethanesulfonate in [Step 1], thereby obtaining the title compound (0.2 g). P NMR (DMS0-d6): 11.5 (s, 1H), 8.45 (s, 1H), 7.95 (t, 1H), 7.82 (d, 1H), 7.04 (s, 1H), 6.90 (d, 1H), 6.05 (s, 1H), 4.27 (d, 2H), 4.14 (d, 2H),
[0720] 3.53-3.57 (m, 2H) , 2.89-2.91 (m, 2H) , 2.41 (s, 3H) , 2.34-2.41 (m, 3H), 2.17
[0721] (s, 3H), 2.13 (s, 3H), 1.89-1.95 (m, 3H), 1.66-1.68 (m, 1H), 1.61-1.65 (m,
[0722] 2H), 1.57 (s, 3H), 1.20-1.34 (m, 4H), 1.13 (s, 3H), 1.12 (s, 3H).
[0723] LC-MS (ESI, m / z) = 758.6 (M+H + )
[0724] <Experimental Example> The cell lines used in the experiment were purchased from America Type Culture Collection (ATCC). Experimental Example 1. Evaluation of inhibitory activity on EZH1 and EZH2 In order to confirm the inhibitory effect of 1,3 -benzodioxole derivative compounds represented by Chemical Formula I of the present invention on EZH1 and / or EZH2 activity, the activity was measured using the AlphaLISA test method. The test substance dissolved in dimethyl sulfoxide (DMSO) was diluted in a test solution (20 mM Tris pH 8.0, 0.1% BSA, 0.01% Triton X-100, 0.5 mM DTT) according to the final treatment concentration (5 nM or 10 nM), mixed with EZH1 and EZH2 respectively, and then histone H3 peptide and S-adenosylmethionine (SAM) were added to initiate the enzymatic reaction. After 2 hours of reaction, acceptor beads were added, and after 1 hour of reaction, donor beads were added. After an additional 30 minutes of reaction, the reaction was completed. Activity was measured using the Magellan program on a SparklOM device. DMSO was used as a control, and the inhibition rate of enzyme activity was calculated using the following equation, and the results are shown in Table 1.
[0725] <Calculation formula> Activity inhibition rate (%) = (1-(test substance treatment group / control group))* 100
[0726] [Table 1] As can be confirmed in the above Table 1, it was confirmed that the compound of the present invention exhibits an excellent inhibitory effect on EZH1 and / or EZH2 enzyme activity. Experimental Example 2. Evaluation of cancer cell proliferation inhibition The cancer cell proliferation inhibition ability of the 1,3-benzodioxole derivative compounds represented by the chemical formula I of the present invention was evaluated. Among solid cancer cells, the proliferation inhibition ability of the 1,3-benzodioxole derivative compounds represented by the chemical formula I of the present invention was evaluated in G401 cells, a rhabdoid tumor cell line that is expected to have a therapeutic effect through dual inhibition of EZH1 / 2, and a defective SMARCB1 expression component of SWI / SNF (switch / sucrose non-fermenting), and in MKN-45 cells, a gastric cancer cell line and a defective ARID1A expression component of SWI / SNF. In addition, the proliferation inhibitory activity of 1,3-benzodioxole derivative compounds represented by the chemical formula I of the present invention was evaluated in examples of solid cancers in which overexpression of EZH2 and its disease association have been reported, such as colon cancer cell line Lovo cells, adrenal cancer cell line SW-13 cells, pancreatic cancer cell line MIA-PaCa-2 cells, and lung cancer cell line NCI-H1299 cells. Each cell line in Table 2 below (G401 cells, MKN-45 cells, Lovo cells, SW-13 cells, MIA-PaCa-2, NCI-H1299) was cultured using RPMI1640, McCoy's 5a, L-15, or DMEM containing 10% fetal bovine serum, and 100 to 1,000 cells were seeded per well of a 96-well culture dish, and the test substance 100OnM was cultured for 7 to 11 days after drug treatment. After culture, cells were counted using Cell Counting Kit-8 according to the manufacturer's instructions, and the cell proliferation inhibition effect (% inhibition rate) of the test substance was obtained. The results are shown in Table 2 below. The cell proliferation inhibition effect (% inhibition rate) of the test substance was calculated using the following formula.
[0727] % inhibition rate = {1-(test group / control group)} X 100
[0728] [Table 2]
[0729]
[0730] Cell proliferation inhibition effect (% inhibition)
[0731] +++: >70%, ++: More than 30% and less than 70%, +: <30% As can be confirmed in the above Table 2, it was confirmed that the compound of the present invention can be usefully used for the prevention or treatment of solid cancer by effectively inhibiting the proliferation of tumor cells. While specific parts of the present invention have been described in detail above, it will be apparent to those skilled in the art that such specific descriptions are merely preferred embodiments and that the scope of the present invention is not limited thereby. Therefore, the actual scope of the present invention will be defined by the appended claims and their equivalents.
Claims
【Scope of Claims】 【 Claim 11 A pharmaceutical composition for the prevention or treatment of a disease related to EZH1 (Enhancer of zeste homolog 1 og 1) or EZH2 (Enhancer of zeste homolog 2) activity, comprising a compound represented by the following chemical formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or a solvate thereof as an active ingredient, wherein the disease related to EZH1 or EZH2 activity is a solid cancer, the pharmaceutical composition: <화학식 1> In the above chemical formula I, R1 is H; C1-C6 alkyl; C2-C6 alkenyl; C2-C6 alkynyl; C3-C8 cycloalkyl; C3-C8 cycloalkenyl; Ci-C6 alkoxy; 3- to 12-membered heterocycloalkyl or heterocycloalkenyl containing 1 to 3 heteroatoms independently selected from the group consisting of N, 0 and in the ring; 6- to 14-membered aryl; 5- to 12-membered heteroaryl containing 1 to 3 heteroatoms independently selected from the group consisting of N, 0 and in the ring; - (C=0)- (Ci- C6 alkyl); -CN; benzodioxolyl or halogen, and Ci-C6 alkyl; C3-C8 cycloalkyl; N, 0 and containing 1 to 3 heteroatoms independently selected from the group consisting of Ri 3- to 12-membered heterocycloalkyl or heterocycloalkenyl; 6- to 14-membered aryl; 5- to 12-membered heteroaryl or benzodioxolyl having 1 to 3 heteroatoms independently selected from the group consisting of N, 0 and S within the ring, wherein one or more groups of R a may be substituted or unsubstituted, wherein R a is Ci-C6 alkyl; Ci-C6 alkoxy; 3- to 12-membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from the group consisting of N, 0 and - NR x R y ; or halogen, and one or more groups of R a may be substituted or unsubstituted with R b, wherein R b is Ci-C6 alkyl; 3- to 12-membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from the group consisting of N, 0 and within the ring; or halogen, R2 is H; Ci- C6 alkyl; C3-C8 cycloalkyl; 3-12 membered heterocycloalkyl or heterocycloalkenyl containing 1 to 3 heteroatoms independently selected from the group consisting of N, 0 and in the ring; 6-14 membered aryl; or 5-12 membered heteroaryl containing 1 to 3 heteroatoms independently selected from the group consisting of N, 0 and S in the ring, and at least one of R2 may be substituted or unsubstituted, wherein Ci-C6 alkyl; C3-C8 cycloalkyl; 3-12 membered heterocycloalkyl containing 1 to 3 heteroatoms independently selected from the group consisting of N, 0 and in the ring; - NRpRq; - (HC=O); -(C=0)-(Ci-C6 alkyl); - S(=0)『 (Ci- C6 alkyl); or halogen, and one or more of the above groups may be substituted or unsubstituted with Rd, The above Rd is Ci-C6alkoxy which may be substituted or unsubstituted with halogen; 3- to 12-membered heterocycloalkyl containing 1 to 3 heteroatoms independently selected from the group consisting of N, 0 and in the ring; 6- to 14-membered aryl; halogen; or - 0H, R3 is H; or Ci-C6 alkyl, R4 is H; Ci-C6 alkyl; or halogen, Rs and R6 are each independently H; or Ci-C6 alkyl, Rx and Ry are each independently H; or Ci- C6 alkyl, Rp and Rq are each independently H; Ci- C6 alkyl, C3-C8 cycloalkyl or - (C=0)-(Ci-C6 alkyl), V is a single bond; or -(Ci- C6 alkylene)-. 【
2. In claim 1, Ri is a 6- to 14-membered aryl; a 5- to 12-membered heteroaryl or benzodioxolyl having 1 to 3 heteroatoms independently selected from the group consisting of N, 0 and S in the ring, and at least one group of Ri may be substituted or unsubstituted with Ra, and Ra is Ci-C6 alkyl; Ci-C6 alkoxy; a 3- to 12-membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from the group consisting of N, 0 and - NRxRy; or halogen, and at least one group of Ra may be substituted or unsubstituted with Rb, 197 wherein Rb is Ci-C6 alkyl; 3- to 12-membered heterocycloalkyl containing 1 to 3 heteroatoms independently selected from the group consisting of N, 0 and ; or halogen, R2 is C3-C8 cycloalkyl; or 3- to 12-member heterocycloalkyl containing 1 to 3 heteroatoms independently selected from the group consisting of N, O and S in the ring, and one or more substituents of the R2 may be substituted or unsubstituted, and the substituent is Ci-C6 alkyl; C3-C8 cycloalkyl; 3- to 12-member heterocycloalkyl containing 1 to 3 heteroatoms independently selected from the group consisting of N, O and S in the ring; -NRpRq or -(C=0)-(C1-C6 alkyl), and one or more substituents of the substituent may be substituted or unsubstituted with Rd, and the Rd is C1-C6 alkoxy which may be substituted or unsubstituted with halogen; 3- to 12-member heterocycloalkyl containing 1 to 3 heteroatoms independently selected from the group consisting of N, O and S in the ring; 6- to 14-member aryl; halogen; or -OH, Rs to R6 are each independently C1-C6 alkyl, Rx and Ry are each independently C1-C6 alkyl, Rp and Rq are each independently H; C1-C6 alkyl, C3-C8 cycloalkyl or -(C=0)-(C1-C6 alkyl), V is a single bond, a pharmaceutical composition.
3. 198 According to claim 2, R1 is phenyl, pyridinyl, pyrimidinyl, indolyl, thiophenyl, isoxazolyl, furanyl, benzofuranyl or benzodioxolyl, and one or more substituents of the R1 may be substituted or unsubstituted with Ra, and the Ra is methyl, methoxy, -N(CH3)2, -N(CH3)(CH2CH3), N(CH3)(CH2CH2CH2CH3), morpholinyl, thiomorpholinyl, pyrrolidinyl, piperidinyl, piperazinyl, or halogen, one or more substituents may be substituted or unsubstituted with Rb, and the Rb is methyl, ethyl, morpholinyl or halogen, R2 is cyclohexyl or piperidinyl, and one or more substituents of the R2 may be substituted or unsubstituted with the substituent, and the substituent is methyl, ethyl, propyl, isopropyl, butyl, cyclohexyl, azetidinyl, -NH2, -N(CH3)2, -N(CH3)(CH2CH3), -N(CH3)(CH2CH2CH3), N(CH3)(CH)(CH3)2, -N(CH3)(CH2CH2CH2CH3), -N(CH3)(C6HII), -N(CH3)(C=0)CH3 or - (C=0)CH3, and one or more of the above mentioned groups may be substituted or unsubstituted with Rd, wherein Rd is methoxy, ethoxy which may be substituted or unsubstituted with halogen, propoxy, butoxy which may be substituted or unsubstituted with halogen, isopropoxy, dioxolanyl, phenyl, halogen or - 0H, A pharmaceutical composition wherein Rs to R6 are methyl. 199
4. A pharmaceutical composition according to claim 1, wherein the compound represented by the chemical formula I is a compound described in the following table:
5. An EZH1 (Enhancer of zeste) composition comprising the following compound, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or a solvate thereof as an active ingredient. A pharmaceutical composition for the prevention or treatment of a disease related to the activity of homo 1 og 1) or EZH2 (Enhancer of zeste homo 1 og 2), wherein the disease related to the activity of EZH1 or EZH2 is a solid cancer. 1) 2-(trans-4-(dimethylamino)cyclohexyl)-7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo- 1,2-Dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide 2) 2-(trans-4-(dimethylamino)cyclohexyl)-7-(2-((2S,6R)-2,6-dimethylaminomorpholino)pyrimidin-5-yl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide 3) 7-(6-(4,4-difluoropiperidin-1-yl)pyridin-3-yl)-2-(trans-4-(dimethylamino)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide 4) 2-(trans-4-(dimethylamino)cyclohexyl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(2-(piperidin-1-yl)pyrimidin-5-yl)benzo[d][1,3]dioxole-5-carboxamide 5) 2-(trans-4-(dimethylamino)cyclohexyl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(2-(pyrrolidin-1-yl)pyrimidin-5-yl)benzo[d][1,3]dioxole-5-carboxamide 6) 2-(trans-4-(dimethylamino)cyclohexyl)- 2,4-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3 -yl)methyl)- 7-(4- (morpholinomethyl)phenyl)benzo[d][1,3]dioxole-5-carboxamide 7) 2-(trans-4-(dimethylamino)cyclohexyl)- 2, 4 -dimethyl- 7-(1-methyl- 1H- 211 Indole- 5 -yl)- N- ((6 -methyl- 4- (methylthio)- 2 -oxo- 1 , 2 -dihydropyridin- 3-yl) methyl) benzo [d] [l , 3]dioxole- 5 -carboxamide 8) 7-(2-(4,4-difluoropiperidin-1-yl)pyrimidin-5-yl)-2-(trans-4-(dimethylamino)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide 9) 2-(trans-4-(dimethylamino)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(4-morpholinophenyl)benzo[d][l,3]dioxole-5-carboxamide 10) 2-(trans-4-(dimethylamino)cyclohexyl)-7-(4-fluorophenyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][l,3]dioxole-5-carboxamide 11) 2-(trans-4-(dimethylamino)cyclohexyl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(thiophen-3-yl)benzo[d][l,3]dioxole-5-carboxamide 12) 2-(trans-4-(dimethylamino)cyclohexyl)-7-(5-fluoro-2-methoxyphenyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide 13) 2-(trans-4-(dimethylamino)cyclohexyl)-7-(3,5-dimethylisoxazol-4-yl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide 14) 7-(2, 6-difluoropyridine- 3-yl)- 2-(trans- 4- (Dimethylamino)cyclohexyl)- 2,4 -dimethyl- N- ((6 -methyl- 4- (methylthio)- 2 -oxo- 1,2 - 212 Dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide 15) 7-(2-(2-oxa- 7-azaspiro [3.5]nonane- 7-yl)pyrimidin-5-yl) -2- (trans- 4-(dimethylamino)cyclohexyl)- 2,4-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3-yl)methyl)benzo [d] [1,3]dioxole- 5-carboxamide 16) 2-(trans-4-(dimethylamino)cyclohexyl)-7-(6-(3,5-dimethylpiperidin—!—yl)pyridin— 3 —yl)— 2,4 -dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo- 1,2 -dihydropyridin- 3 -yl)methyl)benzo [d] [ 1,3 ]dioxole- 5 -carboxamide 17) 2-(trans-4-(dimethylamino)cyclohexyl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(6-thiomorpholinopyridin-3-yl)benzo[d][1,3]dioxole-5-carboxamide 18) 2-(trans-4-(dimethylamino)cyclohexyl)-7-(furan-3-yl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][l,3]dioxole-5-carboxamide 19) 7-(5-chlorothiophene-2-yl)-2-(trans-4-(dimethylamino)cyclohexyl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide 20) 7-(6-((2S, 6R)-2,6-dimethylmorpholino)pyridin-3-yl)- 2,4-dimethyl- 2-(trans- 4-(methyl(2,2,2-trifluoroethyl)amino)cyclohexyl)- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3-yl)methyl)benzo[d][1,3]dioxole- 5-carboxamide 21) 2, 4 -Dimethyl- 2- (trans- 4- (methyl (2,2,2-trifluoroethyl) amino) cyclohexyl)- N- ( (6 -methyl- 4- (methylthio)- 2 -oxo- 1 , 2 - 213 Dihydropyridin-3-yl)methyl)-7-(2-(piperidin-1-yl)pyrimidin-5-yl)benzo[d][l,3]dioxole-5-carboxamide 22) 7-(2-(dimethylamino)pyrimidin-5-yl)- 2,4-dimethyl- 2-(trans- 4-(methyl(2,2,2-trifluoroethyl)amino)cyclohexyl)- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3-yl)methyl)benzo[d][1,3]dioxole- 5-carboxamide 23) 7-(2-((2S, 6R)-2,6-dimethylmorpholino)pyrimidin-5-yl)-2,4-dimethyl-2-(trans-4-(methyl(2,2,2-trifluoroethyl)amino)cyclohexyl)- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide 24) 7-(6-((2S, 6R)-2,6-dimethylmorpholino)pyridin-3-yl)- 2-(trans-4-((2-methoxyethyl)(methyl)amino)cyclohexyl)- 2,4-dimethyl- N-((6-methyl- 4- (Methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide 25) 7-(2-((2S, 6R)-2,6-dimethylmorpholino)pyrimidin- 5 -yl)- 2-(trans- 4- ((2-methoxyethyl)(methyl)amino)cyclohexyl)- 2,4-dimethyl- N-((6-methyl- 4- (Methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide 26) 7-(2-(dimethylamino)pyrimidin-5-yl)- 2-(trans- 4-((2-methoxyethyl)(methyl)amino)cyclohexyl)- 2,4-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3-yl)methyl)benzo[d][ 1,3 ]dioxole- 5-carboxamide 27) 7-(6-(4, 4 -difluoropiperidin- 1-yl)pyridin- 3 -yl)- 2-(trans- 4-((2-methoxyethyl)(methyl)amino)cyclohexyl)- 2 , 4 -dimethyl- N-((6 -methyl- 4-(methylthio)- 2 - 214 Oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide 28) 2-(trans-4-((2-methoxyethyl)(methyl)amino)cyclohexyl)-7-(6-methoxypyridin—3-yl)- 2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo- 1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole- 5-carboxamide 29) 7-(6-((2S,6R)- 2,6 -dimethylmorpholino)pyridin- 3 -yl)- 2-(trans- 4- (((S)- 2 -hydroxypropyl)(methyl)amino)cyclohexyl)- 2,4 -dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo- 1,2 -dihydropyridin- 3 -yl)methyl)benzo [d] [1,3]dioxole- 5-carboxamide 30) 7-(6-((2S, 6R)-2,6-dimethylmorpholino)pyridin-3-yl)- 2,4-dimethyl- 2- (trans- 4-(methyl(2-propoxyethyl)amino)cyclohexyl)- N-((6-methyl- 4- (Methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide 31) 2-(trans-4-((2,2-dimethoxyethyl)(methyl)amino)cyclohexyl)- 7-(6-((2S, 6R)-2,6-dimethylmorpholino)pyridin- 3 -yl)- 2,4-dimethyl- N-((6-methyl- 4- (Methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide 32) 2-(trans-4-(((1,3-dioxolan-2-yl)methyl)(methyl)amino)cyclohexyl)- 7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)- 2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo- 1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide 33) 7-(6-((2S , 6R)-2 , 6 -dimethylmorpholino)pyridin- 3 -yl)- 2 , 4 -dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo- 1 , 2 -dihydropyridin- 3 -yl)methyl)- 2-(1-(2 , 2 , 2 - Trifluoroethyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide 34)2,4-Dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridine- 3-yl)methyl)-7-(6-thiomorpholinopyridine-3-yl)-2-(1-(2, 2,2-trifluoroethyl)piperidine-4-yl)benzo[d][1,3]dioxole-5-carboxamide 35) 7-(2-(dimethylamino)pyrimidin- 5 -yl)- 2,4 -dimethyl- N-((6 -methyl- 4- (methylthio)- 2 -oxo- 1,2 -dihydropyridin- 3 -yl)methyl)- 2-(1-(2,2,2 -trifluoroethyl)piperidin- 4 -yl)benzo [d] [1,3]dioxole- 5 -carboxamide 36) 7-(6-methoxypyridin- 3-yl)- 2, 4-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1 , 2 -dihydropyridin- 3 -yl)methyl)- 2-(1-(2 , 2 , 2 -trifluoroethyl)piperidine- 4-day)benzo[d][l,3]dioxole-5-carboxamide 37) 7-(6-(3,5-dimethylpiperidin-1-yl)pyridin-3-yl)- 2,4-dimethyl- N-((6-methyl— 4-(methylthio)- 2-oxo- 1,2-dihydropyridin-3-yl)methyl)- 2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzo[d][1,3]dioxole- 5-carboxamide 38) 7-(2-((2S, 6R)-2,6-dimethylmorpholino)pyrimidin-5-yl)- 2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo- 1,2-dihydropyridin-3-yl)methyl)- 2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide 39)2,4-Dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3 -yl)methyl)- 7-(2-(piperidin- 1-yl)pyrimidin- 5 -yl)- 2-(1-(2,2,2-trifluoroethyl)piperidin- 4 -yl)benzo[d][1,3]dioxole- 5 -carboxamide 40) 7-(6-((2S,6R)- 2, 6 -dimethylmorpholino)pyridin- 3 -yl)- 2-(1-((S)- 2-hydroxypropyl)piperidin- 4 -yl)- 2 , 4 -dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo- 1,2-Dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide 41) 2-(l-(2, 2 -dimethoxyethyl)piperidin- 4 -yl)- 7-(6-((2S , 6R)-2 , 6 -dimethylmorpholino)pyridin- 3 -yl)- 2 , 4 -dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo- 1,2-Dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide 42) 2-(4-(dimethylamino)cyclohexyl)- 2,4-dimethyl- N-((6-methyl- 4- (methylthio)- 2-oxo- 1,2-dihydropyridin- 3 -yl)methyl)- 7-(thiophen- 3-yl)benzo [d] [l,3]dioxole- 5 -carboxamide 43) 2-(4-(dimethylamino)cyclohexyl)- 7-(5-fluoro- 2-methoxyphenyl)- 2,4-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3-yl)methyl)benzo [d] [l,3]dioxole- 5-carboxamide 44) 7-(6-((2S , 6R)-2 , 6 -dimethylmorpholino)pyridin- 3 -yl)- 2 , 4 -dimethyl- N- Stereoisomer B of ((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide 45) 7-(6-((2S , 6R)-2 , 6 -dimethylmorpholino)pyridin- 3 -yl)- 2 , 4 -dimethyl- N- Stereoisomer A of ((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide 46) 2-(1-(2, 2-difluoroethyl)piperidin- 4 -yl)- 7-(6-((2S , 6R)~2 , 6 -dimethylmorpholino)pyridin- 3 -yl)- 2 , 4 -dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo- 1,2-Dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide 47) 2-(1-(2, 2-difluoroethyl)piperidin- 4 -yl)- 7-(6-((2S , 6R)-2 , 6 -dimethylmorpholino)pyridin- 3 -yl)- 2 , 4 -dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo- 217 Stereoisomer B of 1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide 48) 2-(1-(2, 2 -difluoroethyl)piperidin- 4 -yl)- 7-(6-((2S , 6R)~2 , 6 -dimethylmorpholino)pyridin- 3 -yl)- 2 , 4 -dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo- Stereoisomer A of 1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide 49) Stereoisomer B of 7-(6-((2S,6R)- 2,6 -dimethylmorpholino)pyridin- 3 -yl)- 2-(1-ethylpiperidin- 4 -yl)- 2,4 -dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo- 1,2 -dihydropyridin- 3 -yl)methyl)benzo [d] [ 1,3]dioxole- 5 -carboxamide 50) Stereoisomer A of 7-(6-((2S,6R)- 2,6-dimethylmorpholino)pyridin- 3 -yl)- 2-(1-ethylpiperidin- 4 -yl)- 2,4-dimethyl- N-((6-methyl- 4-(methylthio)- 2 -oxo- 1,2-dihydropyridin- 3 -yl)methyl)benzo[d][ 1,3]dioxole- 5-carboxamide 51) Stereoisomer B of 7-(6-((2S,6R)- 2,6 -dimethylmorpholino)pyridin- 3 -yl)- 2-(1-isopropylpiperidin- 4 -yl)- 2,4 -dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo- 1,2 -dihydropyridin- 3 -yl)methyl)benzo [d] [ 1,3]dioxole- 5 -carboxamide 52) Stereoisomer A of 7-(6-((2S,6R)- 2,6-dimethylmorpholino)pyridin- 3 -yl)- 2-(1-isopropylpiperidin- 4 -yl)- 2,4-dimethyl- N-((6-methyl- 4-(methylthio)- 2 -oxo- 1,2-dihydropyridin- 3 -yl)methyl)benzo[d][ 1,3]dioxole- 5-carboxamide 218 53) 2-(1-Cyclohexylpiperidin-4-yl)- 7-(6-((2S, 6R)-2,6-dimethylmorpholino)pyridin-3-yl)- 2,4-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- Stereoisomer B of 1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide 54) 2-(1-Cyclohexylpiperidin-4-yl)- 7-(6-((2S, 6R)-2,6-dimethylmorpholino)pyridin-3-yl)- 2,4-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- Stereoisomer A of 1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide 55) Stereoisomer B of 7-(6-((2S, 6R)-2,6-dimethylmorpholino)pyridin-3-yl)- 2,4-dimethyl- N-((6-methyl-4-(methylthio)- 2-oxo- 1,2-dihydropyridin-3-yl)methyl)- 2-(1-phenethylpiperidin-4-yl)benzo[d][l,3]dioxole- 5-carboxamide 56) Stereoisomer A of 7-(6-((2S, 6R)-2,6-dimethylmorpholino)pyridin-3-yl)- 2,4-dimethyl- N-((6-methyl-4-(methylthio)- 2-oxo- 1,2-dihydropyridin-3-yl)methyl)- 2-(1-phenethylpiperidin- 4-yl)benzo[d][l,3]dioxole- 5-carboxamide 57) 7-(6-((2S , 6R)-2 , 6 -dimethylmorpholino)pyridin- 3 -yl)- 2 , 4 -dimethyl- N- Stereoisomer B of ((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(4,4,4-trifluorobutyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide 58) 7-(6-((2S , 6R)-2 , 6 -dimethylmorpholino)pyridin- 3 -yl)- 2 , 4 -dimethyl- N- Stereoisomer A of ((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(4,4,4-trifluorobutyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide 219 59) 7-(6-((2S , 6R)-2 , 6 -dimethylmorpholino)pyridin- 3 -yl)- 2 , 4 -dimethyl- N- Stereoisomer B of ((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(2,2,2-trifluoroacetyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide 60) Stereoisomer A of 7-(6-((2S, 6R)-2,6-dimethylmorpholino)pyridin-3-yl)- 2,4-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3-yl)methyl)- 2-(1-(2,2,2-trifluoroacetyl)piperidin- 4-yl)benzo[d][1,3]dioxole- 5-carboxamide 61) 2, 4 -Dimethyl- N- ((6 -methyl- 4- (methylthio) - 2 -oxo - 1 , 2 - dihydropyridin - 3 -yl)methyl) - 7- (6 -morpholinopyridin - 3 -yl) - 2- (1- (2 , 2 , 2 - trifluoro) piperidin - 4-yl) benzo [d] [l , 3]dioxole - 5 -carboxamide 62) Stereoisomer B of 2,4-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3-yl)methyl)- 7-(6-morpholinopyridin- 3-yl)- 2-(1-(2,2,2-trifluoro)piperidin- 4-yl)benzo[d][1,3]dioxole- 5-carboxamide 63)2, 4 -Dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo- 1 , 2 -dihydropyridine- Stereoisomer A of 3-methyl-7-(6-morpholinopyridine-3-yl)-2-(1-(2,2,2-trifluoro)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide 64) 2-(1-(2, 2 -difluoroethyl)piperidin- 4 -yl)- 2, 4 -dimethyl- N-((6 -methyl- 4-(Methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(6-morpholinopyridine- 3-day) Stereoisomer B of benzo[d][1,3]dioxole-5-carboxamide 65) 2-(1-(2, 2 -difluoroethyl)piperidin- 4 -yl)- 2, 4 -dimethyl- N-((6 -methyl- 4-(Methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(6-morpholinopyridine- 220 3-day) Stereoisomer A of benzo[d][1,3]dioxole-5-carboxamide 66) Stereoisomer B of 2-(1-ethylpiperidin-4-yl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(6-morpholinopyridin-3-yl)benzo[d][1,3]dioxole-5-carboxamide 67) Stereoisomer A of 2-(1-ethylpiperidin-4-yl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(6-morpholinopyridin-3-yl)benzo[d][1,3]dioxole-5-carboxamide 68)2,4-Dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridine- 3-yl)methyl)- 7-(2-morpholinopyrimidine-5-yl)- 2-(1-(2, 2, 2-trifluoro)piperidine- 4-day)benzo[d][l,3]dioxole-5-carboxamide 69)2,4-Dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridine- 3-yl)methyl)- 7-(2-morpholinopyrimidine-5-yl)- 2-(1-(2, 2, 2-trifluoro)piperidine- 4-day) Stereoisomer B of benzo[d][1,3]dioxole-5-carboxamide 70)2,4-Dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridine- 3-yl)methyl)- 7-(2-morpholinopyrimidine-5-yl)- 2-(1-(2, 2, 2-trifluoro)piperidine- 4-day) Stereoisomer A of benzo[d][1,3]dioxole-5-carboxamide 71) Stereoisomer B of 2-(1-(2, 2-difluoroethyl)piperidin- 4-yl)- 2, 4-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1, 2-dihydropyridin- 3-yl)methyl)- 7-(2-morpholinopyrimidin- 5-yl)benzo[d][l, 3]dioxole- 5-carboxamide 72) 2-(1-(2, 2 -difluoroethyl)piperidin- 4 -yl)- 2, 4 -dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo- 1 , 2 -dihydropyridin- 3 -yl)methyl)- 7-(2 - 221 Stereoisomers of morpholinopyrimidin-5-yl)benzo[d][l,3]dioxole-5-carboxamide A 73) Stereoisomer B of 2-(1-ethylpiperidin-4-yl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(2-morpholinopyrimidin-5-yl)benzo[d][1,3]dioxole-5-carboxamide 74) Stereoisomer A of 2-(1-ethylpiperidin-4-yl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-7-(2-morpholinopyrimidin-5-yl)benzo[d][1,3]dioxole-5-carboxamide 75) 7-(2-(4-ethylpiperazin-1-yl)pyrimidin-5-yl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide 76) Stereoisomer B of 7-(2-(4-ethylpiperazin-1-yl)pyrimidin-5-yl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide 77) Stereoisomer A of 7-(2-(4-ethylpiperazin-1-yl)pyrimidin-5-yl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide 78) 7-(2-(ethyl(methyl)amino)pyridin- 5 -yl)- 2,4 -dimethyl- N-((6 -methyl- 4- (methylthio)- 2 -oxo- 1,2 -dihydropyridin- 3 -yl)methyl)- 2-(1-(2,2,2 -trifluoroethyl)piperidin- 4 -yl)benzo [d] [1,3]dioxole- 5 -carboxamide 222 79) Stereoisomer B of 7-(2-(ethyl(methyl)amino)pyridin- 5 -yl)- 2,4 -dimethyl- N-((6 -methyl- 4- (methylthio)- 2 -oxo- 1,2 -dihydropyridin- 3 -yl)methyl)- 2-(1-(2,2,2 -trifluoroethyl)piperidin- 4 -yl)benzo [d] [1,3]dioxole- 5 -carboxamide 80) Stereoisomer A of 7-(2-(ethyl(methyl)amino)pyridin- 5 -yl)- 2,4 -dimethyl- N-((6 -methyl- 4- (methylthio)- 2 -oxo- 1,2 -dihydropyridin- 3 -yl)methyl)- 2-(1-(2,2,2 -trifluoroethyl)piperidin- 4 -yl)benzo [d] [1,3]dioxole- 5 -carboxamide 81) Stereoisomer B of 2-(1-(2, 2-difluoroethyl)piperidin- 4 -yl)- 7-(2- (ethyl(methyl)amino)pyrimidin- 5 -yl)- 2, 4 -dimethyl- N-((6-methyl- 4-(methylthio)- 2 -oxo- 1, 2 -dihydropyridin- 3 -yl)methyl)benzo [d] [ 1, 3 ]dioxole- 5 -carboxamide 82) Stereoisomer A of 2-(1-(2, 2-difluoroethyl)piperidin- 4 -yl)- 7-(2- (ethyl(methyl)amino)pyrimidin- 5 -yl)- 2, 4 -dimethyl- N-((6-methyl- 4-(methylthio)- 2 -oxo- 1, 2 -dihydropyridin- 3 -yl)methyl)benzo [d] [ 1, 3 ]dioxole- 5 -carboxamide 83) Stereoisomer B of 7-(2-(ethyl(methyl)amino)pyrimidin- 5 -yl)- 2-(1-ethylpiperidin- 4 -yl)- 2,4 -dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo- 1,2 -dihydropyridin- 3-yl)methyl)benzo [d] [1,3]dioxole- 5 -carboxamide 84) Stereoisomer A of 7-(2-(ethyl(methyl)amino)pyrimidin- 5 -yl)- 2-(1-ethylpiperidin- 4 -yl)- 2,4 -dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo- 1,2 -dihydropyridin- 3-yl)methyl)benzo [d] [1,3]dioxole- 5 -carboxamide 223 85) 7-(6-(ethyl(methyl)amino)pyridin- 3 -yl)- 2 , 4 -dimethyl- N-((6 -methyl- 4- (Methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(2,2,2-trifluoro)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide 86) Stereoisomer B of 7-(6-(ethyl(methyl)amino)pyridin-3-yl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide 87) Stereoisomer A of 7-(6-(ethyl(methyl)amino)pyridin-3-yl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide 88) 2-(1-(2, 2-difluoroethyl)piperidin- 4 -yl)- 7-(6- (ethyl(methyl)amino)paridin- 3 -yl)- 2, 4 -dimethyl- N-((6-methyl- 4-(methylthio)- 2 -oxo- Stereoisomer B of 1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide 89) Stereoisomer B of 7-(6-(ethyl(methyl)amino)pyridin- 3 -yl)- 2-(1-ethylpiperidin- 4 -yl)- 2,4 -dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo- 1,2 -dihydropyridin- 3-yl)methyl)benzo [d] [1,3]dioxole- 5 -carboxamide 90)2,4-Dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridine- 3-yl)methyl)- 7-(4-(piperidin- 1-yl)phenyl)- 2-(1-(2, 2, 2-trifluoroethyl)piperidine- 4-day)benzo[d][l,3]dioxole-5-carboxamide 91) 2, 4 -Dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo- 1 , 2 -dihydropyridine- 224 3-yl)methyl)-7-(6-(piperidin-1-yl)pyridin-3-yl)-2-(1-(2, 2,2-trifluoroethyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide 92)2,4-Dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3 -yl)methyl)- 7-(2-thiomorpholinopyrimidin- 5 -yl)- 2-(1-(2,2,2-trifluoroethyl)piperidin- 4 -yl)benzo[d][1,3]dioxole- 5 -carboxamide 93) 2',2'-difluoro- 2,7-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3 -yl)methyl)- 2-(1-(2,2,2-trifluoroethyl)piperidin- 4 -yl)- [4,5'-bibenzo[d][1,3]dioxole]- 6-carboxamide 94)2,7-Dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridine- 3-yl)methyl)-2-(1-(2,2,2-trifluoroethyl)piperidine-4-yl)-[4,5'-bibenzo[d][1,3]dioxole]-6-carboxamide 95) 2-(1-(2, 2-difluoroethyl)piperidin- 4-yl)- 2, 7-dimethyl- N-((6-methyl- 4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-[4,5'-bibenzo[d][1,3]dioxole]-6-carboxamide 96)7-(Benzofuran-5-yl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzo[d][l,3]dioxole-5-carboxamide 97) 7-(Benzofuran- 5-yl)- 2-(1-(2, 2-difluoroethyl)piperidin- 4-yl)- 2,4-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1, 2-dihydropyridin- 3-yl)methyl)benzo [d] [l, 3]dioxole- 5-carboxamide 98)7-(6-(butyl(methyl)amino)pyridin-3-yl)- 2, 4-dimethyl- N-((6-methyl- 4- (methylthio)- 2-oxo- 1 , 2 -dihydropyridin- 3 -yl)methyl)- 2-(1-(2 , 2 , 2 - 225 Trifluoroethyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide 99) 7-(6-(butyl(methyl)amino)pyridin-3-yl)-2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzo[d][1,3]dioxole-5-carboxamide 100) 2-(trans-4-aminocyclohexyl)-7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide hydrochloride 101) 7-(6-((2S,6R)- 2, 6 -dimethylmorpholino)pidirin- 3 -yl)- 2-(trans- 4- (3 -hydroxyazetidine- 1-yl)cyclohexyl)- 2 , 4 -dimethyl- N-((6 -methyl- 4- (Methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide 102) 7-(6-((2S, 6R)-2,6-dimethylmorpholino)pyridin-3-yl)- 2,4-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3-yl)methyl)- 2-(trans- 4- (3-(2,2,2-trifluoroethyl)azetidin- 1-yl)cyclohexyl)benzo[d][1,3]dioxole- 5-carboxamide 103) 2-(trans-4-(3-(2,2-difluoroethoxy)azetidin-1-yl)cyclohexyl)-7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][l,3]dioxole-5-carboxamide 104) 2-(trans-4-(3-(2,2-difluoroethoxy)azetidin-1-yl)cyclohexyl)- 7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)- 2,4-dimethyl- N-((6-methyl-4-(methylthio)-2-oxo- 1,2-dihydropyridine- 3- 226 (1)methyl)benzo[d][l,3]dioxole-5-carboxamide 105) 7-(6-((2S,6R)- 2,6 -dimethylmorpholino)pyridin- 3 -yl)- 2-(trans- 4- (3 -isopropoxyazetidine- 1-yl)cyclohexyl)- 2,4 -dimethyl- N-((6 -methyl- 4- (methylthio)- 2 -oxo- 1,2 -dihydropyridin- 3 -yl)methyl)benzo [d] [1,3]dioxole- 5-carboxamide 106) 7-(6-((2S,6R)- 2,6 -dimethylmorpholino)pyridin- 3 -yl)- 2-(trans- 4- (3 -methoxyazetidine- 1-yl)cyclohexyl)- 2,4 -dimethyl- N-((6 -methyl- 4- (methylthio)- 2-oxo- 1,2 -dihydropyridin- 3 -yl)methyl)benzo [d] [ 1,3 ]dioxole- 5 -carboxamide 107) Stereoisomer B of 7-(6-((2S, 6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethyl-2-(trans-4-(methyl(2,2,2-trifluoroethyl)amino)cyclohexyl)- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide 108) Stereoisomer A of 7-(6-((2S, 6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethyl-2-(trans-4-(methyl(2,2,2-trifluoroethyl)amino)cyclohexyl)- N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide 109) 2-(trans-4-((2,2-difluoroethyl(methyl)amino)cyclohexyl)-7-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide 110) 7-(6-((2S,6R)- 2, 6 -dimethylmorpholino)pyridin- 3 -yl)- 2-(trans- 4- (isopropyl(methyl)amino)cyclohexyl)- 2 , 4 -dimethyl- N-((6 -methyl- 4-(methylthio)- 2 - 227 Oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide 111) 7-(6-((2S,6R)- 2, 6 -dimethylmorpholino)pyridin- 3 -yl)- 2-(trans- 4- (ethyl(methyl)amino)cyclohexyl)- 2 , 4 -dimethyl- N-((6 -methyl- 4-(methylthio)- 2 -oxo- 1,2-Dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide 112) 7-(6-((2S , 6R)-2 , 6 -dimethylmorpholino)pyridin- 3 -yl)- 2 , 4 -dimethyl- 2-(trans- 4-(methyl(phenethyl)amino)cyclohexyl)- N-((6 -methyl- 4-(methylthio)- 2 -oxo- 1,2-Dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide 113) 7-(6-((2S, 6R)-2,6-dimethylmorpholino)pyridin-3-yl)- 2,4-dimethyl- 2- (trans- 4-(methyl(phenethyl)amino)cyclohexyl)- N-((6-methyl- 4-(methylthio)- 2 -oxo- 1,2-Dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide 114) 2-(trans-4-(cyclohexyl(methyl)amino)cyclohexyl)- 7-(6-((2S, 6R)-2,6-dimethylmorpholino)pyridin- 3 -yl)- 2,4-dimethyl- N-((6-methyl- 4- (Methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide 115)7-(6-((2S, 6R)-2,6-dimethylmorpholino)pyridin-3-yl)- 2,4-dimethyl- N-((6-methyl- 4-(methylthio)- 2-oxo- 1,2-dihydropyridin- 3-yl)methyl)- 2-(trans- 4-(2,2,2-trifluoro- N-methylacetamido)cyclohexyl)benzo[d][ 1,3]dioxole- 5-carboxamide .
6. In claim 1 or claim 5, the solid tumor is rhabdoid tumor, melanoma, 228 A pharmaceutical composition, wherein the composition is at least one selected from pancreatic cancer, colorectal cancer, adrenal cancer, prostate cancer, bladder cancer, lung cancer, breast cancer, ovarian cancer, liver cancer, brain cancer, stomach cancer, renal cancer, thyroid cancer, epithelioid sarcoma, and synovial sarcoma. 【
7. A method for preventing or treating a disease associated with EZH1 or EZH2 activity, comprising administering to a subject a compound according to any one of claims 1 to 5, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or a solvate thereof, wherein the disease associated with EZH1 or EZH2 activity is a solid cancer.
8. A use of a compound according to any one of claims 1 to 5, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof for the prevention or treatment of a disease associated with EZH1 or EZH2 activity, wherein the disease associated with EZH1 or EZH2 activity is a solid cancer. 【Claims A compound according to any one of claims 1 to 5, a stereoisomer thereof, or a pharmaceutical composition thereof for the manufacture of a drug for the prevention or treatment of diseases associated with EZH1 or EZH2 activity. 229 A use of a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein the disease associated with EZH1 or EZH2 activity is a solid cancer. 230
